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ABSTRACT 
Lung cancer is the biggest cancer killer. Most patients present with advanced disease. These 
diseases are not amenable to surgery which currently provides the best chance of cure. New 
treatment approaches are urgently needed, and these will come from a greater understanding 
of the disease biology. Our group has identified growth factor signaling molecules, 
downstream of growth factor receptors, which are overexpressed in all SCLC tumours 
examined compared to lung epithelial cells. These include the growth controlling kinase the 
mammalian target of rapamycin (mTOR). Here the importance of mTOR in lung cancer was 
examined. 
We examined the expression of mTOR in NSCLC and SCLC patients. We demonstrated 
that total mTOR was overexpressed in early stage NSCLC patients and in SCLC patients. 
More specifically mTOR predicts poor outcome in early stage NSCLC patients. It appears to 
identify poor outcome in lymph node negative and stage IA patients where previously other 
markers have failed to consistently yield prognostic benefit. This information may help 
identify those at high risk of relapse. 
We demonstrate that using total protein immunohistochemistry may be more useful than 
using phospho-protein expression in assessing the contribution of a signaling protein to 
cancer biology in patient specimens. We show that in cell lines, formalin fixed cell line and in 
tumour biopsies phospho-mTOR signals varies in intensity with time from removing from 
media/blood supply. We suggest that no conclusions can be drawn from commonly used 
phospho-protein immunohistochemical studies and total protein studies may be more 
reliable. 
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Previously our laboratory has shown that high concentrations of rapamycin, an mTOR 
inhibitor, block MEK/ERK signaling which is necessary for pro-survival/chemoresistance 
effects induced by FGF-2 in SCLC cells. We demonstrate that this phenomenon is also 
observed with the clinically relevant mTOR inhibitor- RAD001 and other growth 
factors/chemicals in other SCLC cell lines, but not in NSCLC cell lines. It is therefore 
possible that high concentrations of RAD001 might help to reduce FGF-2-induced 
chemoresistance in SCLC. Moreover, by impairing growth factor induced ERK signaling; 
RAD001 has an additional mechanism of blocking growth factor induced proliferation. This 
could be a potentially novel therapeutic method.  
We investigated the mechanism of how mTOR mediates the ability of high concentrations 
of rapalogues to suppress MEK/ERK signaling and FGF-2 triggered chemoresistance. 
Using siRNAi and a PP2A inhibitor to various components of the pathways involved, we 
have found that neither FKBP12 nor mTOR is directly involved whilst the phosphatase 
PP2A may aid the mTOR regulation of MEK/ERK signaling. 
We established, using combination analysis, that the H69 SCLC cell line is more sensitive to 
combined mTOR inhibitor/cytotoxic chemotherapy killing compared to the H510 SCLC 
cell line and the order of drug exposure may not be important. 
Collectively, our results show that mTOR is important in NSCLC as well as SCLC biology 
providing a possible biomarker for poor outcome and a suitable target for new therapies 
such as RAD001. 
 7 
ACKNOWLEDGEMENTS 
 
Firstly I would like to thank Michael Seckl, my supervisor for all his support, encouragement 
and patience. He was a great supervisor who was previously my clinical consultant too. It 
was a pleasure to work with him in the laboratory; he always was cheerful and positive. He 
knew how to get the best out of me and understood the particular demands on being a 
medic in the laboratory. Thank you Michael, you will always be the ‘boss’ to me! 
A special thanks to Dr Francesco Mauri, who helped me with all of the histopathology. It 
was always a pleasure to go and see you, learn about immunohistochemistry and talk about 
France! 
For all things statistical Bernard North has been always ever present and very helpful. 
Thanks for all your patience with me-I finally got there! 
Mr John Anderson, Consultant Thoracic Surgeon at the Hammmersmith Hospital for the 
patient lung cancer tissue and for calling me when an operation was imminent. 
I would also like to thank past and present members of the Seckl laboratory who helped me 
in many different ways during my 3 years at Imperial College. In particular Emma Nunn, 
Susan Willis, Smaragda Angelidou, Imanol Arozarena, Diane Watling, Catarina Ramos Do 
Carmo, Janet Lyons-Lewis and Anja Markert. 
Special mentions to Paul Thiruchelvum, Simon Gamble and Fiona Kyle for their friendship 
whilst in the cyclotron building. 
Finally I would like to thank CR-UK who funded me with a competitive CR-UK clinical 
training fellowship. I did not enjoy the interview but it was worth it! 
  
 8 
 9 
CONTENTS 
ABSTRACT…………………………………………………………………………….. 5 
 
ACKNOWLEDGEMENTS…………………………………………………………… 7 
 
CONTENTS…………………………………………………………………………… 9 
 
LIST OF FIGURES…………………………………………………………………… 13 
 
LIST OF TABLES…………………………………………………………………….. 17 
 
ABBREVIATIONS……………………………………………………………………. 18 
 
CHAPTER I………………………………………………………………………….....24 
INTRODUCTION 
 
I.1 Lung Cancer.........…………………………………………………………………….25 
I.1.1 Aetiology………………………………………………………………………….. .27 
 
I.1.2 Treatment of Lung Cancer………………………………………………………......27 
 
NSCLC…………………………………………………………………………………...27 
SCLC…………………………………………………………………………………...... 31 
 
I.2 Biology of Lung cancer……………………………………………………………..... 34 
 
Growth Signals…………………………………………………………………………...34 
Epidermal growth factor receptor and signaling in NSCLC………………………………35 
Activating Ras mutations…………………………………………………………………39 
C-MYC…………………………………………………………………………………...39 
Growth factors and SCLC………………………………………………………………..40 
Apoptosis and Lung Cancer……………………………………………………………....41 
Tumour suppressor inactivation…………………………………………………………..43 
P53……………………………………………………………………………………….44 
Retinoblastoma (RB)……………………………………………………………………...44 
Chromosome 3p………………………………………………………………………….45 
Angiogenesis……………………………………………………………………………...45 
Invasion and metastasis…………………………………………………………………...47 
 
I.3 Intracelllar signaling pathways…………………………………………………………48 
 
The RAF/MAPK signaling pathway……………………………………………………....48 
Mechanisms of activation…………………………………………………………………48 
Substrates and functions…………………………………………………………………..51 
Ras/Raf/MAPK inhibitors………………………………………………………………..52 
The PI3K/AKT/mTOR signaling pathway……………………………………………….53 
 10 
PI3kinase (PI3Ks) - Structure and Activation…………………………………………….53 
 
I.4 Downstream effectors of PI3Ks- AKT and mTOR…………………………………...56 
AKT 
 
The mammalian Target of Rapamycin- mTOR…………………………………………...57 
Structure………………………………………………………………………………….58 
mTOR activation/inactivation………………………………………………………….....64 
mTOR and cancer………………………………………………………………………...67 
mTOR and lung cancer…………………………………………………………………...68 
mTOR inhibitors…………………………………………………………………………72 
Effects of mTOR inhibition……………………………………………………………....75 
mTOR in clinical trials……………………………………………………………………76 
 
I.5 The Thesis…………………………………………………………………………….78 
 
CHAPTER II 
MATERIALS AND METHODS………………………………………………………80 
 
II.1 MATERIALS………………………………………………………………………..81 
 
II.1.1 Cell lines……………………………………………………………………………81 
II.1.2 Antibodies………………………………………………………………………….83 
II.1.3 Reagents……………………………………………………………………………84 
II.1.4 Buffers……………………………………………………………………………...85 
 
II.2 METHODS………………………………………………………………………...86 
 
II.2.1 SDS-PAGE………………………………………………………………………....86 
II.2.2 Western Blotting……………………………………………………………………86 
II.2.3 Growth factor stimulation assays…………………………………………………....87 
II.2.4 Phospho-signal stability studies……………………………………………………..87 
II.2.5 Cell death/chemoresistance assays………………………………………………….88 
II.2.6 Immunohistochemistry Studies……………………………………………………..88 
Patients…………………………………………………………………………………....88 
Tissue microarray construction…………………………………………………………....89 
Immunostaining and Immunohistochemistry scoring for mTOR…………………………89 
Statistical analyses………………………………………………………………………....90 
II.2.7 Drug Combination Analysis………………………………………………………...91 
Growth Inhibition Assay………………………………………………………………….91 
Drug combination analysis by the isobologram/combination index method……………....91 
II.2.8 RNA interference (siRNA)………………………………………………………….92 
 
CHAPTER III 
mTOR IS OVEREXPRESSED IN LUNG CANCER………………………………..94 
 
III.1 
INTRODUCTION…………………………………………………………………….....95 
 11 
 
III.2 RESULTS…………………………………………………………………………....97 
II.2.1 mTOR is overexpressed in NSCLC patient specimens and is prognostically linked to 
survival……………………………………………………………………………………97 
III.2.2 mTOR is overexpressed in SCLC patient specimens……………………………...103 
 
III.3 DISCUSSION……………………………………………………………………...109 
 
CHAPTER IV 
PHOSPHO-SIGNALS ARE NOT STABLE WHEN GROWTH MEDIA/BLOOD 
SUPPLY ARE REMOVED FROM LUNG CANCER/TUMOURS……………….111 
 
IV.1 INTRODUCTION………………………………………………………………...112 
 
IV.2 RESULTS………………………………………………………………………….114 
IV.2.1 The strength of phospho-mTOR signals varies with time in HCC78 adenocarcinoma 
NSCLC cells removed from growth media but not in one NSCLC patient sample 
(Adenocarcinoma histology)……………………………………………………………..114 
IV.2.2 The strength of phospho-mTOR signals varies with time in HCC95 squamous 
NSCLC cells removed from growth media and in one NSCLC patient sample (squamous 
histology)………………………………………………………………………………...117 
IV.2.3 The strength of phosphoprotein signals varies with time in fixed H510 SCLC cells 
removed from growth media…………………………………………………………….120 
 
IV.3 DISCUSSION……………………………………………………………………...124 
 
 
CHAPTER V 
CHEMORESISTANCE and mTOR IN LUNG CANCER………………………...127 
 
V.1 INTRODUCTION……………………………………………………………….....128 
 
V.2 RESULTS…………………………………………………………………………...130 
V.2.1 FGF-2 and PDB stimulation of ERK and S6 Kinase 1 in H510 SCLC cells can be 
blocked by RAD001……………………………………………………………………..130 
V.2.2 SCF and ADH stimulation of ERK and S6 Kinase 1 in H510 SCLC cells can be 
blocked by pre-treatment with RAD001…………………………………………………131 
V.2.3 Growth factor/chemical stimulation of ERK and S6 Kinase 1 in H524 and H69 SCLC 
cells can also be blocked by pre-treatment RAD001……………………………………..132 
V.2.4 Growth factor stimulation of ERK and S6 Kinase 1 in NSCLC cells (HCC78 and 
HCC95) can not be blocked by pre-treatment with RAD001…………………………….142 
V.2.5 FGF-2 stimulation of ERK and S6 Kinase 1 in MCF-7 cells (breast cancer) can be 
blocked by pre-treatment with RAD001……………………………………………….....147 
V.2.6 Can high concentrations of rapalogues block FGF-2 and/or PDB-mediated 
chemoresistance in H510, HCC78 or HCC95 cells?...................................................................149 
 
V.2.8 DISCUSSION…………………………………………………………………….156 
 
 12 
 
CHAPTER VI 
mTOR AND MEK/ERK SIGNALING……………………………………………...159 
 
VI.1 INTRODUCTION………………………………………………………………...160 
 
VI.2 RESULTS…………………………………………………………………………..162 
 
VI.2.1 RNAi to FKBP12 does not seem to prevent high dose RAD001 blocking FGF-2 
stimulated phosphorylation of ERK in MCF-7 breast cancer cells……………………….162 
VI.2.2 RNAi to FKBP12 does not prevent RAD001 blocking FGF-2 stimulated 
phosphorylation of S6 Kinase 1 in MCF-7 cells………………………………………….164 
VI.2.3 RNAi to mTOR does not prevent high dose RAD001 blocking FGF-2 stimulated 
phosphorylation of ERK1/2 in MCF-7 cells……………………………………………..167 
VI.2.4 RNAi to mTOR does not prevent high dose RAD001 blocking FGF-2 
phosphorylation of S6 Kinase 1 in MCF-7 cells………………………………………….168 
 
VI.2.6 DISCUSSION……………………………………………………………………170 
 
 
CHAPTER VII 
COMBINATION STUDIES OF mTOR and CYTOTOXIC CHEMOTHERAPY IN 
SCLC CELLS…………………………………………………………………………..173 
 
VII.1 INTRODUCTION……………………………………………………………….174 
 
VII.2 RESULTS…………………………………………………………………………177 
 
VII.2.1 Dose response curves for H69 and H510 for cisplatin, etoposide and RAD001…177 
VII.2.2 Combination studies of H69 SCLC with RAD001 and Etoposide……………….180 
VII.2.3 Combination studies of H510 SCLC with RAD001 and Etoposide……………....182 
VII.2.4 Combination studies of H69 SCLC with RAD001 and Cisplatin………………....184 
VII.2.5 Combination studies of H510 SCLC with RAD001 and Cisplatin………………..186 
 
VII.3 DISCUSSION……………………………………………………………………..189 
 
CHAPTER VIII 
FINAL DISCUSSION AND FUTURE DIRECTIONS…………………………….192 
 
REFERENCES………………………………………………………………………...198 
PUBLICATIONS………………………………………………………………………. 
 
 
 
 13 
LIST OF FIGURES 
Figure 1.1 Highly simplified summary of EGFR-signaling pathway………………………37 
Figure 1.2 Simplified diagram of major pathways in apoptosis……………………………46 
Figure 1.3 The MEK/ERK signaling pathway…………………………………………....50 
Figure 1.4 PI3K/AKT signaling………………………………………………………….60 
Figure 1.5 Structure of mTOR and mTOR complexes…………………………………...62 
Figure 1.6 mTOR signaling……………………………………………………………....63 
Figure 1.7 S6K1 and S6K2 are regulated differently with respect to mTOR……………...73 
Figure 1.8 Structure of rapamycin………………………………………………………..74 
Figure 3.1 mTOR is overexpressed in NSCLC patients………………………………….99 
Figure 3.2 Martingale residual plot for lung cancer survival in 134 NSCLC patients…….100 
Figure 3.3 Kaplan-Meier survival plot of survival of 134 NSCLC patients for mTOR 
positive and mTOR negative…………………………………………………………......102 
Figure 3.4 Kaplan-Meier survival plot of survival of 134 NSCLC patients for mTOR 
positive and mTOR negative…………………………………………………………….105 
Figure 3.5 Kaplan-Meier plot demonstrating the influence of mTOR staining on LN 
negative NSCLC patient survival………………………………………………………...106 
Figure 3.6 Kaplan-Meier survival plot of survival of stage 1A NSCLC patients for mTOR 
positive and mTOR negative…………………………………………………………….107  
Figure 3.7 mTOR is overexpressed in SCLC patients…………………………………...108 
Figure 4.1 Phospho-mTOR signals varies with time in HCC78 NSCLC cells…………....115 
Figure 4.2 Phospho-mTOR signals do not vary in time in a patient’s lung cancer tissue 
sample (Adenocarcinoma)……………………………………………………………….116 
 
Figure 4.3 Phospho-mTOR signals varies with time in HCC95 NSCLC cells…………...118 
 14 
Figure 4.4 Phospho-mTOR signals varies in time in a patient’s lung cancer tissue sample 
(Squamous)……………………………………………………………………………....119 
 
Figure 4.5 Phospho-mTOR signals varies in time in H510 SCLC cells fixed in formalin...122 
 
Figure 5.1 FGF-2 and PDB stimulation of ERK and S6 Kinase 1 in H510 SCLC cells can 
be blocked by RAD001…………………………………………………………………..133 
Figure 5.2 SCF stimulation of ERK and S6 Kinase 1 in H510 SCLC cells can be blocked by 
RAD001…………………………………………………………………………………134 
Figure 5.3 ADH stimulation of ERK and S6 Kinase 1 in H510 SCLC cells can be blocked 
by RAD001……………………………………………………………………………...135  
Figure 5.4 5% serum and PDB stimulation of ERK and S6 Kinase 1 in H524 SCLC cells 
can be blocked by RAD001……………………………………………………………...136 
Figure 5.5 SCF stimulation of ERK and S6 Kinase 1 in H524 SCLC cells can be blocked by 
RAD001………………………………………………………………………………....138 
Figure 5.6 ADH stimulation of ERK and S6 Kinase 1 in H524 SCLC cells can be blocked 
by RAD001……………………………………………………………………………...139 
Figure 5.7 SCF and PDB stimulation of ERK and S6 Kinase 1 in H69 SCLC cells can be 
blocked by RAD001……………………………………………………………………..140 
Figure 5.8 ADH stimulation of ERK and S6 Kinase 1 in H69 SCLC cells can be blocked by 
RAD001………………………………………………………………………………....141  
Figure 5.9 PDB stimulation of ERK in HCC78 NSCLC can not be blocked by RAD001 
however FGF-2 stimulation of S6 Kinase 1 in HCC78 NSCLC cells can be blocked by 
RAD001…………………………………………………………………………………143 
 15 
Figure 5.10 FGF-2 stimulation of ERK in HCC95 NSCLC can not be blocked by RAD001 
however FGF-2 stimulation of S6 Kinase 1 in HCC95 NSCLC cells can be blocked by 
RAD001…………………………………………………………………………………145  
Figure 5.11 High doses of RAD001 do not block FGF-2 stimulation of ERK in HCC95 
NSCLC cells……………………………………………………………………………..146 
Figure 5.12 FGF-2 stimulation of ERK and S6 Kinase 1 in MCF7 breast cancer cells can be 
blocked by RAD001……………………………………………………………………..148  
Figure 5.13 RAD001 blocks FGF-2 induced rescue from etoposide cell death in H510 
SCLC cells……………………………………………………………………………….151 
Figure 5.14 RAD001 does not block FGF-2 induced rescue from etoposide cell death in 
HCC95 NSCLC cells…………………………………………………………………….153 
Figure 5.15 RAD001 does block PDB induced rescue from etoposide cell death in HCC78 
NSCLC cells……………………………………………………………………………..155 
Figure 6.1 RNAi to FKBP12 does not prevent high dose RAD001 blocking FGF-2 
stimulated phosphorylation of ERK1/2 in MCF-7 cells…………………………………163 
Figure 6.2 RNAi to FKBP12 does not prevent RAD001 blocking FGF-2 stimulated 
phosphorylation of S6 Kinase 1 in MCF-7 cells…………………………………………165 
Figure 6.3 RNAi to mTOR does not prevent high dose RAD001 blocking FGF-2 
stimulated phosphorylation of ERK1/2 in MCF-7 cells…………………………………166 
Figure 6.4 RNAi to mTOR does not prevent RAD001 blocking FGF-2 stimulated 
phosphorylation of S6 Kinase 1 in MCF-7 cells…………………………………………169 
Figure 7.1 H69 SCLC cells and dose-response effects with RAD001, Cisplatin and 
Etoposide……………………………………………………………………………….178 
 16 
Figure 7.2 H510 SCLC cells and dose-response effects with RAD001, Cisplatin and 
Etoposide………………………………………………………………………………..179  
Figure 7.3 Combination studies of H69 SCLC with RAD001 and Etoposide over 4 days.181 
Figure 7.4 Combination studies of H510 SCLC with RAD001 and Etoposide………….183 
Figure 7.5 Combination studies of H69 SCLC with RAD001 and Cisplatin……………..185 
Figure 7.6 Combination studies of H510 SCLC with RAD001 and Cisplatin……………187 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17 
LIST OF TABLES 
 
 
Table 1.1 Histological classification of lung cancer………………………………………..26 
Table 1.2 5-year percentage survival for NSCLC stages I-IV……………………………...30 
Table 1.3 Signaling mediators involved in activating growth factor signaling in lung cancer38  
Table 1.4 Abnormalities in the PI3K/AKT signaling pathway in cancer………………….59 
Table 2.1 Characteristics of cell lines……………………………………………………...81  
Table 2.2 List of antibodies..............................................................................................................83 
Table 2.3 RNAi target sequences for individual oligonucleotides for mTOR and FKBP12.93 
Table 3.1 Clinico-pathological characteristics of 134 patients with early NSCLC…………98 
Table 3.2 Univariate and multivariate analysis of patient characteristics for survival……..101 
Table 4.1 Mean immunohistochemical score (IHS) of formalin fixed NSCLC cell lines and 
NSCLC patient tissue………………………………………………………………….....123 
Table 7.1 In vitro growth inhibitory effect of cisplatin, etoposide and RAD001 in human 
SCLC cell lines…………………………………………………………………………..177  
Table 7.2 CI values of combinations of etoposide and RAD001 in H69 SCLC cells……180  
Table 7.3 CI values of combinations of etoposide and RAD001 in H510 SCLC cells…...182  
Table 7.4 CI values of combinations of cisplatin and RAD001 in H69 SCLC cells……...184 
Table 7.5 CI values of combinations of cisplatin and RAD001 in H510 SCLC cells…….186  
 18 
ABBREVIATIONS 
 
4E-BP1  4E Binding Protein 1   
ADH    Vasopressin 
AIDS   Acquired Immune Deficiency Syndrome 
AKT   Protein kinase B 
AMP   Adenosine Monophosphate 
AMPK   Adenosine Monophosphate –activated protein kinase 
APAF-1  Apoptotic protease activating factor-1 
ATP   Adenosine Triphosphate 
BAD   BCL-2 associated death promoter 
BAK   BCL-2 homologous antagonist/killer 
BAX   BCL-2- associated X protein    
BCL-2   B-cell leukemia-2 protein 
BRAC1  Breast cancer 1 
BSA   Bovine serum albumin 
CD   Cluster of Differentiation 
CDK   Cyclin-dependent Kinase 
CI   Combination Index 
DISC   Death inducing signaling complex 
DMEM   Dulbecco’s Modified Eagle’s Medium  
DMSO   Dimethyl sulfoxide      
DR   Death Receptor 
ECL   Enhanced chemo-luminescence   
 19 
ECM   Extracellular Matrix 
EGF   Epidermal Growth Factor 
EGFR   Epidermal Growth Factor Receptor 
eIFE   Eukaryotic Translation Initiation Factor 4E 
ERCC1  Excision Repair Cross-Complementation Group 1 Protein  
ERK   Extracellular signal-regulated kinase 
FasL   Fas Ligand 
FAT   FRAP–ATM–TTRAP  
FCS   Foetal Calf Setum 
FDA   Federal Drug Administration 
FGF   Fibroblast Growth Factor 
FHIT   Fragile Histidine Triad  
FKHR   Forkhead homolog 1 rhabdomyosarcoma  
FRAP   FK506 binding protein 12-rapamycin associated protein  
FRB   FKBP-Rapamycin Binding domain 
FTI   Farnesyl Transferase inhibition 
GAP   GTPase-activating protein 
GDP   Guanine Diphosphate 
Grb2   Growth Factor Receptor-bound Protein2  
GRP   Gastrin releasing peptide 
GTP   Guanine Triphophate 
HEAT   Huntington, Elongation factor 3 
HGF   Hepatocyte Growth Factor 
HIF1α   Hypoxia Inducible Factor 1α  
 20 
HRP   Horseradish Peroxidase 
IACD   Inhibitor of Caspase-3- activated DNase 
IAG   Immediate Early Genes 
IAP   Inhibitor of apoptosis protein 
IC   Inhibitory Concentration 
IGF-I   Insulin-like Growth Factor I  
IHC   Immunohistochemistry 
IHS   Immunohistochemistry Score 
JNK   Jun N-terminal kinase 
LAT-1   L-type amino acid transporter 1 
LDH   Lactate Dehydrogenase 
LOH   Loss of Heterozygosity 
MAPK   Mitogen-activated Protein Kinase 
MEK   Mitogen activated protein/extracellular signal-regulated kinase kinase 
mLST8   mTOR associated protein, LST8 homolog 
mSIN1   Mammalian Stress-Activated Protein Kinase interacting Protein 1 
mTOR   mammalian Target of Rapamycin 
NaSe   Sodium Selinite 
NCI   National Cancer Institute 
NSE   Non-Specific Enolase 
NSCLC  Non-small Cell Lung Cancer  
ODC1   Ornithine Decarboxylase 1 
PARP   Poly (ADP-ribose) polymerase 
PBS   Phosphate Buffer Solution 
 21 
PCI   Prophylactic Cranial Irridiation 
PDB   Phorbol Ester 
PDCD   Phosphorylating Programmed Cell Death 
PDGFR  Platelet Derived Growth Factor Receptor 
PDK1   Phosphoinositide-Dependent Kinase-1   
PH   Plekstrin Homology 
PI   Phosphoinositides 
PI3K   Phosphatidylinositol-3-Kinase  
PIP3   Phosphatidylinositol (3, 4, 5)-triphosphate 
PIKK   Phosphatiylinositol Kinases   
PKC   Protein Kinase C 
PP2A   Protein Phosphatase 2A 
PPR5   Proline Rich Protein 5 
PRAS40  Proline Rich AKT Substrate 40kDa 
PS   Performance Status 
PtdIns   Phosphatidylinositol-4, 5-Bisphosphate    
PTEN   Phosphatase and Tensin Homolog   
PVDF   Polyacrylamide Fluoride 
RAPTOR  Regulatory Associated Protein of mTOR 
RASSF1A  RAS association family 1 gene 
RHEB   Ras Homolog Enriched in Brain 
Rb   Retinoblastoma 
RICTOR  Rapamycin-Insensitive Companion of mTOR 
RPMI   Roswell Park Memorial Institute 
 22 
RSK   Ribosomal S6 Kinases 
RTK   Receptor Tyrosine Kinases 
S6K1   S6 Kinase 1  
S6K2   S6 Kinase 2 
SCC   Squamous Cell Carcinoma 
SCF   Stem Cell Factor 
SCLC   Small Cell Lung Cancer 
SDS   Sodium Dodecyl Sulphate    
SEM   Standard Error of the Mean   
SFM   Serum Free Medium 
SH2   Src Homology   
SNP   Single Nucleotide Polymorphism 
SoS   Son of Sevenless 
SPSS   Statistical Package for Social Sciences   
STATs   Signal Transducers and Activators of Transcription Factors  
TBST   Tris Buffered Saline-Tween   
TK   Tyrosine Kinase  
TMA   Tissue Microarray 
TNF   Tumour Necrosis Factor 
TNM   Tumour Node Metastasis 
TOP   Terminal Oligopyrimidine  
TOR   Target of Rapamycin 
TOS   Target of Rapamycin signaling  
TRAIL   TNF-related apoptosis-inducing ligand    
 23 
TSC   Tuberose Sclerosis Complex 
VEGF   Vascular Endothelial Growth Factor 
WHO   World Health Organisation 
        
     
    
   
 
 
 
 24 
CHAPTER I 
 
 
INTRODUCTION 
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I.1 Lung cancer 
Lung cancer is a major global health problem. It accounts for more deaths worldwide than 
any other malignant disease (Parkin et al., 2005). About 1.2 million people die of lung cancer 
each year and the incidence is increasing. In western countries the incidence is declining but 
in Eastern Europe and the developing world where the number of smokers remain high, 
lung cancer rates are increasing. 
Only 13% of lung cancer patients survive more than 5 years. The disease has no particular 
symptoms or signs for its detection at an early stage. Most patients therefore present with 
advanced disease and hence are inoperable. Clearly advances are needed in early diagnosis 
and in new therapeutic strategies. 
Lung cancer is histologicaly divided into small cell lung cancer (SCLC) and non-small cell 
lung cancer (NSCLC) and within each type many sub-divisions (Travis et al., 1999) (Table 
1.1). However the main distinction is between SCLC and NSCLC because of the manner of 
how SCLC presents its metastatic spread and response to treatment. 
Histological sub-classification of NSCLC includes adenocarcinoma (30% of cases) (whose 
incidence is rising at the expense of squamous cell), squamous cell (45% of cases) and large 
cell (<10% of cases) whilst SCLC comprises small cell carcinomas, mixed small cell and 
combined small cell carcinomas. Approximately 80-85% of presenting lung cancer cases are 
NSCLC and 15-20% are SCLC. 
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Small Cell Lung Cancer 
Variant 
Combined small cell carcinoma 
Mixed small cell/large cell carcinoma 
 
Non- Small Cell Lung Cancer 
Adenocarcinoma 
 
Acinar 
Papillary 
Bronchioloalveolar 
Solid adenocarcinoma with mucin subtypes 
Adenocarcinoma with mixed subtypes 
 
Squamous cell carcinoma 
 
Papillary 
Clear cell 
Small cell 
Basoloid 
 
Large Cell carcinoma 
 
Adenosquamous carcinoma 
Carcinomas with pleomorphic sarcomatoid, or sarcomatous elements 
Carcinoid tumour 
 
Typical 
Atypical 
 
Carcinomas of salivary gland type 
Mucoepidermoid carcinoma 
Adenoid cystic carcinoma 
 
 
Table 1.1 Histological classification of lung cancer (WHO 1999) 
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I.1.1 Aetiology  
Most lung cancer patients are smokers (85-90%) (Parkin et al., 1994). In fact, smokers are 22 
times more likely to die from lung cancer than non-smokers, and 90% of the major 
histological types of lung cancer cases, including SCLC are attributed to smoking (Chua et 
al., 2004). Genetic damage to the respiratory epithelium caused by smoking persists for years 
after smoking cessation and 50% of American lung cancer cases occur in ex-smokers (Hecht, 
1999; Wistuba et al., 1997). 
The 10-15% who do not smoke implies that other factors are also involved such as passive 
smoke, air pollution, work related risk factors (exposure to arsenic, chromium and nickel 
(Siemiatycki et al., 2004)) and environmental radon exposure. 
The fact that only 1 in 10 of lifetime smokers develop lung cancer suggests genetic 
susceptibility is important too. For example, three large genome wide association studies 
identified an association between single-nucleotide polymorphism (SNP) variation at 15q24-
15q25.1 and susceptibility to lung cancer (Amos et al., 2008). Host specific factors such as 
differences in carcinogen metabolism and detoxification, DNA repair e.g. germ line 
alterations in nucleotide excision repair genes such as excision repair cross-complementation 
group 1 protein (ERCC1) (Yu et al., 2008), cell cycle control, cell signaling and apoptosis may 
play a part. 
 
I.1.2 Treatment of Lung Cancer 
NSCLC 
Most NSCLC patients present with advanced disease (stage IV) or locally advanced disease 
(Stage IIIB) which is inoperable however those that present at an earlier stage (Stages I-
IIIA), for selected patients surgical resection is the only chance of cure. Stage is determined 
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by the tumour, node and metastasis system (TNM). Table 1.2 shows the 5-year percentage 
survival of each stage. 
Patients with stage I disease (T1-2N0) usually present with no symptoms and most are cured 
with surgical excision of the affected lobe of the lung. These patients do not benefit from 
adjuvant chemotherapy i.e. chemotherapy given after surgical resection (Douillard et al., 
2006; Wakelee et al., 2007). Five-year survival rates are only around 70% (Tsuchiya et al., 
2007). 
Stage II disease (T1-2 N1 and T3N0) is treated with surgery (lobectomy or 
pneumonectomy). Current data indicate that these patients gain additional benefit from 
adjuvant platinum based chemotherapy (Arriagada et al., 2004; Douillard et al., 2006). Those 
with incomplete resection and/or mediastinal lymph nodes should receive post-operative 
radiotherapy to reduce local recurrence (Group, 1998). 
Stage IIIA disease (T3N1, T3N2) patients if suitable will have complete resection via 
lobectomy with mediastinal lymph node dissection. Adjuvant platinum based chemotherapy 
is again offered post operatively with radiotherapy (Arriagada et al., 2004). 
NSCLC patients with advanced disease (stage IIIB/IV) with a good performance status are 
treated with up to 6 cycles of platinum-containing combination chemotherapy (Group, 
1995). Platinum-based regimes, reduces risk of death by 27% and leads to a 10% absolute 
increase in one-year survival compared to best supportive care. Three drug based regimes do 
not perform better than 2 drug based regimes (Alberola et al., 2003; Laack et al., 2004). 
However recent trial data looking at the combination of cisplatin and the multi-targeted 
antifolate drug pemetrexed has superior survival compared to cisplatin and gemcitabine with 
respect to adenocarcinoma and large-cell histology (Scagliotti et al., 2008). 
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For patients who progress to 2nd line treatment with a good performance status (PS) drugs 
such as docetaxol and pemetrexed have been given approval after trials showed improved 
survival against best supportive care for docetaxol and similar survival for pemetrexed 
against docetaxol but with less febrile neutropenia (Hanna et al., 2004; Shepherd et al., 2000). 
Inhibition of the epidermal growth factor receptor (EGFR) is at the forefront of targeted 
small molecule therapies in advanced NSCLC, with drugs such as gefitinib, cetuximab and 
erlotinib, with inhibition of angiogenesis via vascular endothelial growth factor (VEGF) 
inhibition with the monoclonal antibody bevacizumab also showing promising results.  
Erlotinib has been used in clinical trials in patients who have failed one previous line of 
chemotherapy, in patients who also express the EGFR. In clinical trials, survival was 
superior in the erlotinib treated group compared to the placebo group (Shepherd et al., 
2005). Sub-group analysis showed that patients with adenocarcinoma histology, female, non-
smokers and with an eastern ethnicity responded well to erlotinib. These patients tended to 
have somatic mutations in the EGFR. A recent study showed that roughly 16% of NSCLC 
patients have activating mutations in the EGFR (Rosell et al., 2009). 
Recently the combination of cetuximab, cisplatin and vinorelbine was found to have 
superior survival (in advanced EGFR-expressing stage IIIB or stage IV NSCLC) compared 
to just chemotherapy alone (Pirker et al., 2009). 
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Stage 5-year survival (%) 
Stage I 
 
T1N0M0 
T2N0M0 
 
Stage II 
 
T1-2 N1M0 
T3N0M0 
 
Stage III 
 
Stage IV 
 
 
76 
 
84 
68 
 
 
 
47 
40 
 
21 
 
2 
 
 
 
 
 
Table 1.2 5-year percentage survival for NSCLC stages I-IV 
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Bevicizumab when added to platinum based chemotherapy, in the first line advanced setting 
showed a significant progression free and overall survival benefit against chemotherapy 
alone. Squamous cell patients were excluded from the study due to safety reasons (Sandler et 
al., 2005). 
 
SCLC 
The TNM staging system is widely used to determine therapy for NSCLC. However, in 
SCLC this system does not appear to be superior to the much simpler Veterans 
Administration Lung Group classification based on suitability of patients for thoracic 
radiotherapy (Simon & Wagner, 2003). In this system patients are divided into two groups, 
limited or extensive stage, depending on whether the disease is confined to one hemi-thorax 
which can be encompassed within a single radiotherapy field. About 30% of patients present 
with limited disease and this in conjunction with performance status are good independent 
predictors of prognosis. Other features which may predict prognosis include lactate 
dehydrogenase (LDH), albumin, non specific enolase (NSE) and fibroblast growth factor-2 
(FGF-2) levels, ERCC1 expression and gender (Bremnes et al., 2003; Ruotsalainen et al., 
2002; Wakelee et al., 2007). Treatment is currently determined by stage. The median and 
overall survival for limited stage disease is about 18 months and 15% at 3 years, respectively. 
For extensive stage disease these figures are 8 months and <3% (Kurup & Hanna, 2004). 
Approximately 30% of patients present with limited disease and roughly 80% respond to 
combination chemotherapy. In the last 30 years, there have been two important advances in 
the management of SCLC. The first has been the recognition that early thoracic radiotherapy 
concurrent with chemotherapy improves local control and survival. A meta analyses 
demonstrated that conventionally fractionated thoracic radiation added to chemotherapy 
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improved survival by 5.4% and local disease control by 25.3% (Pignon et al., 1992). These 
survival advantages were observed with old regimens containing cyclophosphamide, 
adriamycin and vincristine. More recent studies (Bremnes et al., 2003) have demonstrated 
even better survival and less oesophageal toxicity when combining thoracic radiotherapy 
with etoposide and a platinum chemotherapy drug. The addition of a third drug to the 
etoposide-platinum combination did not further improve survival (Ettinger et al., 2005). 
Etoposide and platinum chemotherapy combined concurrently with thoracic radiotherapy 
has emerged as the standard of care for patients with limited disease SCLC. A question as to 
whether thoracic radiotherapy should be given with early or later cycles of chemotherapy has 
recently resolved by a systematic review of seven randomised trials. This review found a 
survival benefit of 5% at two years for early (<9 weeks from starting chemotherapy), 
compared to late (>9 weeks) irradiation (Fried et al., 2004). 
The second advance was the discovery that prophylactic cranial radiotherapy (PCI) also 
improves survival by halving the risk of brain relapse. A meta-analysis of seven trials found a 
5.4% survival increase at 3 years together with a reduction in incidence of brain metastasis 
from 59% to 33 % using PCI (Auperin et al., 1999). Thus all patients with limited stage 
disease who are free of brain metastases at the end of therapy should have PCI. 
Disease beyond one hemi-thorax is present at diagnosis in more than 60-70% of patients. 
Platinum/etoposide combinations have become the current standard of care (Pujol et al., 
2001; Sundstrom et al., 2002). Unlike other disease settings such as NSCLC and testicular 
cancer where cisplatin produces superior survival results than carboplatin, at the current time 
there is insufficient data to indicate inferiority of carboplatin in SCLC (Okamoto et al., 
2007). Prophylactic cranial radiotherapy in this group shows a reduction in the incidence of 
symptomatic brain metastases and prolonged disease free and overall survival (Slotman et al., 
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2007). Importantly and in contrast to NSCLC, therapy should not be withheld in SCLC 
patients whose PS is over 2 as they can still be salvaged with treatment (Johnson et al., 1996). 
Treatment of relapsed SCLC is a major problem for oncologists. Prognosis is very poor at 
this stage. Predicting who will respond is important. The response-complete/partial, the 
duration of response after 1st line treatment (>3 months) and PS are helpful predictors. If 
patients relapse at least 3 months after conclusion of 1st line treatment then they have a 
reasonable chance to respond to the same or a different treatment. Patients relapsing within 
1-2 months have a poor chance of responding. Nevertheless, even this cohort can benefit as 
demonstrated by a phase III randomised study of oral topotecan versus best supportive care. 
Survival was 25.9 weeks with topotecan versus 13.9 weeks for best supportive care (O'Brien 
et al., 2006). If patients do not respond or are ‘refractory’; clinical trials and best supportive 
care should be considered. 
For both NSCLC and SCLC despite present treatments survival is still poor. In particular, 
for SCLC new treatments have not been forthcoming. New treatments and novel 
therapeutic strategies are urgently needed. These will come from a better understanding of 
the disease biology. The biology of lung cancer will now be reviewed. 
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I.2 Biology of Lung cancer 
Growth Signals 
Within an organism, growth is a tightly regulated process. It is the result of a dynamic 
equilibrium between two forces, one tending to increase the cell population (cell 
proliferation) and one that tends to reduce it (cell death). In most tissues, cell turnover is 
slow, most cell remaining in the non proliferative G0/G1 phase of the cell cycle. However, 
many cells retain the capacity to re-enter the cell cycle and undergo cell division. This 
property is essential for many biological processes including tissue repair and immunological 
responses. 
In the last thirty years, growth factors most of which act externally via specific cell surface 
receptors have been shown to regulate growth and apoptosis. This is achieved through 
complex intracellular signaling, which once integrated, are translated into cellular responses. 
In cancer, these intracellular signaling pathways are modified leading to an escape from the 
normal control of cellular proliferation causing excessive growth. Proto-oncogenes encode 
normal cellular proteins which are highly conserved and are often of crucial importance in 
controlling cell proliferation. Activated proto-oncogenes encode molecules involved in 
aberrant growth factor signaling, either by directly promoting cell growth, by mimicking 
other growth factors, or by neutralizing growth inhibitory signals. Also activating mutations 
in intracellular signaling pathways downstream of these cell surface receptors can affect 
many pathways simultaneously. 
As mentioned, growth factors are proteins that bind to cell surface receptors to elicit their 
cellular activities. They can be separated into two main classes: polypeptide growth factors 
and neuropeptide growth factors. Multiple signaling pathways branch out from their 
respective activated receptors, to the nucleus or other cellular compartments where further 
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events regulating cell functions occur. The initiation of the signaling cascade is dependent on 
tyrosine kinase activity for polypeptide growth factor receptors whereas neuropeptide 
receptors which lack tyrosine kinase activity depend on heterotrimeric G proteins to elicit 
the signaling cascade. 
Tumour cells have lost their dependency to growth factor stimulatory signals from the 
external environment and can proliferate independently. This phenotype of growth 
autonomy is achieved by many molecular changes and gene mutations within the cell, 
typically by being self-sufficient in growth factors. These growth factors can be secreted by 
and act on the same cell (autocrine) or can be secreted by one cell type and act on another 
(paracrine). Aberrant expression and signaling by a number of growth factors and receptors 
have been identified in lung cancer. In NSCLC these include upregulation/mutation of 
certain receptor tyrosine kinases (RTKs), in particular the EGFR. In SCLC overexpression 
of insulin-like growth factor I (IGF-I) and its receptor as well as a number of neuronal 
growth factors are frequently observed. (Table 1.3) 
 
Epidermal growth factor receptor and signaling in NSCLC 
Overexpression of EGFR is common in NSCLC and in particular in squamous cell 
carcinoma (SCC), whereas EGFR overexpression is rare in SCLC (Rusch et al., 1993; 
Selvaggi et al., 2004). The EGFR is membrane bound and contains three main regions: an 
extracellular ligand binding domain, a hydrophobic membrane spanning region and a 
cytoplasmic region holding the catalytic tyrosine kinase activity. Ligand binding triggers 
receptor dimerization, promoting the autophosphorylation of specific tyrosine residues 
within the intracellular domain, creating binding sites for transduction proteins containing 
Src-homology 2 or phosphotyrosine-binding domains (Hodkinson et al., 2008). Major 
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signaling pathways/proteins are activated by EGFR activation including the Ras/Raf/ 
mitogen-activated protein kinase (MAPK) cascade, phosphotidylinositol-3 kinase 
(PI3K)/Akt/mammalian target of rapamycin (mTOR), and the signal transducers and 
activators of transcription factors (STATs). These pathways promote cell proliferation, 
prevent apoptosis, angiogenesis and increase cell migration (Figure 1.1). 
As mentioned, the Ras/Raf/MAPK pathway is activated on ligand binding to EGFR. The 
effects of this pathway are diverse, with a large numbers of Ras effectors, but in general Ras 
signaling upon Epidermal Growth Factor (EGF) stimulation has been associated with 
increase cell growth and proliferation. One of the three Ras genes, Kirsten-Ras (K-Ras, p21-
Ras), is mutated in ~ 30% of NSCLC. 
In NSCLC, increased EGFR signaling is obtained by an increase gene copy number and by 
activating mutations within the EGFR gene (Hirsch & Witta, 2005).One mutated EGFR 
variant termed EGFRvIII, found in ~16% of NSCLC, has gained increasing interest in 
recent years. EGFRvIII lacks the extracellular ligand-binding domain, preventing ligand 
binding, yet the receptor is constitutively active and capable of activating downstream 
modulators (Pedersen et al., 2001). In recent years, novel activating mutations within the 
tyrosine kinase (TK) domain of EGFR have been identified in NSCLC. Mutations in the 
first four exons of the EGFR TK domain have been observed. These include in-frame 
deletions in exon 19 (up to 60% of EGFR mutations) and the L858R missense mutation in 
exon 21 (up to 35% of EGFR mutations). These mutations have gained massive interest, 
since they have been found to correlate with increased response to treatment with EGFR 
tyrosine kinase inhibitors (Paez et al., 2004) and are present in 16% of all NSCLC patients 
(Rosell et al., 2009). These responders are more likely to be women, have adenocarcinoma 
histology, non smokers and to be asian (Herbst et al., 2008). 
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Figure 1.1 Highly simplified summary of EGFR-signaling pathway and their most 
important effects on biological processes 
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Oncogene NSCLC % SCLC % 
EGFR 
 
HER2-Neu 
 
IGF-I 
 
C-Kit/C-Met 
 
K-Ras 
 
Neuropeptides 
Bombesin 
Bradykinin 
CCK 
Endothelin-1 
Galanin 
Neurotensin 
Somatostatin 
Vasopressin 
VIP 
 
C-MYC 
50-90 
 
30 
 
- 
 
- 
 
20-30 
 
16-47 
 
 
 
 
 
 
 
 
50 
- 
 
- 
 
>95 
 
70 
 
- 
 
100 
 
 
 
 
 
 
 
 
10-40 
 
 
Table 1.3 Signaling mediators involved in activating growth factor signaling in lung 
cancer.  
Percentages are for aberrant activity/mutation frequency (Hansen, 2008)
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Activating Ras mutations 
 
Ras proteins are guanine nucleotide-binding proteins that belong to the small guanosine 
triphosphate (GTP)-binding protein (G protein) superfamily (Takai et al., 2001). It is a signal 
transduction protein. As previously mentioned, mutations in the intracellular membrane 
associated signaling mediator Ras (K-Ras) are detected in up to 30% of NSCLC (Gao et al., 
1997) but rarely in SCLC. Ras protein becomes activated by the binding of guanine 
triphosphate (GTP), allowing for transmission of growth stimulatory signals to the cell 
nucleus. Downregulation of Ras signaling occurs by hydrolysis of GTP to guanine 
diphosphate (GDP), mediated by the GTPase-activating protein (GAP). In NSCLC, 
activating point mutations in the K-Ras gene result in resistance to GAP activity, thereby 
trapping the Ras protein in a constitutively active state and capable of continuous growth 
promoting signaling. A recent global meta-analysis correlated the presence of point mutated 
constitutively active Ras in NSCLC with a poor prognosis (Mascaux et al., 2005). 
 
C-MYC 
This proto oncogene encodes nuclear products which are the targets of Ras signaling. The 
myc family of proto oncogenes have been implicated in various human cancers (Nesbit et al., 
1999). Through its role as transcription factor, c-MYC alters the expression of hundreds of 
target genes, many of which are themselves oncogenes or tumor suppressors (Prochownik, 
2008). Protein overexpression is due to gene amplification or by transcriptional 
dysregulation. In SCLC 18-31% had amplification of c-MYC as compared to 8-20% of 
NSCLC. DNA amplification of myc family genes and in particular c-MYC has been 
associated with shortened survival in SCLC patients (Brennan et al., 1991; Noguchi et al., 
1990). MYC mRNA is more stable in lung cancers (Richardson & Johnson, 1993). 
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Growth factors and SCLC 
The expression level of the mitogen IGF-I is elevated in most cases of SCLC, resulting in a 
self-stimulatory autocrine loop involving the IGF-I receptor which is commonly co-
expressed in SCLC (Reeve et al., 1990). IGF signaling acts by binding of IGF ligands (IGF-I 
and II) to cell surface RTKs (IGF-IR and IIR). IGF-IR signaling is complex but primarily 
occurs through the Ras/Raf/MAPK and the PI3-kinase/AKT pathways. A correlation 
between significantly elevated IGF-I serum levels and lung cancer risk has been reported but 
results of other studies are conflicting (Lukanova et al., 2001; Yu et al., 1999). 
The proto oncogene c-Kit and its ligand stem cell factor (SCF) are highly expressed in SCLC 
(Rygaard et al., 1993). Despite the suppression of SCLC proliferation in vitro with the small 
molecule inhibitor of c-kit, imatinib, there have been conflicting reports as to the prognostic 
significance of c-kit expression in SCLC tumours and several phase II trials with imatinib in 
SCLC patients have showed no tumour responses (Krug et al., 2005; Rohr et al., 2004).  
c-Met is another RTK that is overexpressed in SCLC. In contrast to the c-Kit/SCF system, 
the c-Met ligand-hepatocyte growth factor (HGF) is rarely co-expressed with the receptor in 
SCLC (Rygaard et al., 1993) but is expressed and secreted from surrounding normal lung 
fibroblasts, suggesting a paracrine action. The importance of paracrine c-Met signaling for 
lung cancer pathogenesis has been investigated further in a study where c-Met expressing 
lung cancer cells were transplanted into HGF overexpressing mice, resulting in increased 
metastatic potential of the transplanted cells (Yu & Merlino, 2002). 
Another RTK growth factor involved in SCLC and NSCLC biology is the fibroblast growth 
factor 2 (FGF-2), I will discuss this particular growth factor in depth later. 
Highly elevated expression of different neuropeptides is a characteristic of SCLC and also in 
some (mainly poorly differentiated) NSCLC tumours (Kiriakogiani-Psaropoulou et al., 1994). 
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Neuropeptides signal via heterotrimeric (i.e. 3 subunits) G-proteins. Sequence comparison 
for these receptors reveals that they all possess a seven transmembrane domain structure 
leading to activation of downstream signaling targets including PI3-kinase/AKT/mTOR and 
Ras/Raf/MAPK mediating proliferation, cell cycle regulation, cell migration and 
angiogenesis (Molina & Adjei, 2006). Interestingly, the development of resistance to 
cytotoxic chemotherapy in SCLC is accompanied by an increase in the expression of 
neuropeptide growth factor receptors (MacKinnon et al., 2005; Waters et al., 2003). Gastrin 
releasing peptide/bombesin (GRP) signaling via its receptor is one of the most intensively 
studied neuropeptides in SCLC. This is because of the concentration of the GRP precursor- 
Pro-GRP is highly elevated in the majority of SCLC cases and serum concentrations 
decrease on surgical resection (Weber et al., 1985). Other neuropeptides highly expressed in 
SCLC include bradykinin, vasopressin (ADH) and neuron specific enolase (Sattler & Salgia, 
2003; Simon & Wagner, 2003). 
 
Apoptosis and Lung Cancer 
Apoptosis is a physiological cell death mechanism that first occurs during early development 
of a living organism (Brill et al., 1999). It allows for the elimination of dysfunctional or 
damaged cells so that the organism can carry on unaffected. The ability to apoptose is 
present in a latent form in virtually every cell in the body, and when initiated by a variety of 
stimuli, it unfolds in a well defined and organized series of events. This leads to biochemical 
and physiological alterations that ultimately lead to cell death, typically within 24 hours. 
Alterations include cell membrane disruption, breakdown of cytoplasmic and nuclear 
skeletons, nuclear fragmentation and chromosome degradation (Kerr, 2002; Wyllie et al., 
1980). Evasion of apoptosis is a hallmark of cancer. 
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Two main apoptosis pathways exist-the death receptor and mitochondrial pathway (Figure 
1.2). The former has an important role in the maintenance of tissue homoeostasis and is 
activated by the interaction of cell surface death receptors with their ligands. However, in 
most physiological situations apoptosis is started via the mitochondrial pathway. 
Apoptosis is activated by a family of intracellular cysteine proteases called caspases. They are 
divided into two classes- initiator caspases including caspases P8, P9 and P10 and effector 
caspases including caspases P3, P6 and P7. 
The death receptor pathway is activated by ligands: tumour necrosis factor (TNF), Fas 
Ligand (FasL) and TRAIL (TNF-related apoptosis-inducing ligand) binding to their 
respective receptors: TNFRI, FAS and Death Receptor 4 (DR4) and Death Receptor 5 
(DR5). This triggers initiator caspase activation through a death inducing signaling complex 
(DISC), resulting in caspase-P8 activation of effector caspases, either directly or through B-
cell leukemia-2 protein (BCL-2) interacting domain (BID)-mediated release of cytochrome c 
from mitochondria. The mitochondrial pathway is activated with the release of cytochrome c 
from the intermembrane space of mitochondria. Two proapoptotic family members, BCL-2- 
associated X protein (BAX) and Bcl-2 homologous antagonist/killer (BAK) facilitate 
cytochrome c release by participating in the formation of a pore that releases mitochondrial 
intermembrane space proteins. After its release, cytochrome c binds to apoptotic protease 
activating factor-1 (APAF-1). APAF-1 binds to procaspase-9 forming a multiprotein 
complex, called an apoptosome, which activates effector caspases through caspase-9. 
Anti-apoptotic factors such as Bcl-2 related proteins antagonize BAX and BAK. Also, IAP 
(inhibitor of apoptosis protein) binds and inhibits apoptosome-related caspases. However 
this inhibition can be relieved by the release of another mitochondrial protein called 
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Smac/Diablo, which binds IAP and releases active caspases. The most extensively studied 
IAP is survivin (Shivapurkar et al., 2003). 
Recent data suggest that DR4 and DR5 are upregulated in NSCLC and overexpression of 
DR5 correlates with poor prognosis. Bcl-2 expression is higher in SCLC compared to 
NSCLC. It has also been shown that the BAX: Bcl-2 ratio might be of importance for 
resistance to apoptosis. Caspase-8 and caspase 10 might be deregulated and differences in 
deregulation in SCLC compared to NSCLC especially concerning caspase-8 have been 
observed, resulting in deregulation of DISC. In addition, it has been shown that 
downregulation of caspase-3 is correlated with a poor prognosis in NSCLC (Fennell, 2005; 
Shivapurkar et al., 2003). 
Survivin expression is increased in NSCLC and lack of expression could be associated with a 
good prognosis. Also microarray data show that survivin is upregulated in SCLC cell lines 
and patient tumours (Pedersen et al., 2003). 
Much focus is on BCL-2 inhibition, with some drugs in the pre-clinical trial stage. 
 
Tumour suppressor inactivation 
As previously mentioned proto oncogene activation in lung cancer is common and so is 
inhibition of tumour suppressor activity. Tumour suppressor genes act to prevent and 
control cell growth, mostly by regulation of cell cycle progression. Inactivation of both 
alleles is required and this occurs by a two step process involving a chromosomal 
translocation or deletion resulting in loss of heterozygosity (LOH), followed by an 
inactivating point mutation of the remaining allele. LOH of certain chromosomal regions is 
common in lung cancer, and in these regions tumour suppressors involved in 
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tumourogenesis are frequently found. I will focus now on two important tumour 
suppressors in lung cancer- p53 and retinoblastoma (RB). 
 
P53 
P53 is one of the most studied tumour suppressors. P53 is a key player in the cellular 
response to stress, such as ultraviolet light and chemotherapy, acting as a gatekeeper of the 
cell cycle. Active p53 regulates transcription of a number of genes involved in cell cycle 
control (such as cyclin-dependent kinase inhibitors) leading to cell cycle arrest, allowing for 
repair of damaged DNA. Activation also leads to apoptosis via activation of a number of 
apoptotic mediators and activates genes encoding anti-angiogenic factors. The p53 gene is 
located on chromosome 17 (17p13) which is mutated in the majority of lung cancer cases, in 
particular SCLC and SCC (Chmara et al., 2004; Petersen et al., 1997). p53 mutations result in 
a poorer prognosis in NSCLC. Since so few SCLC patients lack mutations in p53 it is 
difficult to assess prognosis in these patients (Campling & El-Deiry, 2003). 
 
Retinoblastoma (RB) 
The gene for this tumour suppressor encodes a transcription factor involved in the 
regulation of G1 to S-phase transition in the cell cycle. Activation depends on 
phosphorylation, leading to E2F release and then progression of the cell cycle from G1 to S. 
Phosphorylation of Rb is dependent on complex formation with cell cycle proteins like 
cyclin D and Cyclin Dependent Kinase 4 and 6 (CDK4/6). These complexes are inhibited 
by p16. LOH or mutation is very common (90%) in SCLC (Hensel et al., 1990), whilst the 
p16 gene is frequently inactivated in NSCLC (Otterson et al., 1994), leading to lack of Rb 
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activity. Animal models of p53 and Rb null mice who develop SCLC provide further 
evidence that Rb is essential in lung cancer (Minna et al., 2003).  
 
Chromosome 3p 
The most frequent chromosomal abnormality in lung cancer is loss of regions in 
chromosome 3p. LOH at this site is prevalent in 70-100% of NSCLC and more than 50% of 
SCLC (Kok et al., 1987; Naylor et al., 1987). Many genes in this region are considered 
tumour suppressors and are inactivated in both SCLC and NSCLC such as fragile histidine 
triad (FHIT) and RASSF1A (RAS association family 1 gene) (Zabarovsky et al., 2002). 
 
Angiogenesis 
New blood vessel formation (angiogenesis) is a carefully regulated normal physiological 
process. Tumours must develop angiogenic ability to survive since oxygen and nutrients 
cannot be supplied by simple diffusion alone once a certain size is attained. Angiogenesis is 
regulated by pro-angiogenic factors and anti-angiogenic factors. Activation is by a change in 
the balance of pro- and anti- factors (de Castro Junior et al., 2006). The most studied pro-
angiogenic factors are VEGF and acidic and basic FGF-1/FGF-2 which bind to RTKs on 
endothelial cells (Veikkola et al., 2000). Whilst the typical anti-angiogenic factor is 
thrombospondin-1 which binds to CD36, a transmembrane receptor on endothelial cells 
coupled to intracellular Src-like tyrosine kinases (Bull et al., 1994). There are over 100 
different pro- and anti- angiogenic factors. VEGF levels have been demonstrated to 
determine predict poor prognosis in NSCLC, in particular SCC (Imoto et al., 1998). 
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Figure 1.2 Simplified diagram of major pathways in apoptosis 
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Invasion and metastasis 
Another defining characteristic of the malignant phenotype is invasion into local tissues and 
then spread to metastatic deposits. The dissemination of cancer is a complex process 
depending on many interactions between the cancer cell and the host environment. There 
are many steps including detachment from the primary, penetration of the basement 
membrane, invasion of surrounding stromal tissue, gaining access to the blood/lymphatic 
system by crossing the subendothelial basement membrane, seed in an organ and survival in 
that organ (Hart & Saini, 1992). Integrins are heterodimeric cell surface receptors which are 
expressed on all cell types. They mediate adhesion and cell spreading by linking the 
extracellular matrix (ECM) with the cytoskeleton (Martini, 1994). Laminins are 
heterotrimeric ECM proteins which are prominent constituents of the basement membrane. 
Laminin-integrin interactions are common and key markers of tissue invasion through the 
basement membrane and leading to metastasis. The expression of laminin α chains (α3 and 
α5) is often reduced in lung cancer leading to fragmentation of basement membrane 
elements and hence invasion (Akashi et al., 2001). Laminin 5 and its binding receptor α6β4-
integrin, is only expressed in NSCLC and not in SCLC. Laminin 5 overexpression is 
associated with a poor prognosis in NSCLC and is an independent prognostic factor in 
NSCLC (Manda et al., 2000; Moriya et al., 2001). Resistance to chemotherapy is a principal 
problem in the treatment of SCLC. It has been shown that SCLC is surrounded by an 
extensive stroma of ECM at both primary and metastatic sites. Adhesion of SCLC cells to 
ECM enhances tumorigenicity and confers resistance to chemotherapeutic agents as a result 
of beta1 integrin-stimulated tyrosine kinase activation suppressing chemotherapy-induced 
apoptosis (Sethi et al., 1999). 
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I.3 Intracelllar signaling pathways 
Since many of the genetic alterations found in cancer involve genes which code for proteins 
involved with modulation of signal transduction (Hanahan & Weinberg, 2000) recent 
research has focused on the inhibition of molecules involved with signal transduction and 
carcinogenesis. These intracellular signaling pathways transduce signals from the cell surface 
to the nucleus. They are involved with cell proliferation, apoptosis and a variety of other 
biological processes (Brivanlou & Darnell, 2002) involved with cancer. Many of the key 
proteins involved with signal transduction have kinase activity. Protein kinases mediate most 
signal transduction in eukaryotic cells. 
Two critical pathways I will now focus on are the RAF/MAPK mitogen activated kinase 
pathway and the PI3-Kinase/AKT/mTOR pathway. 
 
The RAF/MAPK signaling pathway 
The Ras-Raf-MEK-ERK (MEK for MAPKK and ERK kinase, ERK for extracellular signal-
regulated kinase) signal transduction pathway is present in all eukaryotic cells (Kolch, 2000). 
This important pathway relays extracellular signals to the nucleus via a cascade of highly 
specific phosphorylation events involving Ras, RAF, MEK and ERK to regulate 
fundamental cellular processes such as proliferation, differentiation and cell survival (Kolch, 
2000). 
 
Mechanisms of activation 
The mammalian MEK/ERK signal cascade consists of the MAPKs- ERK1 and ERK2, the 
MAPK kinases (MAPKKs) - MEK1 and MEK2, and the MAPKK kinases (MAPKKKs) - 
Raf family of kinases. Raf kinases phosphorylate and activate the MEK1 and MEK2 dual 
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specificity protein kinases MEK1/2 then phosphorylate and activate ERK1/2 MAPKs. 
Activated ERK phosphorylate and regulate the activities of over 160 proteins (Yoon & 
Seger, 2006). Most ERK substrates are nuclear proteins. Activated ERKs can translocate to 
the nucleus, where they phosphorylate and regulate various transcription factors, ultimately 
leading to changes in gene expression (Zuber et al., 2000) (Figure 1.3). 
The pathway is initially activated by the binding of growth factors such as EGF, Vasopressin 
and VEGF to their respective receptors be that tyrosine kinases or G-protein coupled 
receptors leading to the activation of a kinase cascade that relays signals to the nucleus. 
Typically Ras protein is activated by recruitment of the adaptor protein growth factor 
receptor-bound protein2 (Grb2) to the afore mentioned activated receptor. Grb2 contains 
one Src Homology 2 (SH2) domain and two SH3 domains. Its two SH3 domains direct 
complex formation with proline-rich regions of other proteins and its SH2 domain binds 
tyrosine phosphorylated sequences present on activated RTKs. The proline rich guanine 
nucleotide exchange protein Sos (Son of sevenless) binds to Grb2 when complexed with the 
receptor. Sos is an exchange factor that facilitates the exchange of GDP for GTP on Ras and 
thereby activating this GDP binding protein (Rozakis-Adcock et al., 1993). As previously 
mentioned Ras GTPases consist of a large family of membrane-associated proteins that 
switch between GTP-bound active and GDP-bound inactive conformation (Wittinghofer & 
Pai, 1991). Ras oncogenes are the most frequently mutated in human cancers (Campbell & 
Der, 2004). The mutations leading to a malignant phenotype prevent Ras proteins from 
hydrolysing GTP, therefore maintaining an active state. The active Ras-GTP binds in turn to 
the amino-terminal Ras binding domain of Raf, a family of serine/threonine kinases (A-Raf, 
B-Raf and Raf-1), and recruit them to the cell membrane for activation. Activated Raf 
kinases are the point of entry into the subsequent MEK/ERK  
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Figure 1.3 The MEK/ERK signaling pathway 
The MEK/ERK cascade consists of the MAPKs ERK1 and ERK2, the MAPK kinases 
(MAPKKs) MEK1 and MEK2, and the MAPKK kinases (MAPKKKs) Raf family of 
kinases. ERK1/2 phosphorylates several MAPK-activated protein kinases (MKs), including 
the family of ribosomal S6 kinases (RSK). In the nucleus, ERK1/2 and RSK1/2 
phosphorylate transcriptional regulators, resulting in the transcriptional activation of 
immediate early genes (IEGs). 
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kinase cascade, initiated by activation of MEK1 and MEK2 proteins through 
phosphorylation of serine residues in the activation loop (S217/S221) (Alessi et al., 1994). 
B-Raf has been shown to be the most efficient at activating MEK1/2 (Huser et al., 2001; 
Jaiswal et al., 1994). Moreover B-Raf somatic mutations have been identified in many 
malignancies, especially malignant melanoma, and less so in thyroid, colon and ovary (Davies 
et al., 2002; Garnett & Marais, 2004). 
Activated dual specificity MEK1/2 kinase subsequently phosphorylates and activates p42/44 
mitogen activated kinases, ERK1 and ERK2, by threonine and tyrosine phosphorylation 
within a conserved Thr-Glu-Tyr (TEY) motif in their activation loop (Kolch, 2000). ERK1 
and ERK2 are serine/threonine kinases, share 83% amino acid identify and are expressed to 
various extents in all tissues. Activated ERK1/2 can then catalyze the phosphorylation and 
as mentioned activation of several substrates and, thereby, exert their effects. 
 
Substrates and functions 
Activated ERK1/2 phosphorylate substrates in all cellular compartments, including various 
membrane proteins (CD120a, Syk, and calnexin), nuclear substrates (SRC-1, Pax6, NF-AT, 
E1k-1, MEF2 (Myocyte enhancing factor 2), c-Fos, c-Myc, and STAT3), cytoskeletal 
proteins (neurofilaments and paxillin), and several protein kinases, termed MAPK-activated 
protein kinases (MKs) (Jacobs et al., 1999; Robinson & Cobb, 1997). 
The MK family of ERK 1/2 substrates consists of related kinases that mediate a wide range 
of biological functions in response to mitogens and stress stimuli. Members of the family 
include the ~90 kDa ribosomal S6 kinases (RSKs), the mitogen- and stress-activated kinases 
and MAPK interacting kinases (Roux & Blenis, 2004). Among these, RSK family members 
(RSK1-4) are exclusively activated by the ERKs. ERK 1/2 and RSK 1/2 can translocate into 
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the nucleus, where, together with nuclear members of RSK family, they phosphorylate 
several important transcriptional regulators including E1k-1, the cyclic AMP (cAMP) 
response element binding protein (CREB) and histone H3 (Frodin & Gammeltoft, 1999). 
The result is rapid transcriptional activation of immediate early genes (IEGs), including 
transcriptional factors that control the cell cycle and/or cell survival. 
 
Ras/Raf/MAPK inhibitors 
Since the MAPK signaling pathway plays a critical role in transmitting signals from the cell 
surface to the nucleus, thereby influencing proliferation and cell survival, inhibitors of 
specific components of the pathway have been developed and evaluated in the clinic with 
varying degrees of success in cancer. 
At least three different approaches have been developed to target the activated Ras pathway. 
Firstly, by blocking upstream activation of Ras at cell surface receptors e.g. RTKs. Secondly, 
targeting Ras itself or interrupting protein processing e.g. Farnesyl Transferase inhibition 
(FTI) and thirdly targeting downstream effector pathways e.g. Raf kinase and MEK 
inhibitors (Marshall, 1996). Most focus has been on targeting Ras by inhibiting farnesylation 
of Ras protein using FTIs. Tipifarnib, a specific FTI has made it to phase III trials. 
Gastrointestinal tumours were chosen in the trials because of the high prevalence of Ras 
mutations in pancreatic (90%) and colorectal cancer (50%). In combination with gemcitabine 
in pancreatic cancer and as a single agent after two prior chemotherapy regimes in colorectal 
cancer, no progression or overall survival benefit was observed (Rao et al., 2004; Van 
Cutsem et al., 2004). Further studies are assessing Tipifarnib in NSCLC. 
Sorafenib is a novel bi-aryl urea inhibitor of Raf-1, suppressing both wild type and V599E 
mutant BRAF activity in vitro, and several RTKs involved in angiogenesis and tumour 
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progression, including VEGFR-2, VEGFR-3, PDGFR-beta (Platelet Derived Growth 
Factor), Flt-3 (FMS-like tyrosine kinase 3) and c-KIT (Strumberg, 2005). Sorafenib has made 
it to phase III clinical trials in unresectable renal cell carcinoma who have received at least 
one prior systemic therapy. Clear progression free survival benefits were seen versus placebo 
which led to approval by the US Food and Drug administration (FDA) for Sorafenib in renal 
cell carcinoma (Gore & Escudier, 2006). 
CI-1040 is the first MEK-targeted agent to reach clinical trials. It is a highly potent and 
selective non-competitive inhibitor of both MEK isoforms, MEK1 and MEK2. CI-1040 
bind to the hydrophobic binding pocket of MEK1 and MEK2 that is adjacent to but distinct 
from the magnesium adenosine triphosphate (ATP)-binding site, which induces a 
conformational change in unphosphorylated MEK that locks it into a closed but catalytically 
inactive form (Sebolt-Leopold et al., 1999). Unfortunately phase II clinical studies in breast, 
colon, pancreas and lung cancer showed insufficient antitumour activity to warrant further 
development (Rinehart et al., 2004). Further studies with PD0325901, a second generation 
MEK inhibitor have subsequently been undertaken but have recently been stopped because 
of toxicity issues and a lack of efficacy. Other MEK inhibitors are currently being 
investigated in the clinic.  
 
The PI3K/AKT/mTOR signaling pathway 
The PI3K signaling pathway is another signaling cascade that is important for migration, cell 
growth and survival. The importance of this pathway in cancer comes from the extensive 
evidence that it is frequently dysregulated by various genetic and epigenetic mechanisms in 
many tumour types (Wymann et al., 2003) (Table 1.4). Thus pharmacological inhibition of 
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this activated pathway in cancer provides a reasonable therapeutic strategy to kill or arrest 
cancer cells (Weinstein, 2002; Weinstein & Joe, 2006). 
 
PI3kinase (PI3Ks) - Structure and Activation  
The Phosphatidylinositol-3-Kinase (PI3Ks) are a family of lipid and serine/threonine kinases 
that when activated, catalyse the phosphorylation of the 3’-hydroxy group of 
phosphoinositides (PI) (membrane associated phospholipids, with a modifiable hydrophilic 
inositol head, that can act as a second messenger) (Fruman et al., 1998). There are three 
classes of PI3Ks but only class IA and II has been implicated in human cancer (Arcaro et al., 
2002). Due to the focus of this thesis only Class 1A PI3ks will be discussed. Class 1A PI3Ks 
are composed of heterodimers of an inhibitory adaptor/regulatory (p85α, p55α, p50α, p85β, 
p55γ) and a catalytic (p110, p110β, p110δ) subunit. Only p110α and p85α have been found 
to be mutated and p85α to be translocated in cancer. The p85 protein binds, via two SH2 
domains and integrates signals from activated receptors via phosphorylated tyrosine residues 
(certain receptors directly e.g. PDGFR (Hu et al., 1992) and others e.g. EGFR, FGFR and 
nerve growth factor indirectly via docking proteins such as GRB2-associated binding protein 
1 (Gab1) and Gab2 (Holgado-Madruga et al., 1996; Holgado-Madruga et al., 1997; Ong et 
al., 2001) and intracellular proteins like protein kinase C (PKC), SHP1, Rac, Rho, hormone 
receptors, mutated Ras and Src, providing an integration point for activation of p110 and 
subsequent downstream molecules (Otsu et al., 1991; Pawson & Nash, 2000; Yuan & 
Cantley, 2008). Upon activation, PI3Ks phosphorylate phosphatidylinositol-4, 5-
bisphosphate (PtdIns (4, 5) P2 (PIP2) to form PtdIns (3, 4, 5) P3 (PIP3) in the membrane 
which functions as a second messenger to activate downstream targets. This is achieved by 
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recruitment of proteins that contain a subset of pleckstrin homology (PH) domains 
(Bottomley et al., 1998). 
PIP3 levels are tightly controlled under non-stimulated conditions, due to tight regulation of 
PI3K and the function of PIP3 phosphatases PTEN (phosphatase and tensin homolog gene 
on chromosome 10), SHIP1 and SHIP2 (Huber et al., 1999; Maehama & Dixon, 1998; 
Pesesse et al., 1997). 
PTEN is one the most commonly mutated tumour suppressors in human cancer. Frequent 
genetic inactivation of PTEN occurs in glioblastoma, endometrial cancer, prostate cancer, 
and reduced expression is found in many other tumor types such as NSCLC and breast 
cancer (Steck et al., 1997). In SCLC, PTEN mutations are not common (Forgacs et al., 
1998). PTEN acts as a phosphatase to dephosphorylate PIP3 to PIP2 resulting in inhibition 
of the AKT signaling pathway. 
Genetic screens have identified AKT (Protein Kinase B) as the primary downstream 
mediator of the effects of PI3K.Upon activation; PI3Ks phosphorylate phosphatidylinositol-
4, 5-bisphosphate (PtdIns (4, 5) P2 (PIP2) to form PtdIns (3, 4, 5) P3 (PIP3) in the 
membrane which functions as a second messenger to activate downstream targets. This is 
achieved by recruitment of proteins that contain a subset of pleckstrin homology (PH) 
domains (Bottomley et al., 1998). PIP3 levels are tightly controlled under non-stimulated 
conditions, due to tight regulation of PI3K and the function of PIP3 phosphatases PTEN 
(phosphatase and tensin homolog gene on chromosome 10) SHIP1 and SHIP2 (Huber et al., 
1999; Maehama & Dixon, 1998; Pesesse et al., 1997). 
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I.4 Downstream effectors of PI3Ks- AKT and mTOR 
AKT 
Akt is the cellular homologue of the viral oncogene v-akt (Bellacosa et al., 1991). It is a 
57kDa serine/threonine kinase that is related to human protein kinase A (PKA) and PKC 
(Coffer & Woodgett, 1991). There are three known AKT isoforms- AKT1-3, which are 
derived from three distinct genes. It has a PH domain that allows it to bind to PIP2 and PIP3 
in the inner surface of the plasma membrane, over other PIs (James et al., 1996). However 
for full activation, two amino acids must be phosphorylated: One in the kinase domain 
(threonine 308 in AKT1), phosphorylated by constitutively active phosphoinositide-
dependent kinase 1 (PDK1), which allows for stabilizing the activation loop, whilst 
phosphorylation of the other in the hydrophobic C-terminal domain (serine 473 in AKT1) 
by PDK2 is necessary for full activation (Alessi et al., 1996).Until recently the identity of 
PDK2 has been a mystery. It was found to be the mammalian target of rapamycin (mTOR)-
rictor (rapamycin-insensitive companion of mTOR) complex (see later) (Sarbassov et al., 
2005). Hence mTOR lies above and below AKT in the signaling pathway. 
Once activated, AKT translocates to the cytoplasm to activate many downstream effectors 
with a wide range of cellular effects (Figure 1.4). AKT has been implicated in human cancer. 
AKT2 is amplified in pancreatic, breast and ovarian cancers and point mutations in AKT2 
have been found in colorectal cancer (Bellacosa et al., 1995; Cheng et al., 1992; Cheng et al., 
1996; Parsons et al., 2005). AKT3 is overexpressed in hormone-insensitive breast and 
prostate cancers (Testa & Bellacosa, 2001). 
The discussion will now focus in depth on one of the downstream targets of AKT, the 
subject of this thesis- mTOR. 
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The mammalian Target of Rapamycin- mTOR 
mTOR was discovered 16 years ago, whilst investigating the mechanism of action of its 
original inhibitor–Rapamycin. Rapamycin, which is a macrolide antibiotic product, was 
isolated from a soil sample on the south Pacific island of Easter Island (known as Rapa Nui 
to the inhabitants). Rapamycin is produced by Streptomyces hygroscopicus and was initially 
used as an antifungal agent (Vezina et al., 1975). 
Later the drug was found to have immunosuppressive activity which led to its use with 
Cyclosporine A against organ transplant rejection. Rapamycin was then evaluated by the 
Developmental Therapeutic Branch of the National Cancer Institute (NCI), it was found to 
be a non-cytotoxic agent, with cytostatic activity against several human cancers in vitro and 
in vivo. Rapamycin’s exact mechanism of action was not known at the time, however in the 
early 1990s, it was found that it acted as an inhibitor of cellular proliferation and cell cycle 
progression (Dumont et al., 1990; Flanagan & Crabtree, 1993). In 1991 a group in 
Switzerland discovered two new genes in Saccharomyces cerevisiae, the target of rapamycin 
(TOR) genes (TOR1 and TOR2) (Heitman et al., 1991). These genes were then discovered 
in mammals and named mTOR (Brown et al., 1994). TOR was found to have structural 
similarities with several known phosphatiylinositol kinases (PIKK) including PI3K (Helliwell 
et al., 1994). mTOR is a 289 kDa serine/threonine kinase, which plays a critical role in 
regulating basic cellular functions including growth and proliferation It also acts as a central 
controller, integrating a plethora of signaling pathways which responds to growth factors and 
nutritional status. The signaling pathways that activate mTOR are altered in many cancers. 
 
Structure 
 
mTOR consists of several conserved motifs (Figure 1.5A). At the N-terminus are two 
tandem arrays of HEAT repeats (Huntington, Elongation factor 3 (EF3), A subunit of 
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protein phosphatase 2A (PP2A), TOR1), that are considered to be protein-protein 
interaction domains (Andrade & Bork, 1995). Downstream of the HEAT repeats, is a region 
conserved in PIKK family members called the FRAP–ATM–TTRAP (FAT) domain. 
Phosphoinositide-3-kinase-related protein kinase (PIKK) members with a FAT domain also 
possess a c-terminal FATC domain. The FAT and FATC might contribute to the active 
conformation of the intervening catalytic kinase domain (Bosotti et al., 2000). The FKBP-12 
rapamycin-binding domain (FRB) is required for the binding of the rapamycin-FKBP12 
complex to mTOR (Chen et al., 1995; Choi et al., 1996).  
Rapamycin has a unique mechanism of action. It first binds the cytosolic 12-kDa 
immunophilin FK506-binding protein (FKBP12) and this complex as mentioned binds to 
the FRB domain of mTOR. Point mutation in the FRB domain result in rapamycin 
resistance (Chen et al., 1995).It ‘normally’ plays a role in immunoregulation and basic cellular 
processes involving protein folding and trafficking (Avila et al., 2003). The catalytic domain 
(CD) of mTOR contains autophosphorylation sites as well as the ATP-binding site. The 
regulatory domain region of mTOR contains sites that are phosphorylated in response to 
growth factors, but it is not clear how this affects mTOR function (Nave et al., 1999; Scott 
et al., 1998; Sekulic et al., 2000). 
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Molecule Alteration in 
tumours 
Frequency Tumour type 
PTEN 
 
PTEN 
 
 
PTEN 
 
P85 
P85 
P55γ(p85 
isoform) 
PIK3CA 
 
PIK3CA 
 
AKT1 
AKT2 
AKT2 
AKT3 
PDK1 
S6 Kinase 1 
TSC1/2 
Forkhead 
family 
TCL1 
Mutations (somatic) 
 
Decreased expression, 
methylation, LOH 
 
Germline mutations 
 
Activating mutations 
Fusion 
Deletion mutations 
 
Amplification 
 
Activating mutation 
 
Amplification 
Amplification 
Mutation 
Overexpression 
Mutation 
Amplification 
Mutation 
Translocations 
 
Rearrangement 
 
 
 
>50% 
 
>50% 
 
 
80% of Cowdens  
 
Rare 
Very rare 
Unknown 
 
Up to 50% 
 
>50% 
>25% 
Low 
Low 
Low 
Low 
Low 
30% 
>50% 
>50% 
Low 
Unclear 
Glioma, melanoma, prostate, endometrial, 
variable in sporadic breast cancer 
Breast, melanoma, prostate, microsatellite 
instability-high colorectal cancer, 
endometrial cancer, Leukaemia 
High risk of breast, thyroid and 
endometrial carcinomas 
Ovary, colon, glioma 
Lymphoma 
Lung cancer cell line (HCC15) 
 
Ovary, cervix, lung, breast 
 
Bowel 
Breast 
Gastric 
Ovary, Pancreas 
Colorectal 
Hormone-resistant prostate, breast 
Colorectal 
Breast 
Tuberous sclerosis 
Alveolar rhabdomyosarcoma 
Acute leukaemia 
T-cell leukaemia 
Chronic lymphocytic leukaemia 
 
Table 1.4 Abnormalities in the PI3K/AKT signaling pathway in cancer 
PIk3CA, gene encoding the p110α PI3K subunit; PDK1 phosphoinositide-dependent 
kinase-1; PTEN, Phosphatase and Tensin Homolog; TCL1, T-cell leukaemia 1; TSC, 
tuberous sclerosis complex. 
 
Adapted from Hennessy et al Nat.Rev. Drug Discov 4:12 988-1004 (Hennessy et al., 2005)  
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Figure 1.4 PI3K/AKT signaling 
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Activation of RTKs by growth factors leads to activation of PI3K and then AKT. AKT 
activation leads to multiple effects such as growth, prevention of apoptosis and DNA repair. 
FKHR, (Forkhead homolog 1 rhabdomyosarcoma forkhead); GSK3 (glycogen synthase 
kinase 3); NF-κB (nuclear factor-κB); BAD (Bcl-2-associated death promoter); MDM2 
(murine double minute oncogene); PTEN (phosphatase and tensin homolog gene on 
chromosome 10) PIP2 (phosphatidylinositol-4, 5-bisphosphate (PtdIns (4, 5) P2); PIP3 
(phosphatidylinositol-4, 5-bisphosphate (PtdIns (4, 5) P3). 
mTOR nucleates two separate complexes- a rapamycin, nutrient and growth factor sensitive 
multiprotein complex called mTORC1 (Hara et al., 2002; Kim et al., 2002; Loewith et al., 
2002) and a rapamycin and nutrient ‘insensitive’, growth factor sensitive multiprotein 
complex called mTORC2 (Jacinto et al., 2004; Loewith et al., 2002; Sarbassov et al., 2004). 
mTORC2 does not bind rapamycin, proving that rapamycin does not block all of mTOR’s 
functions. However, recent data suggest that prolonged treatment with rapamycin may affect 
mTORC2 assembly and Akt signaling but only in certain cell types (Sarbassov et al., 2006). 
mTORC1 (Figure 1.5B) consists of mTOR, RAPTOR (regulatory associated protein of 
mTOR), LST8 homolog (mLST8) (also known as GβL) and PRAS40 (proline rich AKT 
substrate 40kDa) (Hara et al., 2002; Kim et al., 2002). RAPTOR functions as a scaffold for 
recruiting mTORC1 substrates (Hara et al., 2002; Kim et al., 2002; Schalm et al., 2003). 
PRAS40 negatively regulates mTOR by binding to the mTOR kinase domain, its interaction 
with mTOR is induced under conditions that inhibit mTOR signaling, such as nutrient or 
serum deprivation (Vander Haar et al., 2007). The function of mLST8 is presently not 
known. 
The mTORC2 (Figure 1.5C) complex consists of mTOR, rapamycin-insensitive companion 
of mTOR (RICTOR), mammalian stress-activated protein kinase interacting protein 1 
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(mSIN1), Protein observed with RICTOR (PROTOR-1 protein), mLST8 and proline rich 
protein 5 (PPR5) (Frias et al., 2006; Jacinto et al., 2004; Pearce et al., 2007; Sarbassov et al., 
2004). 
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Figure 1.5 Structure of mTOR and mTOR complexes 
(A) Functional regions of mTOR. The domain structure consists of about 20 tandem amino 
acid sequences called HEAT repeats (for Huntingtin, EF3, A subunit of PP2A) at the NH2 
terminal end, followed by the conserved FAT domain, FRB (FKBP12-rapamycin binding), 
the catalytic domain and the FATC domain (FAT domain close to the C-terminus). 
(B) mTORC1 complex consists of mTOR, mLST8, Raptor (regulatory associated protein of 
mTOR), PRAS40 
(C) mTORC2 complex consists of mTOR, mLST8, Rictor (rapamycin-insensitive 
companion of mTOR), Proctor-1, mSIN1. 
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Figure 1.6 mTOR signaling 
Diagram illustrating the mTOR signaling network. Growth factors/insulin initiates signaling 
leading to activation of PI3K. The lipid products of PI3K, PIP3 recruit both PDK1 and Akt 
to the plasma membrane. Akt is subsequently phosphorylated on T308 by PDK1 and by 
mTORC2 leading to full activation. Akt then phosphorylates numerous targets to promote 
growth and survival, including the TSC1/2 complex. By phosphorylating TSC2, Akt 
inactivates TSC2s GAP activity for the small G protein Rheb.GTP-bound Rheb is a potent 
activator of mTORC1.mTORC1 phosphorylates many targets, including the translation 
control proteins S6K1 and 4EBP1. 
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mTOR activation/inactivation 
The mTORC1 pathway is activated by growth factors such as EGF, PDGF, IGF-I and 
FGFs (Bjornsti & Houghton, 2004), nutrients and mitogens (Figure 1.6). 
Growth factors activate mTORC1 via the activation of PI3K and its downstream effector-
Akt (Gingras et al., 1998). Akt achieves this by directly phosphorylating the tuberous 
sclerosis complex 2 (TSC2) (Inoki et al., 2002; Manning et al., 2002).  
 TSC1/2 is a heterodimer and consists of TSC1- harmatin and TSC2- tuberin (Gao et al., 
2002). Akt phosphorylates TSC2 (Inoki et al., 2002) which leads to inhibition of TSC2’s 
GTPase-activity (GAP). TSC2’s heterodimerization with TSC1 allows it to exert a GAP 
activity toward the small GTPase called Rheb (Ras homolog enriched in brain). Rheb is a 
positive regulator of mTORC1. The active, GTP-bound form of Rheb binds directly to and 
stimulates mTORC1 (Long et al., 2005a). TSC acts as a signal-modulated suppressor of Rheb 
by driving Rheb into the inactive, GDP-bound state. Thus Akt stimulates the accumulation 
of GTP-bound Rheb, which in turn promotes the activation of mTORC1 by disrupting the 
TSC complex through phosphorylation of the TSC2 subunit (Crino et al., 2006). 
Mutations in either TSC1 or TSC2 lead to the hamartomatous syndrome tuberous sclerosis, 
a cancer prone syndrome characterized by harmartomas in the brain, heart, kidney and skin 
(Brugarolas & Kaelin, 2004). An increase risk of renal cell carcinoma is also observed. This 
was the first documented molecular link between mTOR and cancer. 
The best described downstream effectors of mTORC1 are S6K1 (Ribosomal p70 S6 kinase 
1) and the eukaryotic initiation factor 4E Binding Protein 1 (4E-BP1). Phosphorylation of 
these targets by mTORC1 is mediated by sequences present on both 4EBP1 and S6K1 
called TOS (target of rapamycin signaling) motifs (Schalm & Blenis, 2002). The protein 
raptor (a component of mTORC1), allows for the phosphorylation of 4EBP1 by binding to 
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the TOS domain of 4EBP1 and bringing it close to mTOR (Hara et al., 2002; Kim et al., 
2002; Nojima et al., 2003; Schalm et al., 2003). Phosphorylation of 4EBP1 results in the 
release of eukaryotic translation initiation factor 4E (eIF4E) from 4EBP1 (Mader et al., 
1995). eIF4E then binds to eIF4G and with other translation initiation factors translates 
RNA transcripts containing a 5’ m7GTP cap (Pause et al., 1994). These RNA transcripts 
include cell cycle regulating proteins like ornithine decarboxylase 1 (ODC1) and cyclin D1. 
Other important proteins translated include c-MYC and hypoxia inducible factor 1α (HIF1α) 
(Hashemolhosseini et al., 1998; Mayerhofer et al., 2002; Rosenwald et al., 1995; Shantz & 
Pegg, 1994; Zhong et al., 2000). 
Activation of S6K1 is via phosphorylation by mTOR. How this occurs is not clear. Direct 
phosphorylation of S6K1 has been reported (Burnett et al., 1998) however another 
mechanism has been suggested in which mTOR kinase activity represses the activity of a 
serine/threonine phosphatase (protein phosphatase 2A;PP2A) physically associated with 
S6K1 (Peterson et al., 1999). 
S6K1 promotes protein synthesis by phosphorylating the tumour suppressor programmed 
cell death 4 protein (PDCD4) and targeting it for degradation (Dorrello et al., 2006). 
PDCD4 prevents protein translation by binding and preventing the eIF4A helicase from 
unwinding secondary structure in the 5’ untranslated region of mRNA. Ribosomal S6 is the 
best characterized substrate of S6K1. Phosphorylation of this protein leads to the initiation 
of mRNA translation with a 5’-terminal oligopyrimidine (5’-TOP), which includes mRNAs 
that encode ribosomal proteins and elongation factors (Brown et al., 1995; Burnett et al., 
1998; Seufferlein & Rozengurt, 1996b).  
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Other mTORC1 substrates include CLIP-170, LIPIN and STAT3 but their roles in 
mTORC1 signaling are less clear (Choi et al., 2002; Huffman et al., 2002; Yokogami et al., 
2000). 
Details of mTORC2 regulation are less clear than mTORC1. Growth factors stimulate 
mTORC2 activity, which leads to direct phosphorylation of Akt and negative regulation of 
FOXO1A (Sarbassov et al., 2005). Akt is phosphorylated at S473 by mTORC2 which is 
necessary for full activation (Figure1.6). Another function of Akt is in regulation of the actin 
cytoskeleton and protein kinase C (Bjornsti & Houghton, 2004; Guertin & Sabatini, 2007; 
Jacinto & Hall, 2003; Schmelzle & Hall, 2000; Wullschleger et al., 2006). However further 
work is needed to clarify this role. 
A decrease in the concentration of amino acids in a cell rapidly inactivates mTOR. Exactly 
how this is achieved is not clear but it does seem to be mediated by Rheb and not TSC 
(Nobukuni et al., 2005; Smith et al., 2005). Increased expression of Rheb in mammalian cells 
leads to a failure of mTOR activity to be inhibited in response to amino acid deprivation 
(Long et al., 2005b). TSC does not seem to regulate Rheb in response to amino acid 
deprivation (Smith et al., 2005). 
Another downregulator of mTOR is low cellular energy levels (Inoki et al., 2003). Changes in 
energy levels are sensed by a change in the concentration of intracellular adenosine 
monophosphate (AMP) (resulting from the cleavage of ATP). Elevated AMP levels lead to 
the association of AMP with AMP-dependent protein kinase (AMPK). This association 
converts the enzyme into a substrate for phosphorylation by the kinase serine/threonine 
kinase 11 (STK11)/LKB1. This phosphorylation leads to activation of AMPK. Activated 
AMPK then directly phosphorylates TCS2 and activates the GAP function of TSC2. The 
activation of TSC2 results in an increase in the population of the inactive GDP-bound form 
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of Rheb and leads to downregulation of mTOR activity (Shaw et al., 2004; Woods et al., 
2003). 
Hypoxia leads to rapid inactivity of mTOR, as measured by autophosphorylation and 
phosphorylation of 4E-BP1 and S6K1. Again the mechanism is not known but may involve 
Rheb and TSC2 (Arsham et al., 2003).  
This information shows that the protein Rheb acts as a gatekeeper to mTOR activity, 
sensing the cellular environment for conditions favorable to growth. 
 
mTOR and cancer 
mTOR is an attractive anti-cancer target since in many malignancies distinct mechanisms can 
result in constitutive activation of the PI3K/AKT/mTOR pathway.  
PTEN, the phosphatase that negatively regulates PI3K, is mutated, silenced or deleted in 
many cancers (Table 1.4). The result is an upregulation or constitutive activation of Akt and 
hence mTOR. As previously mentioned, activating mutations in Akt2 or gene amplification 
of Akt2, are also frequently seen in malignancy (Table 1.4). 
Mutations in TSC proteins lead to the cancer prone tuberous sclerosis syndrome. 
Inactivating mutations in the kinase LKB1 are associated with Peutz-Jeghers cancer prone 
syndrome (Park et al., 1998). Inactivation of LKB1 leads to inhibition of the ability of 
AMPK to activate TSC2, which would happen in low energy conditions. Since TSC2 inhibits 
Rheb, the result is that LKB1 mutations lead to a higher level of mTOR activity under low 
energy conditions.  
There are no known mutations of mTOR (Rosner et al., 2008) however, recently it has been 
shown that increased mTOR staining is linked to adverse prognosis in breast, biliary cancers 
and gastric cancers (Herberger et al., 2007; Murayama et al., 2009; Zhou et al., 2004). 
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Downstream of mTOR, cancer related changes are seen in some malignancies. For example, 
S6K1 is overexpressed in certain tumour cell lines (Pardo et al., 2001) and in the early stages 
of transformation in ovarian surface epithelium associated with BRAC1 mutations (Wong et 
al., 2001). In certain breast cancers S6K1 is also amplified (Couch et al., 1999). 
The gene coding eIF4E is altered in many cancers. Amplification is seen in head and neck, 
ductal breast, and thyroid cancers (Haydon et al., 2000; Sorrells et al., 1999; Wang et al., 
2001). The levels of eIF4E are raised in some colon cancers and also increased in some 
bladder and breast cancers that have a poor prognosis (Berkel et al., 2001; Crew et al., 2000; 
Li et al., 2002; Rosenwald et al., 1999). 
 
 mTOR and lung cancer 
Since the focus of this thesis is lung cancer, the discussion will now turn to mTOR and lung 
cancer. 
Many lines of evidence point to the importance of deregulated PI3K/Akt/mTOR signaling 
in lung cancer. This pathway was found to mediate the effects of RTKs, such as c-Met, 
EGFR, c-Kit and IGF-IR on proliferation and survival in SCLC and NSCLC (Arcaro et al., 
2002; Krystal et al., 2002; Mukohara et al., 2003; Pisick et al., 2004; Tsao et al., 2005). In 
primary lung carcinomas, overexpression of p85α and p110α subunits of PI3K has been 
reported (Lin et al., 2001). Amplification of PIK3CA was also observed in many lung 
cancers and in pre-invasive bronchial lesions (Massion et al., 2004). 
As previously mentioned, PTEN mutations are not common in SCLC (only in 15%)(Burbee 
et al., 2001; Yokomizo et al., 1998) but more common in NSCLC (Steck et al., 1997). 
Regarding Akt, increased phosphorylation was reported in pre-malignant (metaplastic) and 
malignant human bronchial epithelial cells as compared to normal bronchial cells and 
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responses to a new pro-apoptotic drug were higher in those with greater Akt activation levels 
(Chun et al., 2003). Other studies showed that phosphorylation or overexpression of Akt 
correlated with poor prognosis in NSCLC patients with stage I disease or with primary 
tumours (David et al., 2004; Tsurutani et al., 2007).  
Data from our group (Seckl laboratory) have shown that mTOR is overexpressed in SCLC 
cell lines as compared to primary normal lung epithelial cells (Arcaro et al., 2002; Marinov, 
2009) and over expressed in SCLC patient samples as compared to normal lung tissue 
(Pardo et al., 2006).  
Activation of PI3K pathway has been shown to increase resistance to chemotherapy and 
radiotherapy (Brognard et al., 2001). Inhibition of PI3K led to increased sensitivity of lung 
cancer cells to radiotherapy (Gupta et al., 2004) and chemotherapy (Krystal et al., 2002). 
Subsequently RAD001 (Everolimus), an mTOR inhibitor/rapalogue sensitized NSCLC cells 
to cisplatin chemotherapy (DNA damaging agent), by down-regulation of p21, which is 
essential for DNA repair (Beuvink et al., 2005). 
Similar studies in SCLC showed that another mTOR inhibitor CCI-779 (Temsirolimus) 
sensitized cisplatin-resistant SCLC to the effects of cisplatin (Wu et al., 2005). Again at the 
cell line level rapamycin can inhibit growth in some lung cancer cell lines and produce cell 
cycle arrest (Boffa et al., 2004; Sun et al., 2005).  
Human and murine preneoplastic lung lesions induced by tobacco exposure are 
characterized by increased activation of the Akt/mammalian target of rapamycin (mTOR) 
pathway, suggesting a role for this pathway in lung cancer development. It was found that 
when mice were exposed to the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone, those given rapamycin, led to markedly reduced development and 
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growth of tumors suggesting that tobacco carcinogen-induced lung tumors in mice are 
dependent upon mTOR (Granville et al., 2007). 
Multiple NSCLC cell lines when treated with mTOR inhibitors leads to a decrease in 
phosphorylation of 4E-BP1 and S6K1 and paradoxically to an increase in phosphorylation 
of Akt (Boffa et al., 2004; Buck et al., 2006; Sun et al., 2005). This is likely to be due to an 
inhibition of a normally occurring feedback loop. The underlying mechanism for this are 
that mTOR inhibitors/rapalogues activate AKT through IGF-1R (Wan et al., 2007). Akt 
phosphorylation may lead to an increase in tumour survival (O'Reilly et al., 2006; Shi et al., 
2005; Wan et al., 2007).  
Unfortunately, CCI-779 did not improve patient survival but did improve progression free 
survival, when administered as a single agent as maintenance therapy in a Phase II clinical 
trial for SCLC patients after previous chemotherapy (Pandya et al., 2005). This trial did not 
utilize a placebo control arm instead used 2 different doses of mTOR inhibitors. 
In the FGF growth factor family, the role of FGF-2 has been elucidated in SCLC and it has 
been found to promote proliferation and chemoresistance in these cells (Pardo et al., 2002; 
Pardo et al., 2001). These effects were found to be consistent with and dependent on 
activation of MEK/ERK signaling in these cells and a novel cross-talk between MEK/ERK 
and ribosomal S6 kinase 2 (S6K2). The FGF-2 induced survival against the 
chemotherapeutic agent etoposide in SCLC cells was found to be regulated by increased 
translation of the anti-apoptotic proteins Bcl-XL, Bcl-2 and IAPs (Pardo et al., 2003). It was 
also shown that FGF-2 treatment of SCLC cells results in the formation of a signaling 
complex comprising PKCε, B-Raf and S6K2, which promotes growth factor prosurvival 
effects (Pardo et al., 2006). 
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S6K2 is a serine/threonine kinase identified as a homologue of S6K1. S6K1 and S6K2 show 
different cellular localization as well as divergent amino acid sequences in the non-catalytic 
N- and C-terminal domains, suggesting that their cellular functions and/or regulation may 
not be identical (Lee-Fruman et al., 1999). Other differences include from animal knockout 
studies show no phenotype for S6K2 -/- but small animals in the S6K1-/. (Pende et al., 2004) 
and that unlike S6K2, MEK/ERK signaling is not required for S6K1 activation by several 
growth factors including FGF-2 (Pardo et al., 2001). Nevertheless, some investigators have 
found that S6K1 and S6K2 are regulated by mTOR although others have found that there is 
a differential effect of mTOR inhibitors/rapalogues on S6K1 and S6K2 activity. Work from 
the Seckl laboratory has shown that at low rapamycin concentrations, growth factor-induced 
S6K1 activation is selectively inhibited without effect on S6K2. In contrast, at 10-fold higher 
concentrations of rapamycin, there is a partial inhibition of S6K2 activation, which 
correlates, with inhibition of MEK/ERK signaling (Pardo et al., 2001) (Figure 1.7).  
Both mTOR and its downstream target S6K1 are known to be involved in growth factor 
induced proliferative signaling and S6K2 was recently implicated in FGF-2-induced 
chemoresistance (Pardo et al., 2006). The potential for rapamycin or similar drugs to block 
FGF-2-induced chemoresistance in lung cancer at high as opposed to low concentrations 
needs investigation and could be relevant in the development of new therapeutic strategies. 
This information clearly indicates that targeting mTOR is a promising therapeutic approach 
in lung cancer. 
The discussion will now focus on the drugs which inhibit mTOR. 
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mTOR inhibitors 
As mentioned rapamycin is a natural antibiotic, a macrocyclic lactone, produced by 
Streptomyces hygroscopicus, a soil bacterium native to Easter Island (Rapa Nui). It is the 
original mTOR inhibitor. 
Rapamycin/Sirolimus forms a ternary complex with FKBP12 and mTOR (Figure 1.8). This 
complex then leads to inhibition of mTOR signaling by binding to FRB region of mTOR. 
Structural studies indicate that there are relatively few contacts between the proteins (Choi et 
al., 1996) This suggests that when FKBP12 binds to rapamycin, this may place rapamycin 
into a position to allow for interaction with mTOR. Other mTOR inhibitors have been 
developed; they all are the result of minor modifications to the structure of rapamycin, 
making them more soluble and stable. They are known as ‘rapalogues’. They are CCI-779/ 
Temsirolimus (Wyeth), RAD001/Everolimus (Novartis), and AP23573/Deforolimus 
(Ariad).The differences are made by modifications of the C40 hydroxyl position of 
rapamycin. Most have substituted this group for an ester or ether. AP23573 substitutes a  
phosphonate for the C40 hydroxyl. CCI-779 is a pro-drug; metabolized to rapamycin in the 
body. Despite these relatively new agents, novel mTOR inhibitors have been developed 
which bind to the ATP site and therefore target mTORC1 and mTORC2 (Feldman et al., 
2009). These molecules are pyrazolopyrimidines and also inhibit other members of the PI3K  
family, including mTOR (Apsel et al., 2008). Two of these molecules, PP242 and PP30 are 
potent selective and ATP-competitive inhibitors of mTOR. These molecules have been 
named TORKinibs for TOR kinase domain inhibitors. Recent data suggest that these agents 
are more active than rapamycin with respect to inhibiting proliferation and are active in 
situations where cells are resistant to rapamycin (Feldman et al., 2009). 
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Figure 1.7 S6K1 and S6K2 are regulated differently with respect to mTOR 
 
(A) The effect of increasing doses of Rapamycin on S6K1 and S6K2 activation by FGF-2 as 
assessed by kinase assay. 
(B) The effect of increasing doses of Rapamycin on FGF-2 induced ERK1/2 
phosphorylation in H510 SCLC line. 
 
From Pardo et al 2002 
 
 
A 
B 
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Figure 1.8 Structure of rapamycin 
Chemical structure of rapamycin, in the conformation known to bind FKBP12 and the 
FKBP12 rapamycin binding domain of mTORC1 complex. 
 
Taken from Molecular Targeting in Oncology, 2008, Kaufman et al. 
 
 
 
 
FKBP12 
mTORC1 
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Effects of mTOR inhibition 
Cell cycle arrest (G1 arrest) is a major effect of blocking mTOR, be that in yeast by deletion 
of TOR1 or by using rapamycin in mammalian cells (Cafferkey et al., 1994; Fingar et al., 
2004). mTOR inhibitors prevent phosphorylation of 4EBP1; which then inhibits m7GTP 
cap-dependent translation, particularly of proteins essential for cell cycle progression such as 
c-MYC, ODC and cyclin D. Not only is the translation of these proteins blocked but the 
level of p27 kip1; an inhibitor of CDK2 is increased. CDK2 is required for cell cycle 
progression to S-phase. How this happens is not clear (Barata et al., 2001). The cell cycle 
effects are not the same in all cells, and are probably dependent on cell type and genetic 
changes in the individual cells. 
Treatment of certain cell types with rapamycin leads to apoptosis. Two proteins have been 
implicated namely c-MYC and Akt. c-MYC translation is regulated in part by cap-dependent 
mechanisms, thus it is dependent on eIF4E. c-MYC has both anti and pro apoptotic effects 
(Secombe et al., 2004). Akt phosphorylates the pro-apoptotic protein BAD (BCL-2 
associated death promoter)(Datta et al., 1997). 
Under serum free conditions, rapamycin treatment causes apoptosis in tumour cell lines with 
mutated p53. Overexpression of wild type p53 or p21 protects these cells from rapamycin 
induced apoptosis (Huang et al., 2001). Apoptosis, from treatment with rapamycin on p53 
mutant cells is a result of stress-dependent activation of the c-Jun N-terminal kinase (JNK) 
pathway. Activation of JNK pathways is dependent on the presence of 4EBP1 and its ability 
to bind eIF4E when mTOR is inhibited by rapamycin (Huang et al., 2003). 
The mTOR pathway is involved in angiogenesis through regulation of HIFα. HIFα is a 
primary activator of VEGF (Jiang et al., 2001; Laughner et al., 2001). Treatment of 
endothelial cells with rapamycin reduces production of VEGF (Guba et al., 2002). 
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mTOR in clinical trials 
Once the original identification of the anti-cancer effects of rapamycin were established, 
rapamycin and later analogues have been tested on many tumour cell lines and xenograft 
tumour models (Douros & Suffness, 1981; Eng et al., 1984; Houchens et al., 1983). 
Proliferation was inhibited in many cell lines including rhabdomyosarcoma, glioblastoma, 
small cell lung carcinoma and renal cell carcinoma (Dilling et al., 1994; Hosoi et al., 1998; 
Seufferlein & Rozengurt, 1996b).  
Starting with Temsirolimus, which has been extensively used in clinical trials and has recently 
been approved for use in the US for advanced renal cell carcinoma (Hudes et al., 2007). 
A phase I clinical study looked at daily and weekly intravenous use. There were significant 
toxicities with daily use such as hypocalcaemia, vomiting, thrombocytopenia and hepatic 
transaminase increases. Weekly schedules did not reveal any grade 3 toxicities (Dancey, 
2002). Based on the results from phase I clinical trials phase II studies were set up with 
advanced stage renal cell carcinoma, refractory mantle cell lymphoma and metastatic breast 
cancer. 
A phase II trial in renal cell carcinoma showed an increase in survival (4 months) (Atkins et 
al., 2004). In mantle cell lymphoma a small increase in time to progression was observed as 
compared to placebo (Witzig et al., 2005). Advanced breast cancer patients responded 
reasonably well- overall response rates were around 9% (Chan et al., 2005). 
Data from these trials and others using RAD001 indicate that the drugs are well tolerated 
and safe (Fouladi et al., 2007; J. C. Yao, 2007). 
A phase III clinical trial showed that as compared with interferon alfa, temsirolimus 
improved overall survival significantly among patients with metastatic renal-cell carcinoma 
with a poor prognosis (Hudes et al., 2007), showing proof of principle that this class of drug 
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can improve survival in cancer patients. Many other phase II/III trial are on going in many 
cancer types (Strimpakos et al., 2008).  
However good these results are, the overall picture at the clinical trial level is somewhat 
disappointing with single agent mTOR inhibitors showing promise in only a few types of 
malignancy. It is not clear how to combine mTOR inhibitors with existing therapies. 
Biomarkers are needed to identify which patients may respond to these drugs. The new 
mTOR kinase inhibitors may provide more impressive results. 
Clearly the mTOR pathway and mechanism of action of mTOR inhibitors are not 
completely understood. 
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I.5 The Thesis 
Rapamycin and the clinically relevant orally bioavailable derivative RAD001 and CCI-779 are 
inhibitors of mTOR. It has previously been shown that low concentrations of rapamycin 
selectively inhibit mTOR/S6K1 mediated proliferation induced by FGF-2 (Pardo et al., 
2001). In preliminary experiments, it was shown that low concentrations of rapamycin or 
RAD001 blocks proliferation induced by multiple growth factors in H510 and H69 SCLC 
cells in vitro. Moreover, orally administered RAD001 blocks H69 xenograft growth in vivo. 
Thus, inhibition of mTOR may provide a useful therapeutic strategy for SCLC by blocking 
tumour proliferation.  
Furthermore as mentioned, clinical data suggests that the mTOR inhibitor-CCI-779, when 
used as maintenance therapy after initial chemotherapy for SCLC prolongs the time to 
relapse (Pandya et al., 2005). Intriguingly, rapamycin may also block prosurvival signals in 
SCLC cells. As mentioned it has also previously been shown that higher concentrations of 
rapamycin block MEK/ERK and S6K2 signaling which is necessary for pro-
survival/chemoresistance effects induced by FGF-2 in SCLC cells (Pardo et al., 2001). 
At least two explanations for this observation can be envisaged:  
i) the drug is hitting a second target or 
ii) High concentrations of drug cause an additional conformational change in 
FKBP12/mTOR resulting in these secondary effects.  
Importantly, the original data with rapamycin suggest that at higher, but clinically achievable 
concentrations, this compound blocks chemoresistance induced by FGF-2 in SCLC cells. 
Can the more clinically relevant RAD001 do the same? If so, one might expect that adding 
an mTOR inhibitor such as RAD001 to chemotherapy should result in additive and/or  
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synergistic effects. Since it is possible that sequencing of the drugs may effect whether 
additive/synergistic as opposed to antagonistic effects are seen, it will also be determined 
whether giving RAD001 before or after cisplatin or etoposide makes a difference to cell 
death.  
In this study to further investigate these findings both in SCLC and NSCLC cell lines and 
tissue biopsies, we will determine the following: 
-What is the expression of mTOR in lung cancer biopsy specimens and how does this relate 
to clinical outcome?  
-Do high concentrations of RAD001 like rapamycin also block FGF-2-induced 
MEK/ERK/S6K2 activation and chemoresistance and is this dependent on mTOR or 
another target? 
-Assessment of the combination of mTOR inhibitors with cytotoxic drugs in vitro. 
 
The information derived from these studies should provide new mechanistic information 
and help to underpin phase I/II trials of mTOR inhibitors in lung cancer. 
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CHAPTER II 
 
 
 
Materials and Methods 
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II.1 Materials 
 
Cell lines 11.1.1 
 
 
Cell Line HCC 78 HCC 95 MCF-7 
Source Non-small cell lung 
carcinoma 
(Adenocarcinoma) 
pleural effusion 
Non-small cell lung 
carcinoma (Squamous), 
pleural effusion 
Breast  
Adenocarcinoma, pleural 
effusion 
Gender, Age M, 65 years M,65 years F, 69 years 
Karyotype data hypotetraploid 
karyotype 
 Modal chromosome 
number=82 
Range =66 to 87, tetraploid 
Morphology Adherent epithelial cells Adherent epithelial cells Adherent epithelial cells 
Growth Medium DMEM with 10%FCS, 
100units/ml 
penicillin,100μg/ml 
streptomycin,2mM 
Glutamine 
DMEM with 10%FCS, 
100units/ml 
penicillin,100μg/ml 
streptomycin,2mM 
Glutamine 
DMEM with 10%FCS, 
100units/ml 
penicillin,100μg/ml 
streptomycin,2mM 
Glutamine 
Temperature, 
Atmosphere 
37ºC, 10% CO2 37ºC, 10% CO2 37ºC, 10% CO2 
Subcultivation 1:3 to 1:5, 2-3 times a 
week 
1:3 to 1:5, 2-3 times a 
week 
1:3 to 1:5, 2-3 times a week 
Cell Line P2G H69 H510 H524 
Source Type II 
pneumocytes, 
immortalised from 
human lung 
resection specimen 
lung tissue 
Small cell lung 
carcinoma, pleural 
effusion 
Small cell lung 
carcinoma, pleural 
effusion 
Small cell lung 
carcinoma, 
lymph node 
Gender, Age Not available M, 55 years M, 56 years M, 63 years 
Karyotype data Chromosome 
number=46 
Modal 
chromosome 
number=76-78 
Range=40 to 87, 
Aneuploid cell line 
Modal 
chromosome 
number=54, 
hypotriploid cell 
line 
Modal 
chromosome=51-
55, hypotriploid cell 
line 
Morphology Adherent epithelial 
cells 
Suspension cells, 
grown in aggregates 
Suspension cells, 
grown in aggregates 
Suspension cells, 
grown in aggregates 
     
Growth Medium DCCM-1 with 10% 
newborn calf 
serum, 100units/ml 
penicillin,100μg/ml 
streptomycin, 2mM 
Glutamine 
RPMI1640 with 
10%FCS, 
100units/ml 
penicillin,100μg/ml 
streptomycin, 2mM 
Glutamine 
RPMI1640 with 
10%FCS, 
100units/ml 
penicillin,100μg/ml 
streptomycin, 2mM 
Glutamine 
RPMI1640 with 
10%FCS, 
100units/ml 
penicillin,100μg/ml 
streptomycin, 2mM 
Glutamine 
Temperature, 
Atmosphere 
37ºC, 5% CO2 37ºC, 5% CO2 37ºC, 5% CO2 37ºC, 5% CO2 
Subcultivation 1:2, once a week 1:2, once a week 1:2, once a week 1:2, once a week 
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Three SCLC cell lines (H510, H524, and H69), two NSCLC cell lines (HCC78, HCC95), a 
breast cancer cell line (MCF-7) and one type II lung pneumocyte (P2G) were used in this 
study. They have all been well characterized and detailed information is in Table 2.1. The 
cells were grown in complete media and were changed to conditioned media prior to 
experiments.  
 
Condition media 
SCLC cell lines: Every week, a proportion of cells were passaged into serum free Roswell 
Park Memorial Institute 1640 (RPMI) media containing glutamine/penicillin/streptomycin 
and supplemented with insulin, transferrin, sodium selenite (NaSe) and bovine serum 
albumin (BSA) also referred to as SITA in the following concentrations: 
 
   Concentration in medium   Stock solution 
Insulin    5μg/ml   2.5 mg/ml in dH2O (4ºC) 
Transferrin   10μg/ml   50mg/ml in PBS (-20ºC) 
NaSe    30nM    100 μM in PBS (-20ºC) 
BSA    0.25% (w/v)   125 mg/ml in dH2O (-20ºC) 
The cells were grown in this media for 4-7 days prior to experiments. 
 
For NSCLC cells the growth media was changed to serum free Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing glutamine/penicillin/streptomycin the day before 
experiments. 
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II.1.2 Antibodies 
Antibody and 
working 
dilution 
Supplier Source Working 
Antibody 
Dilution 
  
ERK1/2 Santa-Cruz 
Biotechnology, 
Germany  
Rabbit  1:1500   
AKT Cell Signaling, 
USA 
Mouse 1:1000   
Biphospho-
ERK1/2 
Sigma-Aldrich 
Company Ltd 
Mouse  1:1000   
Phospho- AKT 
(Ser473) (IHC 
specific) 
Cell Signaling, 
USA 
Rabbit 1:50   
FKBP12 Cell Signaling , 
USA 
Rabbit 1:500   
mTOR Cell Signaling , 
USA 
Rabbit 1:1000   
Phospho-
mTOR (Ser 
2448) 
Cell Signaling , 
USA 
Rabbit 1:1000   
Phospho-
mTOR 
(Ser2448) (IHC 
specific) 
 
Cell Signaling, 
USA 
Rabbit 1:1000   
 
Phospho- S6K1 
(T389) 
 
Cell Signaling , 
USA 
 
Mouse 
 
 
1:1000 
  
LaminB 
Santa-Cruz 
Biotechnology, 
Germany 
Goat 1:500   
 
 
 
Table 2.2 List of antibodies
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II.1.3 Reagents 
 
Human recombinant FGF-2 (50μg/ml stock in phosphate buffer solution (PBS) containing 
0.1% BSA, stored at -80ºC), SCF (10μg/ml stock in dH2O, stored at -80ºC) and ADH 
(30μM stock in dH2O, stored at -80ºC) were from Merck Biosciences Ltd (UK). Phorbol 
ester (PDB) (400μM stock in Dimethyl sulfoxide (DMSO), stored at -20ºC) was purchased 
from Sigma-Aldrich Company Ltd (Dorset, UK). Etoposide (100mM stock in DMSO, 
stored at -20ºC) and cisplatin (100mM stock in DMSO, stored at -20ºC) were also purchased 
from Merck Biosciences Ltd (UK). RAD001 (Everolimus) (100μM stock in DMSO stored at 
-20ºC) was a gift from Novartis International AG (Basel, Switzerland). Okadaic acid powder 
(10mg stored at-20ºC) was purchased from Sigma-Aldrich Company Ltd (Dorset, UK). 
Enhanced chemo-luminescence (ECL) reagents were purchased from GE Healthcare 
(UK)/Millipore Ltd (UK)/Perbio Science Ltd (UK). RPMI 1640 and Dulbecco’s Modified 
Eagle’s Medium (DMEM) were from Sigma-Aldrich Company Ltd (Dorset, UK) and foetal 
calf serum (FCS) from First Link (Birmingham, UK). mTOR rabbit blocking peptide was 
purchased from Cell Signaling Technology Inc (Danvers, USA). 
Polymer–Horseradish peroxidase (HRP) immunohistochemistry (IHC) detection kit was 
purchased from Biogenex Laboratories Inc (San Remon, USA). Diaminobenzidine tablets 
were purchased from Sigma-Aldrich Company Ltd (Dorset, UK). On target plus siRNA 
oligonucleotides for mTOR/FKBP12, DharmaFECT D4 transfection reagent and 5XsiRNA 
buffer were purchased from Dharmacon RNAi technologies, Thermo Scientific (Lafayette, 
USA).  
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II.1.4Buffers 
Sodium Dodecyl Sulphate- Polyacrylamide Gel electrophoresis (SDS-PAGE) 
1.5m Tris (pH 8.8)   1.0m Tris (pH 6.8)   10% SDS 
182g Tris-base dissolved in  121g Tris-base dissolved in  50g SDS  
800ml ddH2O    800ml ddH2O    dissolved in 
pH to 8.8 with HCL   pH to 6.8 with HCL   500ml ddH2O 
made up to 1l with ddH2O  made up to 1l with ddH2O 
 
 
10% APS   2x SDS Loading Buffer  Running buffer 
  
2g APS dissolved in  100mM Tris-HCL (pH 6.8)  250mM Glycine 
20ml ddH2O stored  4% SDS    25mM Tris 
At 4ºC    0.2% Bromophenol blue  0.1% SDS 
20% Glycerol 
200mM DTT    5x stock: 94g Glycine 
15g Tris, 5g SDS 
dissolved in 1l ddH2O  
 
Transfer buffer 
 
39mM Glycine 
48mM Tris 
0.037% SDS 
20% methanol 
 
10x stock: 29g Glycine, 
58g Tris, 3.7g SDS 
Dissolved in 1l ddH2O  
20% methanol was added prior 
to use. 
 
WESTERN BLOTTING 
 
5X TBS   Blocking buffer  Washing buffer 
 
750mM NaCl   1x TBS containing 0.1% 1 x TBST 
100mM Tris (pH 7.5)  Tween (TBST) 
    3% Marvel (or BSA) 
1x: 60ml 5M Nacl 
     40ml 1M Tris (pH 7.5)   
Up to 2L with ddH2O 
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 II.2 METHODS 
 
 
II.2.1 SDS-PAGE 
 
Gels were made with a 4% stacking gel and a 8-12% acrylamide resolving gel (according to 
the method of Laemmli (Laemmli, 1970)). The samples were boiled at 100°C in 2X sample 
buffer (3% SDS, 5%  glycerol, 2%  β-mercaptoethanol , 10mM Tris HCL, pH 6.8) for 5 
minutes prior to either storage at -20°C or electrophoresis. Electrophoresis was performed at 
maximal 20mA per gel until the bromophenol blue reached the bottom of the gel. The gels 
were then prepared for transfer onto Immobilon Polyvinylidene Fluoride (PVDF) 
membranes. 
 
II.2.2 Western Blotting 
The proteins from samples run on acrylamide gels were subsequently transferred onto 
PVDF membranes using a wet-blotting apparatus. Transfers were run at 400mA for 2 hours 
at 4ºC. The membranes were then in blocking buffer containing milk (5%) and 0.05% 
Tween 20 for 1 hour at room temperature, and probed with the appropriate antibodies 
diluted in Tris buffered saline-Tween (TBST) with 3% milk or BSA. Dilutions were made 
according to the datasheets for the individual antibodies and probing was performed 
overnight at 4 ºC. The membranes were then washed three times for 15 minutes each before 
incubating with the suitable HRP-conjugated antibodies in 3% milk in TBST for 45 minutes. 
Three more 15 minute washes were then performed and the membranes were subjected to 
ECL according to the manufacturer’s instructions (Millipore). The proteins on the 
membranes were revealed using X-ray film. 
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II.2.3 Growth factor stimulation assays  
SCLC cells: Cells were grown in serum free media (SFM) for 4-5 days. They were 
subsequently centrifuged at 1000rpm for 5 minutes and washed in RPMI 3 times, aliquoted 
in 1.5ml eppendorf tubes at a concentration of 2x106cells/ml and left in the incubator (37ºC, 
5%CO2) for 1 hour. When relevant they were treated with RAD001, at the concentrations 
for each experiment for 1 hour and then stimulated with FGF-2, SCF, ADH or PDB at the 
concentrations indicated for each experiment in the results section. At the appropriate time 
points, the samples were transferred on ice, centrifuged at 4000 rpm for 1 minute and 
washed with 1ml cold PBS. The cells were centrifuged for a further 1 minute at 4000rpm 
and then lysed in 2x SDS sample buffer (70μl for the pellets of 2x106cells). Lysates were 
analyzed by SDS-PAGE and immunoblotted with the appropriate phospho-specific 
antibodies.  
 
NSCLC and MCF-7 cells: Cells were plated out to ~80% confluence in 6-well plates and left 
overnight to adhere to the surface of the plates. The cells were subsequently placed in 0.5% 
FCS/DMEM overnight. They were then placed in DMEM the next morning for 1 hour. 
Where relevant, they were pre-treated with RAD001 (indicated concentrations) for 1 hour 
prior to addition of FGF-2 (1ng/ml) or PDB (400nm) for the appropriate times. 
 The cells were centrifuged for a further 1 minute at 4000 rpm and then lysed in 100μl 2x 
SDS sample buffer. Lysates were analysed by SDS-PAGE and immunoblotted with the 
appropriate phospho-specific antibodies.  
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II.2.4 Phospho-signal stability studies 
SCLC and NSCLC cells in growth media were lysed in 70μl of 2x SDS sample buffer at the 
time points indicated in the experiments. Lysates were analysed by SDS-PAGE and 
immunoblotted with the appropriate antibodies. 
For the study of formalin fixed phospho-signals, cells (from growth media)/patient NSCLC 
tissue samples (straight from the operating theatre) were fixed in formalin at the time points 
indicated in the experiments for four hours. Formalin fixed cells were then processed for 
immunostaining described later. 
 
II.2.5 Cell death/chemoresistance assays 
For cell death assays, H510 cells that were grown in SFM for 3-5 days were resuspended in 
fresh SFM and aliquoted in 24-well plates at a density of 5x104 cells/ml. They were then pre-
treated, where appropriate, with RAD001 (mTOR inhibitor) at the concentrations indicated 
for 1 hour and with FGF-2 (1ng/ml) for 4 hours prior to a single addition of etoposide 
(0.1μM). Every condition was set up in triplicate and the cells were counted after 4 days 
using a haemocytometer.  
HCC95 and HCC78 cells were treated similarly; however 100nM PDB and 10µM etoposide 
was used in the HCC78 cell line and 1ng/ml FGF-2 and 20µM etoposide in the HCC95 
cells. 
 
II.2.6 Immunohistochemistry Studies 
Patients 
 
A consecutive series of 134 patients with primary operable NSCLC (Stage IA-IIB) were 
investigated from July 1987 to March 2002 at Perugia University Hospital, Italy. At surgery, 
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an average of 9 lymph nodes (range 1-22) was sampled per patient. Surgical specimens were 
routinely processed and classified according to the World Heath Organisation criteria 
(WHO, 2007). Histopathological data on tumour type, grade, lymph node status, stage and 
angio-invasion together with clinical data including age, sex, performance status, time to 
relapse and overall survival were routinely recorded prospectively in a database as previously 
published (Cagini et al., 2000). The study was approved by the local institution review board. 
Normal lung tissue and SCLC patient tissue microarrays were purchased from Biomax, Inc 
(Rockville, USA), code BN04011 and BS04111 respectively. 
 
Tissue microarray construction 
NSCLC tissue microarrays (TMA) were prepared as previously described (Kononen et al., 
1998). In the tissue technique, a hollow needle is used to remove tissue cores of 1 mm in 
diameter from the most representative areas of tumours in paraffin-embedded tissues. 
These tissue cores are then inserted in a recipient paraffin block in a precisely spaced, 
array pattern. Sections from this block are cut using a microtome, mounted on a 
microscope slide and then analyzed as per below. Each microarray block can be cut into 
100 – 500 sections, which can be subjected to independent tests. Each case was sampled 
three times. 
 
Immunostaining and Immunohistochemistry scoring for mTOR 
 
mTOR immunoreactivity was evaluated on TMA sections using the mTOR rabbit 
monoclonal antibody in a modification of the antigen retrieval technique of Shi and 
colleagues (Shi et al., 1991). Briefly, the sections were rehydrated in graded alcohols, heated 
in a microwave oven at 900W for 20 min in Citrate buffer at pH6. They were cooled at room 
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temperature before immunostaining. mTOR monoclonal antibody was used at 1:50 dilution 
for 1 hour at room temperature and then processed with Polymer-HRP Kit with 
Diaminobenzidine development and Mayer haematoxylin counterstaining. An mTOR 
positive SCLC cell line (H510) cytoblock was used as a positive external control. Negative 
controls were obtained by omitting the primary antibody, using competing peptide used to 
raise the primary antibody and by staining H510 cells in which mTOR had been selectively 
knocked down by RNAi. 
A semi quantitative immunohistochemical score (IHS) was used including assessment of 
both the intensity of staining and the percentage of positive cells. For the intensity, a score 
of 0 to 3, corresponding to negative, weak, moderate and strong positivity, was recorded. 
The range of possible scores was thus 0 to 300. IHS and similar semi quantitative scoring 
systems have been successfully used for other TMA evaluations (Herberger et al., 2007). 
Each core was scored individually. Three cores were evaluated from each tumour and the 
mean of the 3 readings was calculated. If one core was uninformative the score applied was 
the mean of the remaining two cores. All immunohistochemical staining was independently 
evaluated by two pathologists without knowledge of the clinical data. The interobserver 
discrepancy was limited to 3% of cases. These cases were reviewed at the double head 
microscope and an agreement was reached. 
 
Statistical analyses 
Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) for 
Windows (Version 15) (SPSS Inc, Chicago, IL, USA) and the R Project version 7.0. 
Percentages were rounded to the nearest whole integer. The Kaplan-Meier method was used 
to determine survival (Bland & Altman, 1998). The overall survival was defined as the time 
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(in months) from the date of the primary treatment to the time of death. To define the 
optimum mTOR IHS a Martingale graph plotting excess deaths against mTOR value for 
lung cancer was determined (Therneau T, 1990). The optimal cutoff is identified as the point 
where the curve cuts the x axis and the strength of the estimates cutoff is indicated by the 
slope of the increase in excess deaths with increasing mTOR value was performed (Therneau 
T, 1990). We assessed the univariate effect of each variable on survival by log rank test (this 
statistical test has no hazard ratio) for categorical predictors or the univariate Cox model for 
continuous predictors. Variables which were significant univariately (stage, mTOR and 
angioinvasion) were candidates for a multivariate Cox model. Selection of predictors in this 
final model of 0.05 for entry into the model and p=0.1 for removal of insignificant 
predictors. These are the default cutoffs in SPSS 15. The fit of the multivariate and 
univariate Cox models was confirmed by the supremum test of Martingale-based residuals. 
 
II.2.7 Drug Combination Analysis 
Growth Inhibition Assay 
Cell counting using a haemocytometer was used to evaluate the individual growth inhibitory 
activities of RAD001 and the cytotoxic chemotherapy drugs etoposide and cisplatin in SCLC 
cell lines. SCLC cells were seeded at 1,500 per well in 24-well plates; at 24 h after seeding, 
cells were treated with varying concentrations of RAD001, cisplatin or etoposide as indicated 
in the results. After 4 days of treatments, growth inhibition was measured by cell counting. 
The experiments were performed in triplicate. Results were plotted on graphs by using 
Calcusyn software (Biosoft, Missouri, USA) and used to determine respective inhibitory 
concentration (IC) IC12.5, IC25, IC50, IC100, and IC200 for combination studies. 
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Drug combination analysis by the isobologram/combination index method 
To determine synergy, additivity or antagonism of combinations of these drugs in SCLC cell 
lines; the isobologram/combination index method was used which relies upon the 
calculation of the fixed dose combination that cause a given effect, like 12.5%, 50% or 100% 
growth inhibition (Chou, 2006). For each fixed dose combination, the combination index 
(CI) was calculated and plotted on a graph using Calcusyn software. For example, the dose 
of RAD001 and etoposide that causes 50% (IC50) of killing in H510 SCLC cells were 
combined together in the SCLC cells to determine synergy, additivity or antagonism of the 
combination depending on the interaction index, defined as = 1, <1, or >1, respectively. 
SCLC cells in SFM were seeded in 12 well plates, five fixed drug ratios above and below the 
IC50, as mentioned were explored by incubating the drug combinations with cells for 4 days 
and then determining the degree of cytotoxicity by cell counting with trypan blue exclusion 
was used to assess cell viability. The CI values obtained from all experiments (all repeated in 
triplicate) within a cell line and sequence were pooled, and the mean and the variance 
calculated. 
 
II.2.8 RNA interference (siRNA) 
MCF-7 breast cancer cells were plated out to ~80% confluence overnight in 6-well plates. 
The next morning the growth media was aspirated off and the cells were washed with 
DMEM. 800μl neat DMEM was then added to each well. 
Meanwhile pooled RNAi oligonucleotide (20μM) (Pool consists of 4 deconvoluted 
oligonucleotides each at 20μM concentration) (For individual sequences for RNAi 
oligonucleotides for mTOR and FKBP12 see Table 2.3) and a pool of non-specific targeting 
sequences were diluted in DMEM to a final concentration of 75nM per well. Dharmafect D4 
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(transfection reagent) diluted in DMEM (2μl of D4 to 98μl DMEM per oligonucleotide) was 
incubated at room temperature for 5 minutes. Dharmafect D4 was subsequently added to 
the pooled diluted oligonucleotide and incubated for 20 minutes at room temperature. The 
siRNA/D4 complex was added to the cells and incubated at 37ºC for 5 hours. Subsequently 
500μl of 3x media (DMEM/30% FCS/3% glutamine/3% Pencillin/3% streptomycin) was 
added per condition and incubated at 37ºC for 48 hours. 
Cells were then washed in DMEM and then 2ml of DMEM was added. Where relevant, they 
were pre-treated with RAD001 (indicated concentrations) for 1 hour prior to addition of 
FGF-2 (1ng/ml) for the appropriate times. 
 The cells were centrifuged for a further 1 minute at 4000 rpm and then lysed in 100μl 2x 
SDS sample buffer. Lysates were analysed by SDS-PAGE and immunoblotted with the 
appropriate specific antibodies. 
 
 
Gene Target Sequence 
mTOR ACATATGTTTAAAATTCTG; ATTGGCACAAAAATTATTC; 
GGTGTCTAGACATGGCTAC; ACTTTGTGCATTTAGTTGA 
FKBP12 GCCGGCATAAAGCACTTTT;TGAGAAGGGGCTGAGGGAGG; 
AGGAGATGCTGAAGCTGCG; CTACAAACAGCACCTTCAA 
 
Table 2.3 RNAi target sequences for individual oligonucleotides for mTOR and 
FKBP12 
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CHAPTER III 
 
mTOR is overexpressed in lung cancer 
 97 
III.1 Introduction 
Lung cancer is the biggest cancer killer accounting for more deaths than breast, prostate and 
colon cancers combined (Parkin et al., 2005). Non-small cell lung cancer is responsible for 
80% of cases. Most affected patients present with inoperable locally advanced (Stage IIIB) or 
metastatic (Stage IV) disease which is nearly always incurable. The best chance of achieving 
long term survival is in early stage disease when complete surgical resection is possible. 
However, even in resected stage IA patients 30% succumb from their disease within 5 years 
(Tsuchiya et al., 2007). 
To further improve the outcome of early stage (IA-IIIA) resected patients, several studies 
have examined the benefits of post-operative adjuvant chemo- and or radio-therapy. Current 
data indicate that only stage II-IIIA patients gain additional benefit from adjuvant 
chemotherapy (Arriagada et al., 2004; Douillard et al., 2006; Winton et al., 2005). However, 
stage IA and probably stage IB patients as well as those without lymph node involvement 
fail to demonstrate a survival advantage with this treatment (Douillard et al., 2006; Wakelee 
et al., 2007). 
Consequently, there has been considerable interest in defining new biomarkers which could 
accurately identify, for example, the 30% of stage IA patients who relapse and die from lung 
cancer following surgery. Such individuals could then be targeted for novel therapies. 
Vascular or lymphatic vessel invasion have both been suggested as potential markers for 
poor outcome in stage IA patients but results have been controversial and inconsistent 
(Hung et al., 2007; Macchiarini et al., 1993; Shields, 1983; Tsuchiya et al., 2007). Other 
predictive factors such as sex, performance status and sublobar resections have also given 
variable results (Dehing-Oberije et al., 2008). More recently there has been considerable 
interest in new molecular biomarkers such as the ERCC1 but its role in predicting outcome 
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in early stage resected patients is promising but not yet clear (Olaussen et al., 2006; Simon et 
al., 2005; Zheng et al., 2007). Genomic strategies have also showed promising results (Potti 
et al., 2006). As previously mentioned mTOR is overexpressed in lung cancer cells compared 
to ‘normal’ lung epithelial cells (Marinov, 2009).  
SCLC makes up ~20% of cases. Initially it is highly responsive to chemotherapy and 
radiotherapy treatment, however relapse is common and the overall 5-year survival is less 
than 5%. Clearly novel strategies are required to improve this statistic. In recent years, as 
previously mentioned a rising number of biological dysfunctions involved in SCLC 
pathogenesis were reported, including neuro-endocrine regulatory peptides, overexpression 
of Myc family oncogenes and extracellular matrix proteins, and genetic abnormalities in the 
tumour suppressor genes p53 and pRB (Sethi et al., 1999; Wistuba et al., 2001). Moreover it 
has been shown that polypeptide growth factors such as SCF and FGF-2 induce a variety of 
responses in human SCLC cells, including growth and proliferation, chemoresistance and 
motility (Heasley, 2001; Pardo et al., 2002; Pardo et al., 2001). Furthermore it has been found 
that the ribosomal S6K1 and 2 are highly overexpressed in SCLC cells compared to normal 
human type II pneumocytes, and that mTOR transduces mitogen-induced proliferation in 
SCLC (Pardo et al., 2001). Therefore targeting these pathways and in particular with mTOR 
inhibitors may lead to the development of novel treatment for SCLC in patients.  
The aim of this part of the study was to determine if mTOR was overexpressed in SCLC and 
NSCLC patient samples and if possible to determine if this was linked to prognosis. If so 
these patients may benefit from an mTOR inhibitor which would be determined by further 
clinical trials. 
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III.2 RESULTS 
II.2.1 mTOR is overexpressed in NSCLC patient specimens and is prognostically 
linked to survival 
The mean age of the population was 65.6 years (range 31-86) and most (88%) were male 
(Table 3.1). All NSCLC tumour types with stages IA to IIB were present in the series and at 
the time of primary diagnosis, 100 (74%) patients were lymph node-negative and 34 (26%) 
had positive lymph nodes. All the patients had a Karnofsky performance status of at least 
90%. The median follow up was 52.9 months (range 1-202 months) and a total of 91 (68%) 
patients died in the study period. Importantly, the overall survival of this group of patients 
stratified by stage (Figure 3.3) is in keeping with other published series (Demmy & Curtis, 
1999; Jemal et al., 2006). 
We next examined mTOR staining in the tissue arrays established from the resected 
tumours. Immunostaining of mTOR was mostly cytoplasmic (Figure 3.1) and was found in 
0-100% of the tumour cells with a varying intensity (grades 1-3). To define the optimum 
mTOR IHS a Martingale graph plotting excess deaths against mTOR value for lung cancer 
was performed (Figure 3.2) (Therneau T, 1990). The optimal cutoff is identified as the point 
where the curve cuts the x axis and the strength of the estimates cutoff is indicated by the 
slope of the increase in excess deaths with increasing mTOR value for lung cancer survival 
was performed. A similar approach has been used in the past to establish a 10% staining cut-
off for Her2/neu in breast cancer (Zarbo & Hammond, 2003). The best cut-off for mTOR 
staining in NSCLC was provided at an IHS of 30 (Figure 3.2) where 73 (55%) of the patients 
stained positive for mTOR (Table 3.1). Table 3.2 shows that as expected, stage (p = 0.04 by 
log rank; Hazard Ratio (HR) =1.76, 95% confidence interval (CI) =0.992-3.12), lymph node 
status (p=0.049 by log rank, HR = 1.59, 95% CI = 1.0-2.56)  
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Patient Characteristics 
 
No. of cases (%) 
 Age 
 
 
 ≥65 
 
57 (43) 
 ‹65 
 
77 (57) 
 Gender 
 
 
Male 
 
117 (88) 
 
 
Female 
 
17 (12) 
 Stage 
 
 
1a 34 (24) 
 1b 57 (41) 
 2a 13 (9) 
 2b 30 (26) 
 Lymph node  
Positive 34 (25) 
 Negative 100 (75) 
 Histology  
Adenocarcinoma 41 (30) 
 Squamous 56 (42) 
 Large cell 26 (19 
 Broncheo-alveolar 9 (7) 
 Mixed 1 (1) 
 Neuroendocrine 1 (1) 
 Surgical intervention  
Lobectomy 
 
112 (84) 
 Pneumonectomy 
 
22 (16) 
 Grade 
 
 
1 8 (6) 
 2 43 (31) 
 3 82 (60) 
 4 1 (3) 
 Dead  
Yes 91 (68) 
 No 43  (32) 
 mTOR staining 
 
 
+ve 
 
 
73 (55) 
 -ve 
 
 
61 (45) 
 Angioinvasion 
 
 
 
+ve 
 
 
27 (28) 
 -ve 
 
69 (72) 
  
Table 3.1 Clinico-pathological characteristics of 134 patients with early NSCLC  
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Figure 3.1 mTOR is overexpressed in NSCLC patients. 
Panel A example of negative mTOR staining in NSCLC, Panel B weak mTOR staining, 
Panel C moderate mTOR staining and panel D strong mTOR staining. Bar, 100µm 
Sections were stained with mTOR antibody at a 1:50 dilution prior to visualisation by HRP 
as described in the materials and methods. The images shown are representative of 10 
independent control experiments performed prior to performing our tissue array work. 
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Figure 3.2 Martingale residual plot for lung cancer survival in 134 NSCLC patients 
Martingale graph plotting excess deaths against mTOR value for lung cancer was determined 
to define the optimum mTOR IHS. The optimal cutoff is identified as the point where the 
curve cuts the x axis and the strength of the estimates cutoff is indicated by the slope of the 
increase in excess deaths with increasing mTOR value was performed 
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Patient 
Characteristics 
 
Univariate 
analysis P 
value 
  
 
  
 
 
  
 
HR  95% CI Multivariate 
analysis P 
value 
 
HR 95%CI 
Age 
 
0.445 0.990 0.77-1.28 NA   
Gender 
 
0.44 
 
0.87 0.68-1.13 NA   
Stage 
 
0.04   
 
 
  NS   
1b v 1a  0.57 0.37-0.86    
2a v 1a  1.00 0.72 - 1.39    
2b v 1a  1.33 0.79  -2.24    
Lymph node 0.049     
 
1.59 1.0    -2.56 NA   
Histology 0.767 
 
  NA   
Large cell v squamous  1.31 0.55-3.09    
Adeno v squamous  1.24 0.49-3.15    
Alveolar v squamous  1.02 0.41-2.50    
Surgical intervention 0.125 
 
0.656 0.38-1.13 NA   
Lobectomy 
 
      
Pneumonectomy 
 
      
Grade 
 
0.320 
 
  NA   
2 v 1  0.57 0.07-4.77    
3 v 1  0.40 0.05-3.01    
4 v 1  0.62 0.09-4.53    
mTOR staining 
 
0.007         
 
1.77 1.17 - 2.73 0.046    1.66 1.01-2.74 
Angioinvasion 
 
 
0.017         
 
1.91 1.12 - 3.31 0.016 1.95 1.13 – 3.35   
N.B Univariate analysis performed using log rank test therefore no hazard ratio listed (Except for 
age) NA= Not applicable, NS=Not significant 
 
Table 3.2 Univariate and multivariate analysis of patient characteristics for survival 
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Figure 3.3 Kaplan-Meier survival plot of survival of 134 NSCLC patients for mTOR 
positive and mTOR negative by stage. 
Kaplan-Meier curves were performed using SPSS software. Survival was defined as the time 
(in months) from the date of primary treatment to time of death. 
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and angio-invasion (p=0.017; HR = 1.91, 95% CI = 1.12-3.31) were significantly associated 
with poor survival in agreement with previously published findings (Hung et al., 2007; 
Shields, 1983). 
Strikingly, Table 3.2 and Figure 3.4 demonstrate that mTOR staining was also significantly 
associated with poor survival (p=0.007 (log rank), 95% CI=1.16-2.71). Moreover, only 
mTOR positive staining (p=0.046 (log rank), 95% CI 1.01-2.74) and angio-invasion 
(p=0.016 (log rank), 95% CI=1.13-3.35) remained significant as predictors of overall survival 
on multivariate analysis. 
We next investigated whether mTOR staining might predict poor survival in patients who 
were lymph-node negative as this group currently has no clear prognostic factor. Figure 3.5 
shows that the survival of lymph-node negative patients whose primary tumours were 
mTOR positive was significantly lower (p=0.016 (log rank) 95% CI=1.11-3.05). In contrast, 
angio-invasion and other factors were non-predictive (data not shown). These results suggest 
that the survival of patients with stage IA disease who are all lymph-node negative might be 
most influenced by mTOR staining. Indeed, Figure 3.6 demonstrates that mTOR staining 
was a highly significant prognostic marker for this group of patients. The median survival 
was 2.1 years in the mTOR positive verses 5.6 years in the mTOR negative patients (p= 
0.007, HR=4.38, 95% CI=1.62-11.83). Taken together, a positive mTOR IHS of >30 
appears to predict poor outcome in stage IA and lymph-node negative early stage NSCLC 
patients 
 
III.2.2 mTOR is overexpressed in SCLC patient specimens 
The expression of mTOR using immunohistochemistry in a total of 30 normal lung tissue 
samples and 30 SCLC patients was determined (Figure 3.7). 50% of the SCLC specimens 
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were positive for mTOR, whereas mTOR expression was not detectable in the normal lung 
specimens. This data indicates that up-regulation of mTOR may contribute to the abnormal 
growth and survival properties of SCLC. Patient clinical data was not available; so prognostic 
links to mTOR expression could not be determined. 
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Figure 3.4 Kaplan-Meier survival plot of survival of 134 NSCLC patients for mTOR 
positive and mTOR negative. 
Kaplan-Meier curves were performed using SPSS software. Survival was defined as the time 
(in months) from the date of primary treatment to time of death. 
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Figure 3.5 Kaplan-Meier plot demonstrating the influence of mTOR staining on LN 
negative NSCLC patient survival  
Kaplan-Meier curves were performed using SPSS software. Survival was defined as the time 
(in months) from the date of primary treatment to time of death. 
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Figure 3.6 Kaplan-Meier survival plot of survival of stage 1A NSCLC patients for 
mTOR positive and mTOR negative  
Kaplan-Meier curves were performed using SPSS software. Survival was defined as the time 
(in months) from the date of primary treatment to time of death. 
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Figure 3.7 mTOR is  overexpressed in SCLC patients. 
Panel A example of negative mTOR staining in SCLC, Panel B weak mTOR staining, Panel C moderate 
mTOR staining and panel D strong mTOR staining, Panel E normal lung. Bar 100µm 
Sections were stained with mTOR antibody at a 1:50 dilution prior to visualisation by HRP as described in 
materials and methods. The images shown are representative of 10 independent control experiments 
performed. 
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III.3 Discussion 
 
Lung carcinoma is the commonest cancer killer and the best hope of cure lies currently with 
surgical resection of early stage disease. For NSCLC patients with resected stages IIA-IIIA, 
clinical trials have demonstrated additional survival benefits with adjuvant chemotherapy. 
However for stage IA patients and probably IB and those without lymph node involvement, 
additional chemotherapy does not appear to improve survival (Pignon et al., 2008). This 
might be because novel treatments are required and/or because the existing treatments only 
aid a small percentage of patients and most stage IA/B patients are cured. Whatever the 
explanation, it seems likely that outcome might be improved if we could more precisely 
identify the subset of patients destined to do badly following surgery. 
Here we show that mTOR immunohistochemical staining predicts poor outcome in early 
stage NSCLC. More specifically, it appears to identify poor outcome in lymph node negative 
and stage IA patients where previously other markers such as angio-invasion have failed to 
consistently yield prognostic benefit. Obviously, the data presented here just represents a 
single patient cohort and it would be important to know whether this could be reproduced 
in larger independent series. Potti et al in 2006 using a multigene-expression profile 
predicted recurrence for patients significantly better than clinical prognostic factors in early 
NSCLC (Potti et al., 2006). Recently, immunohistochemical staining for L-type amino acid 
transporter I (LAT 1) has also been shown to provide prognostic information in resected 
NSCLC within a Japanese patient population (Kaira et al., 2008). The expression/activity of 
this transporter appears to be closely linked to mTOR (Fuchs & Bode, 2005). It is therefore 
tempting to speculate that the expression of these two molecules in clinical material may be 
linked and that our findings may not be isolated to one patient cohort. In addition, it is 
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noteworthy that others have recently shown increased mTOR staining is linked to adverse 
prognosis in breast and biliary cancers (Herberger et al., 2007; Zhou et al., 2004) However a 
paper published recently showed the opposite- i.e. high expression of mTOR is linked to 
better outcomes in early NSCLC (Anagnostou et al., 2009). This would seem counter-
intuitive with respect to known mTOR biology and to mTOR expression and prognosis in 
other cancers mentioned above. Possible reasons for these differences include differing 
immunohistochemical techniques and having more women in the cohort tested in the more 
recent study. 
Criticism of tissue microarray technology must be acknowledged such as the small cores 
sampled may not be representative of the whole tumor, particularly in heterogenous 
cancers such as prostate adenocarcinoma and non-small cell lung cancer and so validation 
studies against whole tissue sections could have been performed.   
The phosphatidylinositol 3-kinase/Akt/mTOR signaling pathway is frequently deregulated 
in cancers and represents an attractive target for anticancer therapy. Sirolimus and its 
analogues Temsirolimus, Everolimus, and Deforolimus are specific small molecule inhibitors 
of mTOR and some of these agents are now being examined as novel therapies for lung 
cancer. Our results suggest that early stage NSCLC patients who are mTOR positive might 
benefit from an mTOR inhibitor and/or chemotherapy. However, it is recognised that these 
findings are preliminary and a further validation study is now urgently required. 
The SCLC patient findings with respect to mTOR expression suggest that mTOR is 
overexpressed in about 50% of cases. The clinical significance of this observation is not yet 
clear and will be determined by future studies examining how this correlates with 
survival/response to therapy. Nevertheless, clinical trials using mTOR inhibitors in 
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unselected SCLC patients have already started and have shown some promise with 2 
different doses of CCI-779 (Pandya et al., 2005). 
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CHAPTER IV 
 
Phospho-signals are not stable when 
growth media/blood supply are removed 
from lung cancer cells/tumours 
 115 
IV.1 Introduction 
Phosphorylation of proteins on serine, tyrosine or threonine residues are key events 
modulating the activity or cellular localization of many key signaling molecules in cells 
(Hunter, 1987). Therefore, phosphoproteins have been frequently used as markers of 
signaling activity in tumours. Protein phosphorylation depends on a balance between the rate 
of phosphorylation by specific kinases and dephosphorylation by phosphatases. Often, 
phosphorylation events are in fact transient as protein functions are switched on and off 
(Hunter, 1989).  
So for phosphoproteins to be useful as a marker of signaling activity, knowledge of their 
stability after blood supply removal should be determined. This may prove important since 
many publications looking at phosphoprotein expression in tumour biopsies do not state at 
what time point from removal from the patient they were fixed in formalin (Herberger et al., 
2007; Zhou et al., 2004). It may be the case that in these studies, it is better to stain for the 
total protein in question since this may be more stable and give more meaningful and 
consistent results. Indeed, cancer may upregulate or loose expression of signaling proteins as 
part of oncogene addiction. However, total protein does not necessarily reveal altered 
biological function. 
A previous study found rapid dephosphorylation of Akt in cancer xenografts when removed 
from blood supply and in clinical samples (gastro-oesophageal junction tumours) phospho-
Akt was only evaluable in biopsies and not in surgically resected specimens (Baker et al., 
2005) 
In this chapter, this question of whether phosphoproteins in particular mTOR/phospho-
mTOR remain stable after removal of growth media/blood supply was examined in cell 
 116 
lines, formalin fixed cell lines and patient clinical samples, considering in the previous 
chapter we examined the expression of total mTOR in clinical samples. 
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IV.2 RESULTS 
IV.2.1 The strength of phospho-mTOR signals varies with time in HCC78 
adenocarcinoma NSCLC cells removed from growth media but not in one NSCLC 
patient sample (Adenocarcinoma histology). 
We wanted to determine if, at the cell line level, phosphoprotein signals vary with time from 
removal from growth media. We chose to look at mTOR- for obvious reasons and also it is 
an important component of one of the major intracellular signaling pathways. 
Phosphorylation of serine 2448 was selected as it is one of the sites thought to correlate with 
mTOR activation (Chiang & Abraham, 2005). Firstly, HCC78 NSCLC cells were removed 
from their growth media and left at room temperature and lysed with 2x SDS sample buffer 
at various time points up to 2 hours after removal from growth media. Lysates were analysed 
by SDS-PAGE for the presence of phospho-mTOR (Ser2448) and total mTOR. The results 
are shown in Figure 4.1A. It is clear that the phospho-mTOR signal varies with time 
compared to the total mTOR (which was also used as a loading control). Phospho-mTOR 
signal intensity peaked around 10 minutes and was lowest around 120 minutes. The total 
mTOR signal did not vary with intensity with time. 
We then wanted to see the effect of formalin fixation on the variation of the phospho-
mTOR signal with time in the same cell line. Tissue biopsies or surgical specimens are 
normally fixed in formalin before staining with relevant antibodies. A semi quantitative 
immunohistochemical score (IHS) was used including assessment of both the intensity of 
staining and the percentage of positive cells. For the intensity, a score of 0 to 3, 
corresponding to negative, weak, moderate and strong positivity, was recorded. The range of 
possible scores was thus 0 to 300. Figure 4.1B, 4.1C and Table 4.1 shows the results. Again 
the phospho-mTOR signals varies with time (B) compared to the total mTOR (C). At 15  
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Figure 4.1 Phospho-mTOR signals varies with time in HCC78 NSCLC cells. 
(A) HCC 78 NSCLC cells were removed from 10% FCS+media and lysed at the following 
time points- 0, 3, 5, 10, 15, 30, 60 and 120 minutes.Lysates were analysed by SDS-PAGE for 
the presence of phospho-mTOR (Ser2448) and total mTOR. HCC78 cells were removed 
from 10% FCS+media and fixed in formalin at the following time points 0, 15, 60 and 120 
minutes and then the sections were stained with (B) phospho-mTOR (Ser2448) and (C) total 
mTOR antibodys at a 1:50 dilution prior to visualisation by HRP as described in the 
materials and methods. The images shown are representative of 10 independent control 
experiments performed. Results are representative of 3 repeat experiments. 
Phospho-mTOR 
mTOR 
A 
0 3 5 10 15 30 60 120 (Mins) 
Time 
(Mins) 
0 15 60 120 
B 
C 
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Figure 4.2 Phospho-mTOR signals do not vary in time in a patient’s lung cancer 
tissue sample (Adenocarcinoma) 
 
NSCLC (adenocarcinoma) patient tissue stained for (A) mTOR and (B) phospho-mTOR. 
Patient sample was surgically removed and fixed in formalin at the time points indicated. 
mTOR antibodies at a 1:50 dilution prior to visualisation by HRP as described in materials 
and methods.Result is from one experiment. 
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minutes the phospho-mTOR signal is more intense than at 0 and 60 minutes (IHS of 100 
and 150, respectively). The obvious next question is to see if these results are consistent in 
lung cancer patient surgical specimens. We obtained a single sample of a NSCLC- 
adenocarcinoma, the same histological sub-type as the HCC78 NSCLC cell line. I was called 
prior to the elective surgical removal of a lung cancer by the thoracic surgeon at the 
Hammersmith Hospital. I received the surgical specimen minutes after it was removed by 
the surgeon just outside the operating theatre and then fixed parts of the specimen in 
formalin at fixed time points up to 120 minutes post resection before staining with relevant 
antibodies. Figure 4.2A/B and Table 4.1 show the results. The results from one patient did 
not show any variation in (A) phospho-mTOR / (B) total mTOR IHS score with time up to 
120 minutes. 
 
IV.2.2 The strength of phospho-mTOR signals varies with time in HCC95 squamous 
NSCLC cells removed from growth media and in one NSCLC patient sample 
(squamous histology) 
We wanted to verify our findings from the previous section in another NSCLC cell line and 
another NSCLC patient sample of the same phenotype as the cell line. HCC95 NSCLC cells 
were removed from their growth media and left at room temperature and lysed with 2x SDS 
sample buffer at various time points up to 2 hours after removal from growth media.Lysates 
were analysed by SDS-PAGE for the presence of phospho-mTOR (Ser2448) and total 
mTOR. The results are shown in Figure 4.3A. It is clear that the (A) phospho-mTOR signal 
varies with time compared to the (B) total mTOR (which was also used as a loading control). 
Phospho-mTOR signal intensity peaked around 0-15 minutes and then fades out. The total 
mTOR signal did not vary in intensity with time. 
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Figure 4.3 Phospho-mTOR signals varies with time in HCC95 NSCLC cells. 
(A) HCC95 NSCLC cells were removed from 10% FCS+media and lysed at the following 
time points- 0, 3, 5, 10, 15, 30, 60 and 120 minutes.Lysates were analysed by SDS-PAGE for 
the presence of phospho-mTOR (Ser2448) and total mTOR. HCC95 cells were removed 
from 10% FCS+media and fixed in formalin at the following time points 0, 15, 60 and 120 
minutes and then the sections were stained with (C) phospho-mTOR (Ser2448) and (B) total 
mTOR antibodys at a 1:50 dilution prior to visualisation by HRP as described in the 
materials and methods. The images shown are representative of 10 independent control 
experiments performed. Results are representative of 3 repeat experiments. 
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Figure 4.4 Phospho-mTOR signals varies in time in a patient’s lung cancer tissue 
sample (Squamous) 
 
NSCLC (Squamous) patient tissue stained for (A) mTOR and (B) phospho-mTOR. Patient 
sample was surgically removed and fixed in formalin at the time points indicated. mTOR 
antibodys at a 1:50 dilution prior to visualisation by HRP as described in materials and 
methods. Result is from one experiment. 
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We then wanted again to see the effect on formalin fixation on the variation of the phospho-
mTOR signal with time in the same cell line. Figure 4.3B, 4.3C and Table 4.1 shows the 
results. The phospho-mTOR signal varies with time, IHS increasing as time goes by (C), 
whilst the total mTOR signal/IHS stayed stable (B) for example, at 0 minutes IHS was 60 
whilst at 60 minutes it was 100. We again went on to look at a patient surgical specimen 
obtained as previously described in the last results section. We obtained a NSCLC specimen 
of squamous histology; the same phenotype as the HCC95 cell line. The specimens were 
placed in formalin at fixed time points up to 120 minutes post resection before staining with 
relevant antibodies. Figure 4.4A, B and Table 4.1 show the results. The total mTOR HIS did 
not vary with time (A) whilst the phospho-mTOR IHS varies with time (B), after 120 
minutes the signal/IHS was more intense than at 0 minutes (IHS of 80 and 150, 
respectively). 
 
IV.2.3 The strength of phosphoprotein signals varies with time in fixed H510 SCLC 
cells removed from growth media. 
After having examined the stability of phospho-mTOR in two NSCLC cell lines/surgical 
specimens, we moved on to a SCLC cell line- H510. H510 SCLC cells were removed from 
their growth media and left at room temperature and lysed with 2x SDS sample buffer at 
various time points up to 2 hours after removal from growth media. Lysates were analysed 
by SDS-PAGE for the presence of phospho-mTOR (Ser2448) and total mTOR. The results 
are shown in Figure 4.5A. The phospho-mTOR signal peaked in intensity at 3 minutes and 
then dropped down to almost undetectable. We then wanted again to see the effect on 
formalin fixation on the variation of the phospho-mTOR signal with time in the same cell 
line. Figure 4.5B, 4.5C and Table 4.1 shows the results. Figure 4.5B shows a stable total 
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mTOR signal/IHS with time and figure 4.5C shows the strength of the phospho-mTOR 
signal varies with time, with the greatest IHS at around 60 minutes post formalin fixation 
(IHS score increasing from 40 at 0 minutes to 180 at 60 minutes). 
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Figure 4.5 Phospho-mTOR signals varies in time in H510 SCLC cells fixed in 
formalin 
 
(A) H510 SCLC cells were removed from 10% FCS+media and lysed at the following time 
points- 0, 3, 5, 10, 15, 30, 60 and 120 minutes.Lysates were analysed by SDS-PAGE for the 
presence of phospho-mTOR (Ser2448) and total mTOR. H510 cells were removed from 
10% FCS+media and fixed in formalin at the following time points 0, 15, 60 and 120 
minutes and then the sections were stained with (C) phospho-mTOR (Ser2448) and (B) total 
mTOR antibodys at a 1:50 dilution prior to visualisation by HRP as described in the 
materials and methods. The images shown are representative of 10 independent control 
experiments performed. Results are representative of 3 repeat experiments. 
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Time points 
(Mins) 
0 15 60 120 
HCC78 mTOR 90 90 90 80 
HCC78 p-mTOR 100 180 150 180 
Adenocarcinoma 
tissue mTOR 
90 80 90 90 
Adenocarcinoma 
tissue p-mTOR 
180 160 180 180 
HCC95 mTOR 160 180 180 180 
HCC95 p-mTOR 60 60 100 180 
Squamous Tissue 
mTOR 
40 60 40 40 
Squamous Tissue 
p-mTOR 
80 100 100 150 
H510 mTOR 40 40 60 40 
H510 p-mTOR 40 40 180 60 
 
 
Table 4.1 Mean immunohistochemical score (IHS) of formalin fixed NSCLC cell 
lines and NSCLC patient tissue. 
A semi quantitative immunohistochemical score (IHS) was used to assess degree of staining 
(the intensity of staining and the percentage of positive cells.) of mTOR and phospho-
mTOR in HCC78, HCC95, H510, adenocarcinoma lung cancer patient sample and 
squamous cell lung cancer patient sample. For the intensity, a score of 0 to 3, corresponding 
to negative, weak, moderate and strong positivity, was recorded. The range of possible 
scores was thus 0 to 300. The results were means except in the tissue samples where these 
are the sole results. 
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IV.3 Discussion 
In this chapter we looked at the issue of whether phosphorylated proteins are stable after the 
cells/tissue has been removed from growth media/blood supply. Phosphoproteins are 
frequently used to assess the activity of intracellular pathways. In particular, with respect to 
immunohistochemical studies looking at expression of phosphoproteins as markers of 
activation of intracellular signaling pathways. We show here that in 3 lung cancer cell lines – 
two NSCLC (adenocarcinoma and squamous phenotype) and 1 SCLC; that phospho-mTOR 
signal varies with time from removal from growth media. Total mTOR signals stayed stable. 
Total mTOR was used as a loading control and control for the stability of the phospho-
mTOR protein.  
We then looked at the same cell lines removed at fixed time points from growth media, fixed 
in formalin and then immunostained as described in the methods section. We did this since 
formalin fixing could alter the stability of phosphoproteins. Results were similar to those 
observed with cells removed from media and lysed and subjected to SDS-PAGE analysis. 
Phospho-mTOR signals again varied with time from removal from growth media in the 3 
lung cancer cell lines examined and total mTOR stayed stable in all cell lines. 
These experiments were repeated using other phospho-proteins since the stability of 
phosphoproteins may depend on the individual protein studied. Phospho-ERK/ERK and 
phospho-Akt/Akt were examined since they are important components of 2 major 
intracellular signaling pathways- PI3K/Akt/mTOR/S6K1 and MEK/ERK/S6K2. Results 
were very similar to those seen with phospho-mTOR (data not shown); with respect to 
stability of phospho-signals i.e. phospho-signals/IHS varied in intensity with time from 
removal from growth media and total protein signals remained stable. 
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With these results in mind we examined the stability of phospho-mTOR in two NSCLC 
surgical specimens. We were fortunate to have the co-operation of a thoracic surgeon who 
gave us access to patient specimens and gave us notice prior to elective surgery to collect 
tissue just after surgical removal. We obtained one adenocarcinoma and one squamous 
NSCLC patient samples. In our ‘adenocarcinoma’ patient sample no observed difference was 
seen in the intensity of the phospho-mTOR signal with time (Figure 4.2) but signal intensity, 
with respect to phospho-mTOR, did vary with time in the ‘squamous’ phenotype. (Total 
mTOR signals did not vary in intensity). Clearly this sample size is very small to make any 
conclusions and more samples are needed to make any judgment on the stability of 
phosphoproteins. These studies are difficult to organize. Firstly the numbers of patients who 
have surgery for early NSCLC are few and appear unpredictably. This means that it would 
take a long time to obtain sufficient patients for any decent size study. To obtain sufficient 
numbers of patients would probably involve other surgical centres but this may lead to 
variations in methods/timing with respect to collection and immunohistohemical analysis. 
We could use tumour biopsies i.e. a small sample taken by a radiologist to make a diagnosis 
however, different results may have been seen in tissue biopsies since the samples are 
removed straight from the tumours and fixed very quickly. Surgical tumour specimens have 
their blood supply tied and they may stand at 37°C for many minutes. Clearly rapid 
processing would seem essential however timings would have to be stated when this data is 
presented. 
From the data obtained from cell lines, it does seem in lung cancer, at least that phospho-
mTOR/ERK/Akt signals do vary in intensity with time from removal from growth media. 
Clearly a more complete study would involve studying different cell lines/tumour types and 
other phosphoproteins since as mentioned previously proteins may vary in their stability. It 
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must also be made clear that particular phosphoproteins chosen must correlate with 
activation of the particular protein/signaling pathway. 
If we assume that the results shown here are reproducible, in particular in patient surgical 
specimens, this would mean that when patient samples are used to determine activation of 
intracellular signaling pathways time from surgery to formalin fixation would have to be 
documented and taken into account with respect to any conclusions made from such studies. 
It could also mean that previously published reports which use these kinds of studies may be 
invalid unless repeated and ‘fixation times’ documented. 
In the previous chapter we examined the expression of total mTOR in 134 early NSCLC 
patients; total mTOR was chosen because of the results of this chapter. However expression 
may not relate to altered biological function. Despite this we did show that prognosis was 
directly related to survival in these cases. 
 
.  
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CHAPTER V 
 
Chemoresistance and mTOR in lung 
cancer 
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V.1 Introduction 
Small cell lung cancer is an aggressive and mostly incurable cancer. Despite early responses 
to chemotherapy; the disease relapses and responds poorly to further therapy. Most patients 
die within a year of diagnosis. Novel therapeutic strategies are needed and will only arise 
from a greater understanding of the disease biology and causes of resistance to treatment. 
Several growth factors have been implicated in the biology of SCLC and have been shown to 
trigger proliferation in SCLC cells in vitro. Among the FGF family, the role of FGF-2 has 
been studied extensively in SCLC. Previous work from our group has shown that FGF-2 
promotes proliferation via S6K1 and this is dependent on mTOR since rapamycin blocks 
S6K1 activation/proliferation in all SCLC cell lines tested. Not only can FGF-2 promote 
proliferation but resistance to etoposide. Further investigation of the underlying mechanisms 
by which FGF-2 could trigger resistance to etoposide killing revealed that several anti-
apoptotic proteins including Bcl-XL, Bcl-2, XIAP and cIAP1/2 were upregulated. This was 
achieved through enhanced translation rather than transcriptional control mechanisms. So 
how could FGF-2 signaling regulate the translational machinery? Recent work from the 
laboratory has shown that FGF-2 but not other growth factors triggers the assembly of a 
novel complex comprising of B-Raf, PKCε and S6K2 which promotes growth factor 
prosurvival effects (Pardo et al., 2001; Pardo et al., 2003; Pardo et al., 2006).  
It was found that at low rapamycin concentrations, growth factor-induced S6K1 activation is 
selectively inhibited without effect on S6K2. In contrast, at 10-fold higher concentrations of 
rapamycin, there is a partial inhibition of S6K2 activation, which correlates, with inhibition 
of MEK/ERK signaling (Figure 1.7). This may suggest that high dose mTOR inhibition 
with rapalogues could potentially block FGF-2 induced chemoresistance. This could be 
relevant in the development of new therapeutic strategies in SCLC. 
 132 
This phenomenon potentially opens up a new pathway in mTOR biology. The mTORC1 
complex is modulated by MAP kinases (p44/42 MAP) via phosphorylation and inactivation 
of the tuberous sclerosis complex (Tee et al., 2003a; Tee & Blenis, 2005; Tee et al., 2002; Tee 
et al., 2003b). However a connection from mTORC1 modulating activity of MEK/ERK 
signaling has not been reported, however a couple of papers have shown anecdotal evidence 
that mTOR inhibition can influence activation of MEK/ERK signaling, in the VMM18 
melanoma cell line (Molhoek et al., 2005) and Rh1 sarcoma cells (Harwood et al., 2008). 
Therefore, the questions that will be addressed in this chapter are: Do high concentrations of 
the clinically more relevant mTOR inhibitor/rapalogue RAD001 like rapamycin also block 
FGF-2-induced MEK/ERK/S6K2 activation in SCLC cell lines? Is this phenomenon 
relevant to other growth factors/chemicals that activate MEK/ERK/S6K2 signaling in 
SCLC cell lines? Are these observations relevant in NSCLC or other cancers? Can RAD001 
block FGF-2 induced resistance to etoposide killing in lung cancer cell lines? 
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V.2 RESULTS 
V.2.1 FGF-2 and PDB stimulation of ERK and S6 Kinase 1 in H510 SCLC cells can be 
blocked by RAD001 
 
Rapamycin at high concentrations (high but still tolerable to patients) has previously been 
shown to impair MEK/ERK signaling induced by FGF-2 in H510 SCLC cells. Rapamycin is 
not very soluble nor stable so its clinical uses are limited (Easton & Houghton, 2006), the 
newer ‘rapalogs’ are analogues of rapamycin, they are clinically relevant and are already in 
use. However, it is unclear whether similar effects might be seen with other rapalogues such 
as RAD001, with different growth factors and with other cell lines. To gain insight into these 
issues, we initially investigated the effects of increasing concentrations of RAD001 on ERK 
phosphorylation induced by FGF-2 in H-510 cells. 
H510 cells were grown in serum-free medium for 4 days prior to the experiments. RAD001 
at the following doses 1, 3, 10, 50, 100ng/ml were added to the cells 1 hour prior to FGF-2 
(0.1ng/ml) stimulation. The cells were lysed after 5 and 10 minutes of stimulation for 
subsequent analysis by western blotting for bi-phospho ERK1/2 and phospho-S6K1, 
respectively. These doses of RAD001 were chosen since they cover the range of doses which 
are tolerable to patients and are similar to the doses utilized in the ‘original’ rapamycin 
studies from our laboratory. The times chosen for the FGF-2 stimulations were 5 minutes- 
optimal to observe maximal phosphorylation of ERK1/2 (Pardo et al., 2001), a marker of 
activation of MEK/ERK signaling and 10 minutes for observation of phosphorylation of 
S6K1. Phosphorylation of S6K1 was used as a control to ensure the RAD001 was active, 
since low doses of this drug are known to inhibit phosphorylation of S6K1 on threonine 
389. Figure 5.1A shows that even at RAD001 dose of 10ng/ml, the biphospho-ERK1/2 
signal is reduced significantly. Figure 5.1B shows that the RAD001 was active, reducing  
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phosphorylation of S6K1 at 1ng/ml. So compared to the previously published effects of 
rapamycin in H510 cells (Pardo et al., 2001), RAD001 can also block FGF-2 stimulation of 
MEK/ERK signaling and at even lower doses. 
Many types of growth factors; be they neuropeptide and polypeptides are known to be 
involved in SCLC biology. The next question we asked was whether other growth 
factors/chemical activators of MEK/ERK signaling in H510 could be blocked by RAD001 
or whether this was a phenomena restricted to FGF-2. 
Protein kinase C (PKC) is a known regulator of S6K2 (Valovka et al., 2003) via MEK/ERK 
in many cell lines including SCLC cells (Kawauchi et al., 1996; Seufferlein & Rozengurt, 
1996a; Zou et al., 1996). Phorbol esters are plant derived tumour promoters (Blumberg, 
1988). They can activate some PKC members (cPKCs and nPKCs (Way et al., 2000)). We 
assessed if phorbol ester stimulated MEK/ERK signaling could be blocked in H510 cells by 
RAD001. H510 cells were set up as before, and stimulated with 400nM of phorbol ester 
(determined by dose response experiments- data not shown) for 5 minutes before lysis. Blots 
were probed for bi-phospho ERK1/2 and Lamin B followed by SDS PAGE analysis. Figure 
5.1C shows that high doses of RAD001 block phorbol ester stimulation of biphospho-
ERK1/2. This was observed only at 100ng/ml of RAD001 as opposed to 10ng/ml RAD001 
when FGF-2 was used to stimulate MEK/ERK signaling in this cell line. 
 
V.2.2 SCF and ADH stimulation of ERK and S6 Kinase 1 in H510 SCLC cells can be 
blocked by pre-treatment with RAD001 
 
Next we looked at other growth factors important in SCLC biology and known to activate 
MEK/ERK signaling. The transmembrane protein c-Kit is a RTK whose primary ligand is 
stem cell factor (SCF) and is expressed in SCLC (Naeem et al., 2002). SCF was used to 
activate MEK/ERK signaling in H510 SCLC cells. H510 cells were set up as before and 
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stimulated with SCF (3ng/ml) for 5 and 10 minutes and then lysed. Blots were probed for 
bi-phospho ERK1/2 or phospho-S6 Kinase 1 (Threonine 389) (depending on the 
experiment) and Lamin B followed by SDS PAGE analysis. Figure 5.2A shows that high 
dose RAD001 can block SCF activation of biphospho-ERK1/2. Again 100ng/ml of 
RAD001 blocks activation of MEK/ERK. Figure 5.2B shows that 1ng/ml of RAD001, 
blocks SCF activation of S6K1 consistent with active RAD001. 
Vasopressin/ADH is a neuropeptide growth factor able to sustain growth of SCLC cells. 
This peptide exert its characteristic effects on cellular processes by binding to specific G 
protein-coupled receptors on the surface of their targets cells (Sethi & Rozengurt, 1991). 
We wanted to see if ADH, as an example of a neuropeptide growth factor, activation of 
MEK/ERK signaling could be blocked by RAD001. 
H510 cells were set up as before and stimulated with ADH (300μM) for 5 and 10 minutes. 
Blots were probed for bi-phospho ERK1/2 or phospho-S6 Kinase 1 (Threonine 389) 
(depending on the experiment) and Lamin B followed by SDS PAGE analysis. Figure 5.3A 
shows again that high doses of RAD001 (starting from around 50ng/ml) could block ADH 
induced phosphorylation of ERK1/2. Figure 5.3B shows, as a control, low dose (3ng/ml) 
RAD001 blocking ADH stimulated phosphorylation of S6K1. 
 
 
V.2.3 Growth factor/chemical stimulation of ERK and S6 Kinase 1 in H524 and H69 
SCLC cells can also be blocked by pre-treatment RAD001 
 
So far we have shown that in H510 SCLC cells be that polypeptide, neuropeptide and 
tumour promoter/chemical activation of MEK/ERK signaling could be blocked by the 
mTOR inhibitor RAD001. Is this phenomenon isolated to this one SCLC cell line or are 
these observations seen in other SCLC cell lines? 
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Figure 5.1 FGF-2 and PDB stimulation of ERK and S6 Kinase 1 in H510 SCLC cells 
can be blocked by RAD001 
 
H510 SCLC cells stimulated with FGF-2 (0.1ng/ml) for 5 minutes (A) and 10 minutes (B) 
and PDB (400nm) for 5 minutes (C). Increasing doses of RAD001 were added 1 hour before 
(1-100ng/ml). Lysates were analysed by SDS-PAGE for the presence of biphosphorylated 
ERK1/2 (A/C) or phosphorylated S6 Kinase 1 (Thr389) (B). Lamin B detection was used as 
a loading control. Experiments repeated at least three times, blot is representative of results. 
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Figure 5.2 SCF stimulation of ERK and S6 Kinase 1 in H510 SCLC cells can be 
blocked by RAD001  
 
H510 SCLC cells stimulated with SCF (3ng/ml) for 5 minutes (A) and 10 minutes (B). 
Increasing doses of RAD001 were added 1 hour before (1-100ng/ml).Lysates were analysed 
by SDS-PAGE for the presence of biphosphorylated ERK1/2 (A) or phosphorylated S6 
Kinase 1 (Thr389) (B). Lamin B detection was used as a loading control. Experiment 
repeated at least three times, blot is representative of results. 
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Figure 5.3 ADH stimulation of ERK and S6 Kinase 1 in H510 SCLC cells can be 
blocked by RAD001  
 
H510 SCLC cells stimulated with ADH (300µM) for 5 minutes (A) and 10 minutes (B). 
Increasing doses of RAD001 were added 1 hour before (1-100ng/ml). Lysates were analysed 
by SDS-PAGE for the presence of biphosphorylated ERK1/2 (A) or phosphorylated S6 
Kinase 1 (Thr389) (B). Lamin B detection was used as a loading control. Experiments 
repeated at least three times, blot is representative of results. 
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Figure 5.4 5% serum and PDB stimulation of ERK and S6 Kinase 1 in H524 SCLC 
cells can be blocked by RAD001  
 
H524 SCLC cells stimulated with feotal calf serum (5%) for 5 minutes (A) and 10 minutes 
(B) and PDB (400nm) for 5 minutes (C). Increasing doses of RAD001were added 1 hour 
before (1-100ng/ml). Lysates were analysed by SDS-PAGE for the presence of 
biphosphorylated ERK1/2 (A/C) or phosphorylated S6 Kinase 1 (Thr389) (B). Lamin B 
detection was used as a loading control. Experiment repeated at least three times, blot is 
representative of results. 
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H69 and H524 SCLC cell lines were examined. FGF-2 is known to activate MEK/ERK 
signaling in H524 cells (unpublished data). However stimulation of biphospho-ERK by 
FGF-2 was difficult in this cell line, despite trying at least two different batches of FGF-2. 
5% foetal calf serum (FCS) was used instead to activate MEK/ERK signaling in this 
particular cell line. Cells were set up as previously described for H510 cells and stimulated 
with 5% FCS for 5 and 10 minutes respectively. Figure 5.4A shows that again RAD001 
blocked FCS induced stimulation of biphospho-ERK1/2 at doses of around 10ng/ml. 
Figure 5.4B shows that low dose RAD001 blocked phosphorylation of S6K1 as a control for 
RAD001 activity. 
Phorbol ester, known to activate MEK/ERK signaling in many SCLC cell lines, was used 
this time in H524 SCLC cells. H524 cells were set up as for H510 cells and phorbol ester 
(400nM) was used to activate MEK/ERK signaling (5 minute stimulation). Figure 5.4C 
shows that again 100ng/ml of RAD001 could block phorbol ester stimulated biphospho-
ERK1/2, consistent with previous findings described here. 
Similar results are seen in Figures 5.5A and 5.6B. H524 cells were set up as for the H510 
cells. SCF (3ng/ml) and ADH (300μM) respectively were used to activate MEK/ERK 
signaling for 5 and 10 minutes depending on the experiment. High doses of RAD001 
blocked this activation as evidenced by a reduction in the biphospho-ERK1/2 signal at 
100ng/ml. Controls (Figure 5.5C and Figures 5.6C) indicate that the RAD001 was active, as 
evidenced by blocking, at low dose, phosphorylation of S6K1. 
The H69 SCLC cell line was examined next. Previous data from our laboratory showed that 
FGF-2 does not induce MEK/ERK signaling in this cell line since the FGF receptor 
(FGFR) is uncoupled from the MEK/ERK pathway (Pardo et al., 2001). Phorbol ester 
(Figure 5.7A), SCF (Figure 5.7A and B) and ADH (Figures 5.8 A and B) were used to 
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Figure 5.5 SCF stimulation of ERK and S6 Kinase 1 in H524 SCLC cells can be 
blocked by RAD001 
 
H524 SCLC cells stimulated with SCF (3ng/ml) for 5 minutes (A) and 10 minutes (B). 
Increasing doses of RAD001 were added 1 hour before (1-100ng/ml). Lysates were analysed 
by SDS-PAGE for the presence of biphosphorylated ERK1/2 (A) or phosphorylated S6 
Kinase 1 (Thr389) (B). Lamin B detection was used as a loading control. Experiments 
repeated at least three times, blot is representative of results. 
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Figure 5.6 ADH stimulation of ERK and S6 Kinase 1 in H524 SCLC cells can be 
blocked by RAD001  
 
H524 SCLC cells stimulated with ADH (300µM) for 5 minutes (A) and 10 minutes (B). 
Increasing doses of RAD001 were added 1 hour before (1-100ng/ml). Lysates were analysed 
by SDS-PAGE for the presence of biphosphorylated ERK1/2 (A) or phosphorylated S6 
Kinase 1 (Thr389) (B). Lamin B detection was used as a loading control. Experiment 
repeated at least three times, blot is representative of results. 
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Figure 5.7 SCF and PDB stimulation of ERK and S6 Kinase 1 in H69 SCLC cells can 
be blocked by RAD001  
 
H69 SCLC cells stimulated with PDB (400nm) for 5 minutes (A), SCF (3ng/ml) for 5 
minutes (B) and 10 minutes (C). Increasing doses of RAD001 were added 1 hour before (1-
100ng/ml).Lysates were analysed by SDS-PAGE for the presence of biphosphorylated 
ERK1/2 (A/B) or phosphorylated S6 Kinase 1 (Thr389) (C). Lamin B detection was used as 
a loading control. Experiment repeated at least three times, blot is representative of results. 
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Figure 5.8 ADH stimulation of ERK and S6 Kinase 1 in H69 SCLC cells can be 
blocked by RAD001  
 
H69 SCLC cells stimulated with ADH (300µM) for 5 minutes (A) and 10 minutes (B). 
Increasing doses of RAD001 were added 1 hour before (1-100ng/ml). Lysates were analysed 
by SDS-PAGE for the presence of biphosphorylated ERK1/2 (A) or phosphorylated S6 
Kinase 1 (Thr389) (B). Lamin B detection was used as a loading control. Experiment 
repeated at least three times, blot is representative of results. 
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activate MEK/ERK signaling in H69 SCLC cells. All were set up as for the H510 cells. H69 
cells were stimulated for 5 and 10 minutes depending on the experiment. RAD001 blocked 
biphospho-ERK1/2 activation at around 100ng/ml for each growth factor. Figures 5.7C and 
5.8C showed that the RAD001 was active; 1-3ng/ml of RAD001 blocked SCF/ADH 
induced phosphorylation of S6K1. 
 
V.2.4 Growth factor stimulation of ERK and S6 Kinase 1 in NSCLC cells (HCC78 and 
HCC95) can not be blocked by pre-treatment with RAD001 
 
Since we have shown that high dose mTOR inhibitors can block growth factor/chemical 
activation of MEK/ERK signaling in 3 SCLC cell lines, we wanted to assess if the same 
observations were present in NSCLC cell lines. It is presently not known if FGF-2 can 
trigger chemoresistance in these cells and if so whether the mechanism is the same as 
described in H510 SCLC cells. 
We first examined the HCC78 NSCLC cell line which has an adenocarcinoma phenotype- 
one of the two most common histological sub-types of NSCLC. A dose response assessment 
of FGF-2 activation of MEK/ERK signaling revealed no such activation (data not shown) 
so phorbol ester was used to activate MEK/ERK signaling in these cells. Cells were plated 
out to ~80% confluence in 6-well plates and left overnight to adhere to the surface of the 
plates. The cells were subsequently placed in 0.5% FCS/DMEM overnight. They were then 
placed in SFM the next morning for 1 hour. The cells were pre-treated with RAD001 
(indicated concentrations) for 1 hour prior to addition of PDB (400nm) for 5 minutes and 
FGF-2 for 10 minutes. Blots were probed for biphospho ERK1/2 or phospho-S6 Kinase 
(Threonine 389) (depending on the experiment) and Lamin B followed by SDS PAGE 
analysis. Figure 5.9A shows that PDB induced phosphorylation of ERK could not be 
blocked by RAD001, even at relatively high doses.  
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Figure 5.9 PDB stimulation of ERK in HCC78 NSCLC can not be blocked by 
RAD001 however FGF-2 stimulation of S6 Kinase 1 in HCC78 NSCLC cells can be 
blocked by RAD001  
 
HCC78 NSCLC cells stimulated with PDB (200nm) for 5 minutes (A) and FGF-2 (1ng/ml) 
for 10 minutes (B). Increasing doses of RAD001 were added 1 hour before (1-100ng/ml). 
Lysates were analysed by SDS-PAGE for the presence of biphosphorylated ERK1/2 (A) or 
phosphorylated S6 Kinase 1 (Thr389) (B). Lamin B detection was used as a loading control. 
Experiment repeated at least three times, blot is representative of results. 
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Since PDB does not activate PI3K/AKT/mTOR/S6K1 signaling, FGF-2 was used to 
activate this pathway and figure 5.9B shows that the RAD001 was active, blocking S6K1 
activation; as expected at relatively low dose of RAD001 (1ng/ml). 
We assessed another NSCLC cell line- the HCC95 line which has a squamous cell 
phenotype. FGF-2 was found to activate MEK/ERK signaling in this cell line (data not 
shown) and was used in subsequent experiments at 1ng/ml dose. Cells were set up as for the 
HCC78 cell line. Figure 5.10A shows that FGF-2 (1ng/ml) activation of MEK/ERK 
signaling could not be blocked by relatively high doses of RAD001. Figure 5.1B shows FGF-
2 activation of S6K1 was blocked at relatively low doses of RAD001, as expected if the 
RAD001 was active. Similar results were observed when EGF; an important growth factor in 
NSCLC biology, was exchanged for FGF-2/phorbol ester in both HCC78/95 NSCLC cell 
lines (data not shown). 
These observations led to the question of whether higher doses of RAD001 could block 
growth factor activation of MEK/ERK signaling in NSCLC cell lines? It may be the case 
that doses needed to block MEK/ERK signaling in SCLC are lower than those needed in 
NSCLC cell lines. We used HCC95 NSCLC cells to try and answer this particular question. 
Cells were set up as previously mentioned for HCC78 cells. Figure 5.11 shows that in 
HCC95 cells even using doses of up to 1000ng/ml of RAD001, which would be difficult for 
patients to tolerate, could not block FGF-2 induced phosphorylation of biphospho-
ERK1/2. 
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Figure 5.10 FGF-2 stimulation of ERK in HCC95 NSCLC can not be blocked by 
RAD001 however FGF-2 stimulation of S6 Kinase 1 in HCC95 NSCLC cells can be 
blocked by RAD001  
 
HCC95 NSCLC cells stimulated with FGF-2 (1ng/ml) for 5 minutes (A) and 10 minutes (B). 
Increasing doses of RAD001 were added 1 hour before (1-100ng/ml). Lysates were analysed 
by SDS-PAGE for the presence of biphosphorylated ERK1/2 (A) or phosphorylated S6 
Kinase 1 (Thr389) (B). Lamin B detection was used as a loading control. Experiment 
repeated at least three times, blot is representative of results. 
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Figure 5.11 High doses of RAD001 do not block FGF-2 stimulation of ERK in HCC95 
NSCLC cells. 
 
HCC95 NSCLC cells stimulated with FGF-2 (1ng/ml) for 5 minutes. Increasing doses of 
RAD001 were added 1 hour before (100-1000ng/ml). Lysates were analysed by SDS-PAGE 
for the presence of biphosphorylated ERK1/2. Lamin B detection was used as a loading 
control. Experiment repeated at least three times, blot is representative of results. 
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V.2.5 FGF-2 stimulation of ERK and S6 Kinase 1 in MCF-7 cells (breast cancer) can 
be blocked by pre-treatment with RAD001.  
 
 
Since we have established that in at least two NSCLC cell lines that growth factor activation 
of MEK/ERK signaling could not be blocked by mTOR inhibitors, another question to ask 
is whether this phenomenon is only pertinent to SCLC cells. The literature indicates this 
observation varies depending upon the cell line. A melanoma and sarcoma cell line show this 
phenomenon (Harwood et al., 2008; Molhoek et al., 2005) whilst NIH3T3 (Fibroblasts) do 
not manifest this potential connection from mTORC1 to MAPK signaling (Chung et al., 
1992). 
We wished to investigate whether FGF-2 activation of MEK/ERK signaling could be 
blocked by mTOR inhibitors in another cell line-the MCF-7 breast cancer cell. This cell line 
was chosen because FGF-2 has been known to be mitogenic in this cell line (Nurcombe et 
al., 2000; Rahmoune et al., 1998) and FGF-2 is able to counteract the killing of agents such 
as etoposide (Vandermoere et al., 2005).  
MCF-7 cells were plated out to ~80% confluence in 6-well plates and left overnight to 
adhere to the surface of the plates. The cells were subsequently placed in 0.5% FCS/DMEM 
overnight. They were then placed in SFM the next morning for 1 hour. The cells were pre-
treated with RAD001 (indicated concentrations) for 1 hour prior to addition of FGF-2 
(1ng/ml) for 5 minutes and 10 minutes depending on the experiment. Blots were probed for 
biphospho-ERK1/2 or phospho-S6 Kinase (Threonine 389) (depending on the experiment) 
and Lamin B followed by SDS PAGE analysis. 
Figure 5.12A shows that 100ng/ml RAD001 could suppress FGF-2 activation of 
biphospho-ERK1/2 like 3 SCLC cell lines and unlike two NSCLC cell lines. Activity of 
RAD001 was shown by suppression of activation of S6K1 at low dose (Figure 5.12B). 
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Figure 5.12 FGF-2 stimulation of ERK and S6 Kinase 1 in MCF7 breast cancer cells 
can be blocked by RAD001  
 
MCF-7 breast cancer cells stimulated with FGF-2 (1ng/ml) for 5 minutes (A) and 10 
minutes (B).Increasing doses of RAD001 were added 1 hour before (1-100ng/ml).Lysates 
were analysed by SDS-PAGE for the presence of biphosphorylated ERK1/2 (A) or 
phosphorylated S6 Kinase 1 (Thr389) (B). Lamin B detection was used as a loading control. 
Experiment repeated at least three times, blot is representative of results. 
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V.2.6 Can high concentrations of rapalogues block FGF-2 and/or PDB-mediated 
chemoresistance in H510, HCC78 or HCC95 cells? 
 
FGF-2 induces chemoresistance in H510 SCLC cells; these effects were found to be 
consistent with and dependent on activation of MEK/ERK signaling in these cells and a 
novel cross-talk between MEK/ERK and S6K2. The FGF-2 induced survival against the 
chemotherapeutic agent etoposide in SCLC cells was found to be regulated by increased 
translation of the anti-apoptotic proteins Bcl-XL, Bcl-2 and IAPs. High doses of RAD001 
reduce FGF-2 activation of MEK/ERK signaling in H510 cells. Can RAD001 block FGF-
2/PDB induced chemoresistance in NSCLC and SCLC cells? 
To answer this question, H510 SCLC were treated with two different concentrations of 
RAD001 (1ng and 100ng/ml, doses at either end of the clinically relevant range) for 1 hour 
prior to addition of FGF-2 (0.1ng/ml) for 4 hours. Etoposide chemotherapy (0.1μM) was 
then added and cells were counted after 4 days. Etoposide was added with each dose of 
RAD001 (ER1 and ER100) and then FGF-2 to each combination of RAD001 and etoposide 
(EFR1 and EFR100). Both the 4 hour pre-treatment with the growth factor and the 4 day 
incubation, as well as the starting number of cells have been determined from previous work 
from the group (Pardo et al., 2001). Etoposide was chosen because it is commonly to treat 
lung cancer. For HCC95 similar doses of RAD001 were used. FGF-2 at 1ng/ml and 
etoposide at 20μM was utilized. For HCC78 cells again similar doses of RAD001 were used, 
PDB was used to activate MEK/ERK signaling at 100nM. 10μM etoposide was utilised. 
(Dose response curves were performed for etoposide in order to determine the respective 
concentrations that caused approximately 50% cell death after 4 days-data not shown). 
Experiments were repeated at least 3 times. 
The results for H510 cells are shown in figure 5.13. In agreement with our previous work, 
etoposide induced killing was rescued by pre-treating the cells with FGF-2 (F/E). This was 
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unlikely to be a consequence of proliferation as FGF-2 alone did not increase the number of 
cells seen compared to control. RAD001 at 1ng/ml (R1) did not induce much cell killing as 
expected whilst with RAD001 at 100ng/ml (R100) around 65% cell killing was observed. 
Low dose RAD001 and etoposide did not have any synergistic/additive effects (ER1) whilst 
higher dose RAD001 and etoposide did (ER100) have some additive effects on cell killing. 
FGF-2 and RAD001 at low dose together had no effects when combined (FR1), whilst 
FGF-2 did not rescue H510 cells from higher dose RAD001 killing (FR100). Next we 
wanted to see if RAD001 could block FGF-2 induced resistance to etoposide. Low dose and 
high dose RAD001 appear to prevent FGF-2 induced resistance to etoposide (EFR1 and 
EFR100) as evidenced by comparing the columns E/F with EFR1 and EFR100. The level 
of cell killing is higher in the two conditions with RAD001.
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Figure 5.13 RAD001 blocks FGF-2 induced rescue from etoposide cell death in H510 
SCLC cells. 
 
Cell survival study H510 SCLC cells.Cells were grown in serum free medium in the absence 
(C) or presence of either 1 ng/ml FGF-2 (F), 0.1μM etoposide (E), FGF-2 plus etoposide 
(F/E), RAD001 at 1 or 100ng/ ml (R1 or R100), etoposide and RAD001 at 1 or 100ng/ml 
(E/R1 or E/R100) The addition of FGF-2 to etoposide and Rad001 at 100ng/ml and 
1ng/ml, (EFR1 and EFR100) 
The FGF-2 was added 4 hours before the etoposide and in all conditions where RAD001 
was used; this was added 1 hour before all other agents. Cell counting with trypan blue 
exclusion was used to assess cell viability 4 days later. The results shown are the mean of 
three independent experiments with each condition performed in triplicate +/- the SEM. 
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Next we looked at the NSCLC cell line HCC95. Similar conditions were set up as for the 
H510 cell line. Figure 5.14 shows the results. FGF-2 appeared to rescue the cells from 
etoposide induced killing (F/E). Again this was unlikely to be a consequence of proliferation 
as FGF-2 alone did not increase the number of cells seen compared to control. RAD001 at 
1ng/ml (R1) did not induce much cell killing as expected whilst with RAD001 at 100ng/ml 
(R100) around 60% cell killing was observed. Low dose RAD001 and etoposide did not have 
any synergistic/additive effects (ER1) whilst higher dose RAD001 and etoposide did 
(ER100) have some small additive effects on cell killing. FGF-2 and RAD001 at low dose 
together had no effects when combined (FR1), whilst FGF-2 did not rescue HCC95 cells 
from higher dose RAD001 killing (FR100). Next we wanted to see if RAD001 could block 
FGF-2 induced resistance to etoposide. Low dose and high dose RAD001 did not appear to 
prevent FGF-2 induced resistance to etoposide (EFR1 and EFR100) as evidenced by 
comparing the columns E/F with EFR1 and EFR100. The level of cell killing is lower in the 
two conditions with RAD001. 
We then moved on to investigate if RAD001 could block chemoresistance in another 
NSCLC cell line- HCC78. Figure 5.15 shows the results. As mentioned FGF-2 does not 
activate MEK/ERK signaling in HCC78 cells so PDB was used to activate this pathway. 
PDB appeared to rescue the cells from etoposide induced killing (P/E). Again this was 
unlikely to be a consequence of proliferation as PDB alone did not increase the number of 
cells seen compared to control. RAD001 at 1ng/ml (R1) did not induce much cell killing as 
expected whilst with RAD001 at 100ng/ml (R100) around 70% cell killing was observed. 
Low dose and high dose RAD001 with etoposide did not have any synergistic/additive 
effects (ER1/ER100). PDB and RAD001 at low dose together had no effects when 
combined (PR1), whilst PDB did rescue HCC78 cells from high dose RAD001 cell killing.  
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Figure 5.14 RAD001 does not block FGF-2 induced rescue from etoposide cell death 
in HCC95 NSCLC cells.  
 
Cell survival study HCC95 NSCLC cells. Cells were grown in serum free medium in the 
absence (C) or presence of either 1 ng/ml FGF-2 (F), 20μM etoposide (E), FGF-2 plus 
etoposide (F/E), RAD001 at 1 or 100ng/ ml (R1 or R100), etoposide and RAD001 at 1 or 
100ng/ml (E/R1 or E/R100).The addition of FGF-2 to etoposide and RAD001 at 
100ng/ml and 1ng/ml (EFR1 and EFR100). 
The FGF-2 was added 4 hours before the etoposide and in all conditions where RAD001 
was used; this was added 1 hour before all other agents. Cell counting with trypan blue 
exclusion was used to assess cell viability 4 days later. The results shown are the mean of 
three independent experiments with each condition performed in triplicate +/- the SEM. 
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Finally, we wanted to see if RAD001 could block PDB induced chemoresistance to 
etoposide in this cell line. Low dose and high dose RAD001 did not appear to prevent PDB 
induced resistance to etoposide (EFR1 and EFR100) as evidenced by comparing the 
columns E/F with EFR1 and EFR100. The level of cell killing is lower in the two conditions 
with RAD001. Low dose RAD001 did not appear to prevent PDB induced chemoresistance 
to etoposide (EPR1) whilst higher doses of RAD001 did appear to prevent PDB induced 
chemoresistance (EPR100). 
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Figure 5.15 RAD001 does block PDB induced rescue from etoposide cell death in 
HCC78 NSCLC cells.  
 
Cell survival study HCC78 NSCLC cells. Cells were grown in serum free medium in the 
absence (C) or presence of either 100nM PDB (P), 10μM etoposide (E), PDB plus etoposide 
(F/E), RAD001 at 1 or 100ng/ ml (R1 or R100), etoposide and RAD001 at 1 or 100ng/ml 
(E/R1 or E/R100).The addition of PDB to etoposide and RAD001 at 100ng/ml and 
1ng/ml (EPR1 and EPR100). 
The PDB was added 4 hours before the etoposide and in all conditions where RAD001 was 
used; this was added 1 hour before all other agents. Cell counting with trypan blue exclusion 
was used to assess cell viability 4 days later. The results shown are the mean of three 
independent experiments with each condition performed in triplicate +/- the SEM. 
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V.2.8 Discussion 
 
These results show that pre-treatment with high dose RAD001 can block growth factor- be 
that polypeptide or neuropeptide, phorbol ester and serum induced phosphorylation of 
biphospho-ERK1/2 in 3 SCLC cell lines. These results demonstrate that the findings from 
our laboratory using high dose rapamycin in H510 cells to block FGF-2 induction of 
biphospho-ERK1/2 are applicable to other more modern clinically relevant mTOR 
inhibitors/rapalogues. This seems to be consistent in SCLC cell lines despite the growth 
factor/chemical used to activate MEK/ERK signaling. Since stimulation of this pathway can 
lead to activation of a novel translational mechanism to prevent etoposide induced apoptosis 
in H510 cells, it would seem reasonable to suggest that mTOR inhibitors could block this 
resistance to chemotherapy killing. This appears to be the case in H510 cells when using high 
doses and low doses of RAD001 (100ng/ml) in a 4 day cell survival assay. The degree of 
blocking of chemoresistance was not large nor was it quantified statistically, however a trend 
could be seen. The observation that low dose RAD001 blocks FGF-2 rescue of etoposide 
killing is somewhat surprising since in experiments using rapamycin low doses could not 
rescue this killing (Pardo et al., 2002). It may be that the extra hydroxyl ethyl group on 
RAD001 makes it more potent than rapamycin. This clearly needs further investigation. We 
could have seen if low doses of RAD001 could block S6K2 activation, for example to see if 
this is the mechanism. 
This observation lends weight to a potential novel therapeutic strategy in SCLC of using 
mTOR inhibitors to help overcome cytotoxic chemotherapy resistance. 
We demonstrated that FGF-2/PDB/EGF activation of MEK/ERK in 2 NSCLC cell lines, 
representing the two most common histological subtypes, could not be blocked by RAD001. 
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The reason for this was not clear. Drug metabolism could be different in NSCLC however 
RAD001 did block phosphorylation of S6K1. This would be another subject to investigate 
further. Despite these observations, FGF-2 and PDB could induce chemoresistance to 
etoposide chemotherapy over 4 days in HCC95 and HCC78 NSCLC cells, respectively. 
RAD001 could not prevent FGF-2 induced chemoresistance in HCC95 cells, but could do 
so in PDB induced chemoresistance in HCC78 cells. The mechanism for this 
chemoresistance in these NSCLC may not involve activation of MEK/ERK signaling and is 
not known presently. There are many putative chemoresistance mechanisms in NSCLC 
including DNA repair capacity after exposure of chemotherapy, expression of multi drug 
resistance associated-proteins and mutations in the EGFR gene (Berger et al., 1997; Hirsch 
& Witta, 2005; Zamble & Lippard, 1995). 
Breast cancer cells (MCF-7), in whom FGF-2 can activate MEK/ERK signaling; RAD001 
blocked biphospho-ERK1/2 at high dose. Again, confirming that this phenomenon is seen 
in some but not all cancer cell lines.  
In summary these results show that in SCLC cell lines; high dose RAD001 does block 
growth factor/chemical activation of MEK/ERK signaling unlike in NSCLC cell lines. High 
doses of RAD001 also blocked FGF-2 induced chemoresisitance to etoposide induced 
apoptosis in a 4 day assay in H510 SCLC cells; this was not the case in HCC95 NSCLC cells. 
However phorbol ester induced resistance to etoposide killing was blocked by RAD001 over 
4 days in HCC78 NSCLC cells despite RAD001 not being able to block MEK/ERK 
activation in a short stimulation assay. Phorbol esters activate the second messengers- 
classical protein kinase C (cPKC) and non-classical PKCs. They are involved in cell 
proliferation and survival (Musashi et al., 2000; Wert & Palfrey, 2000). Substrates include 
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MAP kinase, RAF kinase and certain receptor tyrosine kinases (Mellor & Parker, 1998), so 
the mechanism of this phorbol ester chemoresistance to chemotherapy is not clear. 
The question still remains- what is the mechanism of high dose RAD001 blocking FGF-2 
activation of MEK/ERK signaling? 
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CHAPTER VI 
 
mTOR and MEK/ERK signaling 
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VI.1 Introduction 
From the previous chapters results we have seen that at in 3 SCLC cell lines and 1 breast 
cancer cell line that pre-treatment with mTOR inhibitors/rapalogues can impair activation of 
MAPks and in two NSCLC cell lines it cannot. It is documented that the extracellular signal 
regulating protein kinases ERK1/2 can phosphorylate and hence negatively regulate TSC 
leading to increased signaling by mTORC1 (Chiang & Abraham, 2007) however the opposite 
– mTORC1 regulating ERK1/2 and MEK/ERK signaling has not been well documented. If 
mTORC1 can regulate MEK/ERK signaling it would signify a new signal transduction 
pathway for mTOR. However there may be other mechanisms involved including high dose 
mTOR inhibitors/rapalogues could cause conformational changes in the FKBP12/mTOR 
complex resulting in secondary effects (drug saturation effects) or that mTOR 
inhibitors/rapalogues, at relatively high doses are hitting another target. 
Another potential mechanism that could explain our observations is that mTOR inhibition 
activates a serine/threonine protein phosphatase that dephosphorylates regulatory sites. 
Research from 1999 showed that mTOR controls 4E-BP1 and S6 kinase 1 phosphorylation 
indirectly by restraining a phosphatase which was found to be protein phosphatase 2A (PP2) 
(Peterson et al., 1999). 
Protein phosphatase 2 (PP2) (previously PP2A), a heterotrimeric protein phosphatase, is a 
ubiquitous and conserved serine/threonine phosphatase with broad substrate specificity and 
diverse cellular functions. PP2 consists of a core enzyme comprising the structural A and 
catalytic C subunits, and a regulatory B subunit. When the PP2 catalytic C subunit associates 
with the A and B subunits; several species of holoenzymes are produced with distinct 
functions and characteristics. The A subunit, a member of the HEAT repeat protein family 
(huntington-elongation-A subunit-TOR), is the scaffold required for the formation of the 
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heterotrimeric complex. When the A subunit binds it alters the enzymatic activity of the 
catalytic subunit, even if the B subunit is absent. While C and A subunit sequences show 
sequence conservation throughout eukaryotes, regulatory B subunits are more 
heterogeneous and are believed to play key roles in controlling the localization and specific 
activity of different holoenzymes. Multicellular eukaryotes express four classes of variable 
regulatory subunits: B (PR55), B’ (B56 or PR61), B’’ (PR72), and B’’’ (PR93/PR110), with at 
least 16 members in these subfamilies. In addition, accessory proteins and posttranslational 
modifications (such as methylation) control PP2 subunit associations and activities. Among 
the targets of PP2 are proteins of oncogenic signaling cascades, such as Raf, MEK, and Akt 
(Ory et al., 2003; Xing et al., 2006; Xu et al., 2006). 
In fact last year a group from the United States found that mTORC1 signaling could regulate 
growth factor activation of p44/42 MAPKs through PP2 (Harwood et al., 2008). This group 
essentially addressed the same issue we investigate here. The cells that were used were the 
Rh1 human Ewing sarcoma cell line. They found that high concentrations of rapamycin 
induced inhibition of EGF induced phosphorylation of p44/42(Thr202) and this was reversed 
by low concentrations of okadaic acid. Okadaic acid at concentrations ~100nM or less is a 
relatively specific inhibitor of PP2A/PP2 (Favre et al., 1997; Honkanen & Golden, 2002). 
In this chapter we will be asking whether mTOR or the intracellular receptor for rapalogues-
FKBP12 is important for high dose mTOR inhibitors/rapalogues blocking FGF-2 activation 
of ERK1/2. 
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VI.2 RESULTS 
 
VI.2.1 RNAi to FKBP12 does not seem to prevent high dose RAD001 blocking FGF-2 
stimulated phosphorylation of ERK in MCF-7 breast cancer cells. 
 
To assess whether the intracellular ‘receptor’ for rapamycin- FKBP12 is important in the 
mechanism of how high dose mTOR inhibitors/rapalogues block growth factor induced 
phosphorylation of MAPks, RNA interference (siRNAi) to FKBP12 was performed in 
MCF-7 breast cancer cells to down regulate FKBP12. Since RNAi in general to H510 SCLC 
has been fraught with difficulties- cells dying after transfection and low transfection rates 
(unpublished data from Seckl group), MCF-7 breast cancer cells were chosen to investigate 
this mechanism since these cells are easily transfected with RNAi oligonucleotides and 
importantly manifest high dose mTOR inhibitor/rapalogues blocking FGF-2 induced 
MEK/ERK signaling. 
The specificity and optimum concentration for ‘knock-down’ of FKBP12 in MCF-7 cells 
was determined. We performed dose responses to determine the minimum amount of 
pooled siRNA required to achieve silencing and compared to a non-specific set of targeting 
sequences. We then deconvoluted the pooled siRNA into 4 individual siRNAs and observed 
that 3 out of the 4 targeting sequences achieved very similar knockdown of FKBP12 protein 
(data not shown). These concentrations were used in subsequent experiments. Cells (where 
relevant) were transfected with FKBP12 oligonucleotides for 48 hour prior to experiments 
as described. 
Figure 6.1 shows the results of experiments using FGF-2 (for 5 minutes) to activate 
phosphorylation of biphospho-ERK1/2. Blots were probed for biphospho-ERK1/2, 
mTOR, FKBP12 and Lamin B followed by SDS-PAGE analysis. On the left hand side of 
the panel, where cells were not transfected, 100ng/ml RAD001 reduced the degree of FGF-  
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Figure 6.1 RNAi to FKBP12 does not prevent high dose RAD001 blocking FGF-2 
stimulated phosphorylation of ERK1/2 in MCF-7 cells. 
 
MCF-7 cells were transfected with pooled siRNA targeting FKBP12 48 hours before 
incubation for 1 hour without (-) or with RAD001 at low (1ng/ml) or high (100ng/ml) 
concentrations. The cells were then exposed (+) or not (-) to 1ng/ml FGF-2. Lysates were 
analysed by SDS-PAGE for the presence of biphospho-ERK1/2. Lamin B detection was 
used as a loading control. Results are representative of 3 repeat experiments. 
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2 induced phosphorylation of ERK1/2 as expected. On the right hand side of the panel, 
cells were prior transfected with RNAi to FKBP12; again 100ng/ml RAD001 reduced 
phosphorylation of ERK1/2. It appears that FKBP12 is not involved in this mechanism. 
mTOR total protein levels did not appear to be affected by siRNAi to FKBP12 which 
appeared to be silenced. We cannot exclude the possibility that there was some FKBP12 still 
present and that the RAD001 at high concentrations may still be acting through this protein 
to impair mTOR function and so MEK/ERK signaling. 
 
VI.2.2 RNAi to FKBP12 does not prevent RAD001 blocking FGF-2 stimulated 
phosphorylation of S6 Kinase 1 in MCF-7 cells. 
 
RAD001 blocks FGF-2 induced activation of S6K1 in H510 SCLC cells; this should be 
prevented by using RNAi knock down to FKBP12 since mTOR inhibitors/rapalogs firstly 
bind to FKBP12 before together targeting the FRB domain of mTOR. To confirm this, 
MCF-7 cells were set up as previously described. Blots were probed for phospho-S6 Kinase 
1 (Threonine 389), mTOR, FKBP12 and Lamin B followed by SDS PAGE analysis. Figure 
6.2 shows the results. On the left side of the panel, as expected in non-transfected cells when 
FGF-2 is used to activate S6K1 (10 minute stimulation), this is blocked by 1ng/ml of 
RAD001. However, this was also the case when these cells were transfected with RNAi to 
FKBP12 (right panel).This would seem counter intuitive, however the original film used to 
develop this experiment showed complete knock down of FKBP12, however when film 
exposure time was increased- as can be seen here, FKBP12, though reduced in expression, is 
still present. So these silencing experiments cannot exclude the possibility that FKBP12 
mediates the high dose effects of rapalogues on MEK/Erk signaling. 
A consistent problem seen when MCF-7 cells are transfected with siRNAi oligonucleotides 
to FKBP12 is that the controls i.e. no other condition apart from RNAi transfection greatly  
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Figure 6.2 RNAi to FKBP12 does not prevent RAD001 blocking FGF-2 stimulated 
phosphorylation of S6 Kinase 1 in MCF-7 cells. 
 
MCF-7 cells were transfected with pooled siRNA targeting FKBP12 48 hours before 
incubation for 1 hour without (-) or with RAD001 at low (1ng/ml) or high (100ng/ml) 
concentrations. The cells were then exposed (+) or not (-) to 1ng/ml FGF-2. Lysates were 
analysed by SDS-PAGE for the presence of phosphorylated S6 Kinase 1 (Thr389). Lamin B 
detection was used as a loading control. Results are representative of 3 repeat experiments. 
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Figure 6.3 RNAi to mTOR does not prevent high dose RAD001 blocking FGF-2 
stimulated phosphorylation of ERK1/2 in MCF-7 cells. 
 
MCF-7 cells transfected with pooled siRNAi targeting mTOR 48 hours before incubation 
for 1 hour without (-) or with RAD001 at low (1ng/ml) or high (100ng/ml) concentrations. 
The cells were then exposed (+) or not (-) to 1ng/ml FGF-2. Lysates were analysed by SDS-
PAGE for the presence of biphospho-ERK1/2. Lamin B detection was used as a loading 
control. Results are representative of 3 repeat experiments. 
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expressed phosphorylated ERK1/2. This was observed in all experiments including those 
involving specificity and dose-response of FKBP12 siRNAi oligonucleotides. 
 
VI.2.3 RNAi to mTOR does not prevent high dose RAD001 blocking FGF-2 
stimulated phosphorylation of ERK1/2 in MCF-7 cells. 
 
The next step was to determine if knock down to mTOR itself can prevent FGF-2 induced 
phosphorylation of biphospho-ERK1/2. If so, that could imply that this mechanism directly 
involves mTOR. MCF-7 cells were set up as described before. The specificity and optimum 
concentration for ‘knock-down’ of mTOR in MCF-7 cells was determined. We performed 
dose responses to determine the minimum amount of pooled siRNA required to achieve 
silencing and compared to a non-specific set of targeting sequences. We then deconvoluted 
the pooled siRNA into 4 individual siRNAs and observed that 3 out of the 4 targeting 
sequences achieved very similar knockdown of mTOR protein. (data not shown). In the 
right panel, the cells were prior transfected with RNAi oligonucleotides to mTOR for 48 
hours. Blots were probed for biphospho-ERK1/2, mTOR and Lamin B followed by SDS 
PAGE analysis. Figure 6.3 (left panel) shows the non-transfected cells and as expected the 
reduction in the FGF-2 induction (5 minute stimulation) of phosphorylation of biphospho-
ERK1/2 with 100ng/ml RAD001. In the right panel, the cells were prior transfected with 
siRNAi oligonucleotides to mTOR for 48 hours. FGF-2 induction of biphospho-ERK1/2 
was blocked at 100ng/ml RAD001 despite knock down of mTOR, implying that this 
phenomenon does not involve mTOR. However, as for FKBP12, we could not exclude the 
possibility that the residual amount of mTOR still present after silencing might be sufficient 
to mediate the effects of high concentrations of rapalogues on MEK/ERK signaling.  
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VI.2.4 RNAi to mTOR does not prevent high dose RAD001 blocking FGF-2 
phosphorylation of S6 Kinase 1 in MCF-7 cells. 
RNAi knockdown of mTOR should prevent RAD001 blocking FGF-2 phosphorylation of 
S6K1. To see if this is the case MCF-7 cells were prepared as described. Blots were probed 
for phospho-S6 Kinase 1 (Threonine 389), mTOR and Lamin B followed by SDS PAGE 
analysis. Figure 6.4 (left panel) shows untransfected cells, where low dose RAD001 blocks 
FGF-2 (10 minute stimulation) phosphorylation of S6K1. The right hand panel, where the 
cells have been transfected with siRNAi oligonucleotides to mTOR, RAD001 again blocks 
FGF-2 induced phosphorylation of S6K1. Taken together, these results suggest that 
knockdown of either mTOR or FKBP12 was not sufficient to prevent rapalogue action 
either at low or high dose. Therefore, we cannot necessarily exclude mTOR or FKBP12 
from mediating the inhibition of MEK/ERK signaling by high dose rapalogues.  
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Figure 6.4 RNAi to mTOR does not prevent RAD001 blocking FGF-2 
stimulated phosphorylation of S6 Kinase 1 in MCF-7 cells. 
 
MCF-7 cells transfected with pooled siRNAi targeting mTOR 48 hours before 
incubation for 1 hour without (-) or with RAD001 at low (1ng/ml) or high 
(100ng/ml) concentrations. The cells were then exposed (+) or not (-) to 1ng/ml 
FGF-2. Lysates were analysed by SDS-PAGE for the presence of 
phosphorylated S6 Kinase 1 (Thr389). Lamin B detection was used as a loading 
control. Results are representative of 3 repeat experiments. 
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VI.2.6 Discussion 
This chapter has tried to shed some light on the mechanism of how high doses of rapalogues 
can impair FGF-2 activation of ERK1/2 in H510 SCLC cells. FGF-2 can protect H510 
SCLC cells from etoposide killing and this involves activation of MEK/ERK signaling 
leading to formation of a complex which upregulates certain anti-apoptotic proteins. 
Understanding the exact mechanism may help design novel treatments for small cell lung 
cancer. 
We first looked at whether the intracellular receptor for rapalogues- FKBP12 has any 
connection with the afore mentioned phenomenon. Normally, FKBP12 combines with 
rapamycin and then together with the FRB domain of mTOR to block mTOR activation. If 
FKBP12 is knocked down by siRNA and FGF-2 induced activation of ERK1/2 is not 
blocked by rapalogues, then it would seem reasonable to infer that FKBP12 is involved. We 
showed that when FKBP12 was ‘knocked down’ by siRNA, RAD001 could block FGF-2 
activation of ERK1/2. This result suggests that FKBP12 was not involved in rapalogues 
impairing FGF-2 activation of ERK1/2. Since RNAi does not completely ‘knock down’ 
protein levels, we can not rule out that low levels of FKBP12 are still present. In fact when 
film exposure times were increased from SDS-PAGE analysis low levels of FKBP12 were 
observed. Similar results were observed when we investigated whether RAD001 could block 
FGF-2 activation of S6K1 when FKBP12 was knocked down by RNAi. RAD001 did block 
S6K1 activation, which is not what we would expect if FKBP12 was completely knocked 
down since for rapalogues to function FKBP12 is needed. Again we could not rule out that 
low levels of FKBP12 were present. This makes conclusions difficult to make regarding the 
role of FKBP12.  
 174 
We next went on to look at the role of mTOR. We showed that RNAi knock down to 
mTOR did not impair RAD001 blocking FGF-2 activation of ERK1/2 nor FGF-2 
activation of S6K1. Conclusions were again were difficult to make due to the presence of 
low levels of mTOR which have not been knocked down by RNAi.  
An alternative to bypass this problem would be to utilize the new ‘TORKinhibs’ which 
target the ATP binding site on mTOR and hence de-activate mTOR and do not require 
FKBP12 to function to determine if signaling through mTOR is essential in reducing FGF-2 
activation of ERK1/2. To determine whether the RAD001 inhibitory effect on MEK/ERK 
signaling was specifically due to RAD001 inhibition of mTORC1 signaling, a mTOR mutant 
could have been used which has reduced binding affinity for RAD001/rapamycin-FKBP12 
complex (Ser2035→I1e)(Brunn et al., 1997). This mutant is then RAD001/rapamycin 
resistant, but still would maintain mTORC1 signaling. 
Phosphorylation of biphospho-ERK1/2 is mediated by a single kinase, MEK1 (Zhou et al., 
2002), it could be that RAD001 is acting not on ERK1/2 but ‘above’ in the signaling 
pathway at MEK1. Previous work from this laboratory showed that in H510 SCLC cells, 
FGF-2 activation of ERK1/2 could be blocked by using a MEK inhibitor, PD098059, at a 
dose of 25μM (Pardo et al., 2001). To further clarify the role of RAD001/rapamycin, we 
would have liked to have seen if these drugs could block activation of MEK1. In the 
Houghton groups work, rapamycin did not inhibit IGF-I induced phosphorylation of MEK 
(Harwood et al., 2008). 
Following the previous experiments, it seems that mTOR and FKBP12 are not involved in 
high dose mTOR inhibitors blocking FGF-2 activation of MEK/ERK signaling in MCF-7 
cells. The next step would be to see if the proposed mechanism of Houghton et al 
(Harwood et al., 2008), that mTORC1 modulates the phosphorylation of biphospho-
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ERK1/2 directly or indirectly through regulation of the phosphatase PP2 (PP2A), is similar 
in MCF-7 cells. Okadiac acid, at relatively low doses is a relatively specific inhibitor of PP2; 
in preliminary experiments (data not shown) we showed that okadiac acid reversed RAD001 
inhibition of FGF-2 activation of ERK1/2. At the concentrations of 10nM-300nM, 
biphospho-ERK was not phosphorylated in the absence of FGF-2 activation i.e. this is not a 
consequence of MEK1 activation by inhibiting PP2 under these conditions. This suggests 
that FGF-2 stimulation inactivates PP2, and this inactivation is prevented by RAD001, 
hence it is mTORC1 dependent. These results fit in to the premise that PP2 is involved in 
the rapid deactivation of the MAPK pathway (Heriche et al., 1997; Zhou et al., 2002). To 
clarify these results we could next use another PP2 inhibitor such as calyculin A, in similar 
experiments. However unlike okadiac acid, calyculin A does also inhibit protein phosphatase 
1 (PP1)(Peterson et al., 1999). 
It would seem phosphatase regulation may be more useful than kinase regulation, when 
rapid dephosphorylation is needed at multiple sites, under the control of many different 
kinases. Hence activation of a phosphatase may allow dephosphorylation of many sites 
without having to inhibit all of the kinases responsible for their phosphorylations. It would 
be interesting to know if other PI3K family members use phosphatases in a similar way. 
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CHAPTER VII 
 
Combination studies of mTOR and 
cytotoxic chemotherapy in SCLC cells 
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VII.1 Introduction 
Combination drug treatment regimens in cancer, acquired immune deficiency syndrome 
(AIDS) and tuberculosis often achieve a greater therapeutic efficacy than that achieved with 
monotherapy. Previous work from this thesis has potentially shown that in SCLC cells, 
mTOR inhibitors can block a growth factor induced chemoresistance pathway. This leads to 
the question of whether mTOR inhibitors when added to cytotoxic chemotherapy produce 
additive, synergistic or inhibitory effects. It is possible that sequencing of the drugs may 
effect whether additive/synergistic as opposed to antagonistic effects are seen. This would 
appear to be pertinent here since mTOR inhibitors arrest the cell cycle (G1) (Cafferkey et al., 
1994; Fingar et al., 2004) and etoposide, a semisynthetic podophyllotoxin-derived 
antineoplastic agent used in SCLC, is active when cells are in cycle and killing cells in G2 and 
S phases (Hande, 1992; Joel et al., 1994). Theoretically at least it would seem that 
administering the two drugs at the same time may lead to antagonistic effects. Instead, it 
might seem logical to treat with the mTOR inhibitor after etoposide to prevent regrowth of 
cells between cycles of chemotherapy. 
These questions are important to ask at the in vitro level since if drug combinations lead to 
clinical trials be that phase II or III, determining the ideal sequence in patients is difficult at 
these stages because there is little flexibility allowed in these trials. The real problem here is 
that clinical trials are expensive and exploring sequencing of drugs is often thought by the 
pharmaceutical industry, whether rightly or wrongly, to not be very cost-effective. 
The success of drug combination in the clinic may be aided by pre-clinical studies examining 
sequencing. (Chang et al., 2006; Chou & Dong, 2005; Chou, 1998). 
Studies to answer these types of questions have been researched and validated by Ting-Chao 
Chou of the Memorial Sloan Kettering Cancer Center in the United States. His derivation of 
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the median effect equation from the law of mass action has been extensively used in 
combination studies in well over 2600 papers (Chou, 2006). 
 
This equation describes dose-effect relationships in the simplest form: 
 
fa/fu = (D/Dm)m 
 
Where D is the dose (concentration) of a drug, fa is the fraction affected by D (i.e. percentage 
inhibition/100), and fu is the fraction unaffected (i.e., fu= 1- fa). Dm is the median-effect dose 
(IC50) that inhibits the system under study by 50% and m is the coefficient signifying the 
shape of the dose-effect relationship, where m=1, >1, and <1 to indicate hyperbolic, 
sigmoidal, and flat sigmoidal dose-effect curves, respectively (Chou, 1976). Chou describes 
this equation as the general theory of dose and effect. 
This equation can be extended to any drug system, for example for first order system i.e. 
m=1: 
 (fa)1,2/(fu)1,2= (fa)1/(fu)1+ (fa)2/( fu)2 = (D)1/(Dm)1 + (D)2/(Dm)2 
 
In 1983 Chou and Talalay introduced the term combination index (CI) for determination of 
the synergism or antagonism for two drugs (Chou et al., 1983): 
CI=(D)1/(Dx)1+ (D)2/(Dx)2= (D)1 /(Dm)1+ (D)2/(Dm)2 {fa/(1-fa)}1/m2 
 
Where CI<1, =1, and >1 indicate synergism, additive effect, and antagonism, respectively.  
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The prerequisite for synergism or antagonism determination is to know both the potency 
and the shape of the dose-effect curve for each drug alone and for the two drug 
combinations. From the individual drug dose-response curves IC50s are determined and are 
used in fixed dose and equipotency combinations so that the contributions of effects of each 
drug are roughly equal as described in the methods section. This method allows for reduced 
numbers of data points and allows for maximal amount of useful information. 
From these equations Chou developed software to allow for automated analysis of data. 
CalcuSyn (Chou & Hayball, 1997) generates graphics and can handle data analysis of large-
scale drug combination studies. 
In this chapter we studied the combination of the mTOR inhibitor RAD001 with etoposide 
or cisplatin in two SCLC cell lines- H510 and H69. Etoposide and cisplatin have clinical 
activity in SCLC and with mTOR inhibitors have no overlapping toxicities, important when 
administered to patients. The hypothesis is that the combination of an mTOR inhibitor and 
cyctotoxic chemotherapy (cisplatin or etoposide) will be able to elicit more cell killing. 
However with the drugs acting at different points of the cell cycle, it is important to know in 
what sequence these drugs work best. 
Previous work from this laboratory and a collaborator showed that H-69 SCLC cells were 
sensitive to RAD001 whilst H510 SCLC cells were more resistant and that when combined 
together with etoposide the H-69 cells showed at least additive effects whilst H-510 cells did 
not show any obvious benefit of the combination. However, these studies were rather 
preliminary as they: (1) did not perform formal isobolgram/combination analysis, (2) only 
looked at etoposide and not cisplatin and (3) did not assess the question of sequencing of the 
drugs (Marinov, 2009). 
 
 180 
VII.2 RESULTS 
 
VII.2.1 Dose response curves for H69 and H510 for cisplatin, etoposide and RAD001 
 
The cytotoxicities of cisplatin, etoposide and RAD001 in 2 small cell lung cancer cell lines- 
H69 and H510 are shown in figures 7.1 and 7.2. The results were obtained from dose 
response curves plotted using Calcusyn software. Cells (H69/H510) were seeded in 24 well 
plates and treated with varying concentrations as described of RAD001 or cisplatin or 
etoposide. After 4 days of treatments, growth inhibition was measured by cell counting. 
IC50’s obtained (Table 7.1) from these curves were used in subsequent combination study 
experiments. 
 
Cell Line Cisplatin IC50 µM 
(mean ± SEM) 
Etoposide IC50 µM 
(mean ± SEM) 
RAD001 IC50 ng/ml 
(mean ± SEM) 
H69 193±12 0.48± 0.04 123± 8 
H510 141±21 0.12±0.02 95±11 
 
Table 7.1 In vitro growth inhibitory effect of cisplatin, etoposide and RAD001 in 
human SCLC cell lines.  
 
SCLC cells were seeded at 1,500 per well in 24-well plates; at 24 hours after seeding, cells 
were treated with varying concentrations of RAD001, cisplatin or etoposide. After 4 days of 
treatments, growth inhibition was measured by cell counting. The experiments were 
performed in triplicate. Results were plotted on graphs by using Calcusyn software and used 
to determine respective inhibitory concentration IC50 for combination studies. Each value is 
the mean ± Standard Error of the Mean (SEM) of the IC50 of three or four independent 
experiments. 
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Figure 7.1 H69 SCLC cells and dose-response effects with RAD001, 
Cisplatin and Etoposide.  
The H69 SCLC cells were seeded (1,500 per well) in 24-well plates; at 24 h after 
seeding, cells were treated with varying concentrations of RAD001(A) or Cisplatin 
(B) or etoposide (C). After 4 days of treatments, growth inhibition was measured 
by cell counting. Blue lines indicate IC50. The results shown are the mean of three 
independent experiments with each condition performed in triplicate +/- the 
SEM.  
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Figure 7.2 H510 SCLC cells and dose-response effects with RAD001, Cisplatin 
and Etoposide.  
 
The H510 SCLC cells were seeded (1,500 per well) in 24-well plates; at 24 h after 
seeding, cells were treated with varying concentrations of RAD001(A) or Cisplatin (B) 
or etoposide (C). After 4 days of treatments, growth inhibition was measured by cell 
counting. Blue lines indicate IC50. The results shown are the mean of three 
independent experiments with each condition performed in triplicate +/- the SEM. 
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VII.2.2 Combination studies of H69 SCLC with RAD001 and Etoposide. 
 
Next we wanted to find out the effect of combining each cytotoxic agent with RAD001 and 
determine the most effective schedule. To determine synergy, additivity or antagonism of 
combinations of these drugs the isobologram/combination index method was used which 
relies upon the calculation of the fixed dose combination that causes a given effect. We 
chose the following fixed dose combinations: IC 12.5, IC 25, IC50, IC 100 and IC 200 i.e. the IC 12.5 
of etoposide in H69 cells is administered with the IC 12.5 of RAD001 in H69 cells. The IC50’s 
were determined from the previous experiments. Each experiment generated a set of 
combination index (CI) values for a particular effect. The CI was used to determine 
additivity, synergy, or antagonism of the combination depending on interaction index = 1, 
<1, or >1, respectively. 
Figure 7.3 shows the combined effect of etoposide administered to H69 cells 2 days before 
RAD001 (A), etoposide and RAD001 given simultaneously (B) and RAD001 2 days before 
etoposide (C). Table 7.2 shows the CI’s for each fixed dose. 
Fixed Dose CI Etoposide before 
RAD001 
CI Etoposide and 
RAD001 
simultaneously 
CI RAD001 before 
Etoposide 
IC 12.5 <1 <1 1 
IC 25 <1 <1 <1 
IC50 1 1 <1 
IC 100  >1 >1 <1 
IC 200 >1 >1 >1 
 
Table 7.2 CI values of combinations of etoposide and RAD001 in H69 SCLC cells. 
Additivity, synergy, or antagonism of the combination depends on the interaction index = 1, 
<1, or >1, respectively. 
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Figure 7.3 Combination studies of H69 SCLC with RAD001 and Etoposide over 4 days. 
(A) Etoposide 2 days before RAD001, (B) Etoposide and RAD001 given simultaneously and (C) RAD001 2 
days before Etoposide. H69 cells in serum free media were seeded in 12 well plates, five fixed drug ratios above 
and below the IC50 were explored by incubating the drug combinations with cells for 4 days and then 
determining the degree of cytotoxicity by cell counting with trypan blue exclusion was used to assess cell 
viability. The combination index (CI) was used to determine additivity, synergy, or antagonism of the 
combination depending on interaction index = 1, <1, or >1, respectively. The results shown are the mean of 
three independent experiments performed in triplicate. 
H69 etop b4 rad 
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From these results when etoposide is administered to H69 SCLC cells before RAD001, low 
fixed dose combinations are synergistic whilst higher doses are additive (IC50) and higher still  
is antagonistic. A similar pattern is seen when the two drugs are given at the same time. 
However when RAD001 is administered before etoposide; low fixed dose combination (IC 
12.5) is additive, higher combinations are synergistic until the IC200 combination where it was 
found to be antagonistic. 
 
VII.2.3 Combination studies of H510 SCLC with RAD001 and Etoposide 
Next we performed similar studies using etoposide and RAD001, with another SCLC cell 
line- H510. 
Figure 7.4 shows the combined effect of etoposide administered to H510 cells 2 days before 
RAD001 (A), etoposide and RAD001 given simultaneously (B) and RAD001 2 days before 
etoposide (C). Table 7.3 shows the CI’s for each fixed dose.  
 
Fixed Dose CI Etoposide before 
RAD001 
CI Etoposide and 
RAD001 
simultaneously 
CI RAD001 before 
Etoposide 
IC 12.5 <1 >1 >1 
IC 25 1 >1 >1 
IC50 >1 >1 >1 
IC 100  >1 >1 >1 
IC 200 >1 >1 >1 
 
Table 7.3 CI values of combinations of etoposide and RAD001 in H510 SCLC cells. 
Additivity, synergy, or antagonism of the combination depends on the interaction index = 1, 
<1, or >1, respectively. 
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Figure 7.4 Combination studies of H510 SCLC with RAD001 and Etoposide. 
(A)Etoposide 2 days before RAD001, (B) Etoposide and RAD001 given simultaneously and (C) RAD001 2 
days before Etoposide. H510 cells in serum free media were seeded in 12 well plates, five fixed drug ratios 
above and below the IC50 were explored by incubating the drug combinations with cells for 4 days and then 
determining the degree of cytotoxicity by cell counting with trypan blue exclusion was used to assess cell 
viability The combination index (CI) was used to determine additivity, synergy, or antagonism of the 
combination depending on interaction index = 1, <1, or >1, respectively The results shown are the mean of 
three independent experiments performed in triplicate. 
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From these results administering etoposide 2 days before RAD001, low doses are synergistic 
or additive (IC12.5 and IC25) whilst higher dose concentrations when combined lead to 
antagonistic effects. When etoposide and RAD001 are given together and when RAD001 
was given before etoposide at all doses examined antagonistic effects were only seen. Our 
previous paper (Marinov, 2009) showed that the H510 cells are not sensitized to etoposide 
killing by RAD001 is largely true except perhaps at low dose pairs when RAD001 is given 
before etoposide. 
 
VII.2.4 Combination studies of H69 SCLC with RAD001 and Cisplatin. 
Another drug commonly used in clinical practise to treat SCLC is cisplatin. We wanted to 
see the effects of combining cisplatin and RAD001. We started with the H69 SCLC cell line. 
Figure 7.5 shows the combined effect of cisplatin administered to H69 cells 2 days before 
RAD001 (A), cisplatin and RAD001 given simultaneously (B) and RAD001 2 days before 
cisplatin (C). Table 7.4 shows the CI’s for each fixed dose.  
Fixed Dose CI Cisplatin before 
RAD001 
CI Cisplatin and 
RAD001 
simultaneously 
CI RAD001 before 
Cisplatin 
IC 12.5 <1 >1 <1 
IC 25 <1 >1 <1 
IC50 <1 >1 <1 
IC 100  <1 <1 <1 
IC 200 <1 <1 <1 
 
Table 7.4 CI values of combinations of cisplatin and RAD001 in H69 SCLC cells. 
Additivity, synergy, or antagonism of the combination depends on the interaction index = 1, 
<1, or >1, respectively. 
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Figure 7.5 Combination studies of H69 SCLC with RAD001 and Cisplatin. 
(A)Cisplatin 2 days before RAD001, (B) Cisplatin and RAD001 given simultaneously and (C) RAD001 2 days before 
Etoposide. H69 cells in serum free media were seeded in 12 well plates, five fixed drug ratios above and below the IC50 
were explored by incubating the drug combinations with cells for 4 days and then determining the degree of cytotoxicity by 
cell counting with trypan blue exclusion was used to assess cell viability. The combination index (CI) was used to determine 
additivity, synergy, or antagonism of the combination depending on interaction index = 1, <1, or >1, respectively. The 
results shown are the mean of three independent experiments performed in triplicate. 
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From these results in H69 cells, giving cisplatin before RAD001 leads to synergistic effects. 
Low doses of cisplatin and RAD001 when given simultaneously are antagonistic whilst 
higher doses (IC100 and IC200) lead to synergistic effects. RAD001 when given 2 days before 
cisplatin at all doses examined, synergistic effects were observed. 
 
VII.2.5 Combination studies of H510 SCLC with RAD001 and Cisplatin. 
We next examined whether similar effects were seen with cisplatin and RAD001 in the H510 
cell line. Figure 7.6 shows the combined effect of cisplatin administered to H510 cells 2 days 
before RAD001 (A), cisplatin and RAD001 given simultaneously (B) and RAD001 2 days 
before cisplatin (C). Table 7.5 shows the CI’s for each fixed dose.  
 
Fixed Dose CI Cisplatin before 
RAD001 
CI Cisplatin and 
RAD001 
simultaneously 
CI RAD001 before 
Cisplatin 
IC 12.5 <1 >1 >1 
IC 25 <1 >1 >1 
IC50 <1 <1 1 
IC 100  <1 <1 <1 
IC 200 <1 <1 <1 
 
Table 7.5 CI values of combinations of cisplatin and RAD001 in H510 SCLC cells. 
Additivity, synergy, or antagonism of the combination depends on the interaction index = 1, 
<1, or >1, respectively. 
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Figure 7.6 Combination studies of H510 SCLC with RAD001 and Cisplatin. 
(A) Cisplatin 2 days before RAD001, (B) Cisplatin and RAD001 given simultaneously and (C) RAD001 2 days before Cisplatin.H69 cells in 
serum free media were seeded in 12 well plates, Cisplatin and RAD001 at 12.5%, 25%, 50%, 100% and 200% of their respective IC50s were 
added to the wells in fixed dose combinations. Cell counting with trypan blue exclusion was used to assess cell viability. The results shown 
are the mean of three independent experiments performed in triplicate. 
A 
B 
C 
Fractional Effect 
Fractional Effect 
Fractional Effect 
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In H510 cells drug combination studies of cisplatin and RAD001, cisplatin given before 
RAD001, all doses examined led to synergistic effects. When the drugs were given 
simultaneously low dose drug combinations are antagonistic whilst higher doses (IC100 and 
IC200) are synergistic. Similar results were observed when RAD001 was given before cisplatin 
except when the drugs were combined at the IC50 where additive effects were seen. 
 
 
 
 
  
 
. 
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VII.3 Discussion 
We studied the effects of combinations of etoposide or cisplatin and the mTOR inhibitor 
RAD001 in two SCLC cell lines- H69 and H510. To do this we used the tried and tested 
fixed dose isobologram/combination index method of Chou (Chou, 1998). We also 
examined the scheduling of two drug combinations. 
To summarize when etoposide and RAD001 are combined in H69 SCLC mostly synergistic 
effects are seen regardless of the schedule in contrast with H510 SCLC cells where mostly 
antagonistic effects were observed. 
When cisplatin was exchanged for etoposide, in H69 cells again synergistic effects were 
observed. In the H510 cell line a different picture was seen when cisplatin was given before 
RAD001 only synergism was seen. Synergism was only seen at higher doses when cisplatin 
was given simultaneously with RAD001 and RAD001 given before cisplatin.  
It seems from these results that in the H69 cell line scheduling of the drugs does not seem to 
matter with regard to response. H510 cells are not very responsive to the etoposide 
/RAD001 combination and more sensitive to the cisplatin/RAD001 combination. How can 
these observations be explained? Previous work confirms the sensitivity of H69 compared to 
H510 with respect to etoposide/RAD001, at least when the drugs are given at the same time 
(Marinov, 2009). Another study using the mTOR inhibitor CCI-779, SCLC were sensitized 
to cisplatin induced apoptosis (Wu et al., 2005). RAD001 seems to induce apoptosis, as 
evidenced by induction of caspase-3, Poly (ADP-ribose) polymerase (PARP) and the 
inhibitor of caspase-3- activated DNase (IACD) cleavage in H69 cells but not in H510 cells. 
mTOR inhibitors induce autophagy (Blommaart EF, 1995; Kamada Y, 2000) and in this 
afore mentioned study, an autophagy inhibitor L 3-methyladenine could block the cytotoxic 
effects of RAD001 alone and the combination of etoposide and RAD001 (Marinov, 2009). 
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Our results are somewhat surprising with respect to scheduling of the drugs in the cell lines. 
When H69 cells were used regardless of cytotoxic agent used and scheduling, most of the 
effects seen were additive or synergistic, whilst in H510 cells synergistic effects were seen 
with cisplatin and RAD001 regardless of scheduling and antagonistic effects seen with 
etoposide and RAD001. The scheduling does not seem to matter but more so the drug, 
namely etoposide or cisplatin or the cell line i.e. H69 or H510. 
We have mentioned in the introduction that relatively high doses of rapamycin can block 
FGF-2 induced chemoresistance to etoposide (Pardo et al., 2001), in our studies here when 
RAD001 was administered 2 days before etoposide in H510 SCLC cells only antagonistic 
effects were observed, somewhat counter intuitive to the previous data. No growth factors 
were present in the media so maybe in vivo growth factor/FGF-2 activation of 
chemoresistance mechanism may give a different result. 
So how do these results help us with further studies? These results suggest that different 
types of small cell lung cancer respond in different ways to combination treatment at least at 
the in vitro level. Further studies are needed to understand the molecular mechanisms for 
these differences which as mentioned above are being elucidated. 
Ideally combination chemotherapy for lung cancer should take advantage of synergistic 
interactions, as these would enhance therapeutic efficacy and lower the risk of 
chemoresistance. If the drugs in combination are antagonistic, the efficacies of such 
regimens might be compromised and the chances of resistance and spread increase, as less 
effective drugs may be allowing weakly resistant clones to survive. It is difficult to predict in 
vivo drug interactions in humans on the basis of findings in vitro studies, although the 
findings from studies with animal models may be more predictive (Chou, 1998).  
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Further work leading to animal studies would include using other SCLC cell lines, 
combinations of etoposide, cisplatin and RAD001 together and changing the number of 
days between the administrations of the drugs. 
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CHAPTER VIII 
 
Final discussion and future directions 
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In the course of this thesis, I have attempted to highlight the role of mTOR in the biology of 
lung cancer. We have focused on certain aspects: The expression of mTOR in early stage 
NSCLC and its link to prognosis and the expression of mTOR in SCLC; the role of mTOR 
and mTOR inhibitors/rapalogues in chemoresistance to the cytotoxic drug etoposide in 
SCLC and its potential role in NSCLC, and finally the effect of combinations and scheduling 
of mTOR inhibitors and cytotoxic chemotherapy in SCLC. Our findings have potentially 
exciting implications. 
 
1. Overexpression of mTOR in early NSCLC cases.  
Our study, looking at 134 cases of surgically treated NSCLC, showed that overexpression of 
mTOR was linked to prognosis. Clearly this study needs repeating in at least another cohort; 
however if these results are reproduced-studies are clearly needed to look at the use of 
mTOR inhibitors and or cytotoxic chemotherapy as adjuvant therapy in these early cases 
that overexpress mTOR. It may be that overexpression of mTOR leads to increased 
sensitivity to mTOR inhibitors. Stage 1A NSCLC patients after surgery only have a 70% 
chance to be alive after 5 years (Tsuchiya et al., 2007) so any way of increasing this 
percentage would be welcome. If these results are repeated and consistent in other lung 
cancer cohorts, it would seem reasonable to think about phase III clinical trials looking at 
mTOR inhibitors and/or chemotherapy as adjuvant treatment in early NSCLC patients that 
overexpress mTOR. 
The supplementary study looking at how phospho-signals deteriorate with time from when 
cells, formalin fixed cells and tissue are removed from media/blood supply led us to use 
total mTOR expression in our formal study on the 134 early NSCLC cases. Nearly all the 
papers published looking at phospho-proteins in immunohistochemistry do not cite at what 
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time point the samples were fixed in formalin. This study again needs to be repeated in other 
tumour types and phospho-proteins. The potential implication of this particular aspect of 
this work is large since immunohistochemistry of phospho-protein studies in cancer are 
common and many conclusions drawn from these studies. In the future, 
immunohistochemistry studies using tissue looking at phospho-proteins must state at what 
time point specimens were fixed in formalin. 
 
2. The role of mTOR and mTOR inhibitors in chemoresistance to etoposide in SCLC 
We confirmed that high doses of the clinically relevant mTOR inhibitor RAD001 could 
block a FGF-2 induced chemoresistance pathway in SCLC cells. This is a potentially novel 
therapeutic management strategy. Chemoresistance is the ultimate cause of therapeutic 
failure in SCLC, in particular to etoposide and cisplatin, which together are the standard first 
line treatments in SCLC. Any way to subvert chemoresistance is greatly welcome for SCLC 
patients, in whom no major advance in treatment has been seen for 30 years.  
There could be many targets to block in this chemoresistance pathway from FGF-2 to 
MEK/ERK to the multiprotein complex of PKCε, B-Raf and S6K2. MEK antagonists are 
in development however mTOR inhibitors have been around for a while including the new 
‘TORKinhibs’ which target the ATP binding site on mTOR and have predictable and 
tolerable toxicities in patients. Using these drugs seems a rational approach to block a 
chemoresistance pathway.  
Specifically targeting the FGF-2 signaling pathway, although seductive, may not be a 
promising strategy for the treatment of SCLC. Indeed, a whole panel of growth factors, both 
neuro- and polypeptide will challenge SCLC in vivo. The MEK/ERK and the S6K1 
signaling pathways are common to many growth factors, and so it may be more attractive to 
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target these common molecules, such as mTOR, rather than the individual growth factors 
receptors. 
There is some data to suggest that increased protein expression of S6K2 in SCLC and 
NSCLC patient biopsies appear to correlate with the development of chemoresistance 
(Pardo et al., 2006). We did not look at S6K2 protein expression in our early NSCLC patient 
biopsies, which would have been a good idea; however in the 2 NSCLC cell lines examined, 
growth factor induced stimulation of MEK/ERK signaling (upstream of S6K2), could not 
be blocked by high doses of RAD001. 
First of all it is not clear if a chemoresistance pathway/complex similar to the one described 
in H510 SCLC cell line exists in the 2 NSCLC cell lines examined. However FGF-2 in the 
squamous cell NSCLC cell line HCC95 could block etoposide induced cell killing and PDB 
in the adenocarcinoma cell NSCLC line HCC78 could also block etoposide killing over 4 
days. In the HCC78 cell line relatively high doses of RAD001 could block this observed 
chemoresistance. The mechanism for this needs further clarification and could be the basis 
of future work. PDB activates by 2nd messengers such as classical and non-classical PKCs 
and they in turn have many substrates so the mechanisms of chemoresistance in this 
particular case could be complex. 
The mechanism of how high doses of mTOR inhibitors/rapalogues block growth factor 
induced MEK/ERK signaling was investigated. Clarification is needed on the role of mTOR 
and FKBP12 since RNAi knockdown experiments can never reduce protein levels to zero. 
This therefore makes conclusions difficult to interpret. An alternative would be to utilize the 
new ‘TORKinhibs’ which target the ATP binding site on mTOR and hence de-activate 
mTOR and do not require FKBP12 to function to determine if signaling through mTOR is 
essential in reducing growth factor activation of ERK1/2. 
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To determine whether the RAD001 inhibitory effect on MEK/ERK signaling was 
specifically due to RAD001 inhibition of mTORC1 signaling, a mTOR mutant could be 
used which has reduced binding affinity for RAD001/rapamycin-FKBP12 complex 
(Ser2035→I1e)(Brunn et al., 1997). This mutant is then RAD001/rapamycin resistant, but still 
would maintain mTORC1 signaling. 
The role of PP2A was briefly investigated; our preliminary results (not shown) confirmed 
recent work suggesting that mTORC1 signaling could regulate growth factor activation of 
p44/42 MAPKs through PP2A (Harwood et al., 2008).  
 
3. Combination studies in SCLC. 
We examined at the cell line level the effect of combinations of cytotoxic chemotherapy and 
RAD001 in 2 SCLC cell lines and looked at what schedule was optimal. These questions are 
important to answer since in clinical trials it is very difficult to investigate these questions 
since large numbers of patients are needed and little flexibility is allowed. 
Another aspect of the study was to investigate the ideal scheduling of combinations of drugs 
which work at different points in the cell cycle. mTOR inhibitors are cell cycle inhibitors 
whilst at least etoposide is active when cells are in cycle and killing cells in G2 and S phases. 
Surprisingly scheduling did not seem to determine response with the H69 SCLC cell line- 
synergistic effects were seen with etoposide and cisplatin, whilst in H510 SCLC cells, 
etoposide and RAD001 regardless of scheduling led to antagonistic effects and only high 
doses of cisplatin and RAD001 give synergistic effects. 
These studies need to be repeated and in other SCLC cell lines. Studies in animal models 
need to be performed as these are often quoted as being more representative of ‘real’ 
patients than in vitro work. 
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Final Comments 
This work has allowed us to investigate the role of mTOR in lung cancer. Much work is still 
required to understand in greater detail mTOR’s involvement in the biology of lung cancer. 
This work suffers from the limitations imposed by all in vitro work: only in vivo experiments 
in animal models could confirm the in vitro work. Therefore, this work should only be 
viewed as the starting point on which further work will be based. 
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